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 1 
INTRODUCTION 
 
This thesis deals with the implications of clinical research – specifically, clinical trials – 
in terms of law and policy at the international level.  This introduction briefly presents 
the thesis and introduces some of the research developments explored following the 
thesis defense that took place in Jena on December 10, 2018.1   
First, some preliminary notions are worth introducing. For the purpose of this thesis, the 
concept of clinical trials is intended to comprise “any research study that prospectively 
assigns human participants or groups of humans to one or more health-related 
interventions to evaluate the effects on health outcomes.”2 The element of human 
participation distinguishes clinical trials from other stages of clinical research and 
chronologically places them after laboratory-based research development activities and 
animal testing.3  
While clinical trials encompass a variety of activities, the first way in which such 
activities can be categorized depends on chronological phases. Clinical trials are 
generally conducted on the basis of a four-stage model in which Phase I tests a treatment 
on a small group of human subjects (e.g. 20-80 participants) in order to test the safety of 
the treatment and identify major side effects; Phase II widens the human subjects pool 
(e.g. 100-300 participants) in order to test the effectiveness of the treatment; Phase III 
further widens the human subjects pool and finalizes the assessment of the treatment; 
finally, Phase IV, takes place following the entry of the product on the market and further 
tracks its safety and efficacy.4 A second traditional way of distinguishing clinical trials 
regards their design (e.g. interventional, observational, or expanded access).5 Finally, a 
                                                 
1  Mandatory attachments to this thesis were not modified following the thesis defense and, therefore, 
remain unchanged in this copy.  The only edits implemented regard this section and the inclusion of a 
slide deck utilized during the thesis defense in the “Additional Documents” section.  
2  “Clinical trials.” WHO, World Health Organization, www.who.int/topics/clinical_trials/en/.  
3  “What Are Clinical Trials?” National Heart Lung and Blood Institute, U.S. Department of Health and 
Human Services, www.nhlbi.nih.gov/studies/clinicaltrials. 
4  “Glossary of Common Terms.” National Institutes of Health, U.S. Department of Health and Human 
Services, 10 Feb. 2016, www.nih.gov/health-information/nih-clinical-research-trials-you/glossary-
common-terms. 
5 “Glossary of Common Site Terms.” ClinicalTrials.gov, clinicaltrials.gov/ct2/about-
studies/glossary#study-type. 
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third way in which clinical trials can be categorized depends on the geographic area in 
which they take place (e.g. exclusively in one country or simultaneously in more than 
one area of the world).  
In this context, the rationale behind this thesis’s focus is three-folded and builds on three 
elements:  
(i) As the clinical trials business grows, clinical trials standards and legislation are 
becoming an increasingly popular and complex topic.6 In 2016, the global clinical trials 
market size was valued at USD 40 billion, and the same market is expected to reach USD 
65.2 billion by 2025.7 In this thesis we argue that the flourishing of the clinical trials 
sector results in an increased need for both institutional and private actors in the legal 
and medical field understand the challenges and opportunities that the growth of clinical 
trials poses.  
(ii) The field of clinical trials is not only a complex one – both from the scientific and the 
regulatory standpoint – but also an area of law and policy in which global 
interconnections and dynamics are increasingly prevalent. The increasingly international 
dimension of clinical trials can be observed in the light of two sets of challenges. The 
first deals with the conduction of multi-regional clinical trials, in which a multitude of 
human subjects are simultaneously recruited in a variety of countries.8 The second is 
connected with the outsourcing of clinical trials “overseas,” where sponsors (more often 
than not based in developed economies) decide to finance and conduct clinical trials in 
jurisdictions different than their own (in some instances, developing economies).9 In this 
thesis, we take the stand that both sets of challenges and their incidence on the action of 
clinical trials’ stakeholders support the development of clinical trials-related research 
with an international outlook.  
                                                 
6  Tereskerz, Patricia M. Clinical research and the law (Hoboken, New Jersey, Wiley-Blackwell, 2012). 
7  Respectively, “Get free access to The Grand Library, a BI enabled research database.” Clinical Trials 
Market Size, Share, Growth, Analysis Report, 2014-2025, www.grandviewresearch.com/industry-
analysis/global-clinical-trials-market and “Get free access to The Grand Library, a BI enabled research 
database.” Clinical Trials Market Size Worth $65.2 Billion By 2025, 
www.grandviewresearch.com/press-release/clinical-trials-market. 
8  Cf. Shenoy, Premnath. “Multi-Regional Clinical Trials and Global Drug Development.” Perspectives 
in Clinical Research, Medknow Publications & Media Pvt. Ltd., 2016, 
www.ncbi.nlm.nih.gov/pmc/articles/PMC4840793/. 
9 Cf. Hull, Darby. “Reining in the Commercialized Foreign Clinical Trial.” Journal of Legal Medicine 
36/3-4 (2015): 367-401. 
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(iii) The growth of the clinical trials market, as well as its globalized dimension, are 
correlated with amplified regulatory efforts – at national, regional, and international level 
– as well as with an increased availability of clinical trials data and information. 
Examples of relatively recent regulatory efforts and best practices include the drafting of 
the European Union Clinical Trials Regulation, which poses a heightened degree of 
attention on information sharing in Europe,10 and the increased accessibility of the WHO 
International Clinical Trials Registry Platform and the pervasiveness of clinical trials 
registration.11 In this context, we believe that the emergence of new sources favors and 
requires the development of up-to-date contributions in the field of clinical trials law and 
policy.  
Taking into consideration the three underlying focuses of this thesis, we briefly present 
the aims of this contribution.  First, in general terms, the research behind this thesis 
attempted to identify some of the risks and opportunities triggered by clinical trials in a 
globalized clinical research environment, specifically with the goal of providing some 
insights on how to improve human subjects’ protection in clinical trials. Furthermore, the 
thesis follows two fil rouge: the global dimension of clinical trials and their status and 
challenges in developing economies vis a vis developed economies; and the role that 
                                                 
10 Regulation (EU) No. 536/2014 of the European Parliament and of the Council of 16 April 2014 on 
clinical trials on medicinal products for human use, and repealing Directive 2001/20/EC (Text with EEA 
relevance). Further examples of recent regulatory efforts include the national action of some states e.g. 
India, which is in the process of rendering it mandatory for sponsors and investigators to disclose clinical 
trials’ outcomes (see: Koshy, Jacob. “Call to make clinical trial data public.” The Hindu, 22 Nov. 2017, 
www.thehindu.com/news/national/call-to-make-clinical-trial-data-public/article20667337.ece) and the 
United States, with regard to the implementation of an “electronic system that enables accurate 
collection of data and promotes data-sharing across multiple clinical trial sites” (see: Commissioner, 
Office of the. “Advancing Regulatory Science - OneSource Checklists: Tools for Integrating Care and 
Research and Catalyzing a Sea Change in the Practice of Medicine.” U.S. Food and Drug Administration 
Home Page, Office of the Commissioner, 
www.fda.gov/ScienceResearch/SpecialTopics/RegulatoryScience/ucm574079.htm). At the 
international level it is worth noting the discussion currently open on a set of guidelines for multi-
regional clinical trials at the level of the International Council for Harmonisation of Technical 
Requirements for Pharmaceuticals for Human Use (see: “ICH E17 Guideline reaches Step 2b of the 
ICH Process.” ICH, www.ich.org/ichnews/newsroom/read/article/ich-e17-guideline-reaches-step-2b-
of-the-ich-process.html). 
11 As of October 207, 456045 records were accessible for 390098 trials. The difference in the two figures 
is due to the fact that – as specified in the first page of the ICTRP’s search portal – “trials are sometimes 
recorded in more than one registry. These records can refer to each other using the ‘Secondary ID’ field. 
The search portal uses these Secondary IDs to group records about the same trial together in the search 
results.” See: ICTRP Search Portal, apps.who.int/trialsearch/Default.aspx.  To read the number vis a vis 
figures that regard the entity of the registration phenomenon before the introduction of the ICMJE policy 
note, for example, that before the implementation of the policy ClinicalTrials.gov, the largest trial 
registry at the time, contained 13,153 trials (see Laine, Christine, et al. “Clinical trial registration—
looking back and moving ahead.” (2007): 2734-2736). 
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different stakeholders play in the field of clinical trials in the light of the need to balance 
their competing interests. Lastly, in order to pursue this research interest, this thesis relies 
on three different approaches, depending on the issues addressed by each chapter: in 
some sections it adopts a descriptive approach, to identify the most relevant issues that 
legislators and private stakeholders currently face or will face in the near future in the 
field of clinical trials; in some sections it adopts a comparative approach, focusing on the 
similarities and divergences between regulatory standards applicable to clinical trials in 
different contexts and jurisdictions; and in some sections it adopts a more practical 
approach, aimed at the collection and interpretation of first-hand clinical trials data.  
Second, more specifically, each of the chapters discuss one or more narrow research 
questions. As a result, some of the chapters included in this contribution can potentially 
stand alone, as research papers, while others need to be read as providing information 
essential for a better understanding of the thesis as a whole. In particular:  
(i) Chapter One presents a comprehensive review of the literature relating to the law and 
policy of clinical trials, with a specific focus on their international dimension. It provides 
the reader with an introduction to the field of clinical trials-related research and it lays 
the groundwork for the following chapters, explaining how the research questions raised 
in this contribution fit into the current stream of clinical trials literature.  
(ii) Chapter Two describes the main rights touched upon by the conduction of and 
participation in clinical trials. The observations developed in this chapter allow readers 
to better understand the challenges that legislators willing to regulate clinical trials and 
protect human subjects regularly face (for example vis a vis the right to health and  right 
to information discourse).  
(iii) Chapter Three describes the main stakeholders involved in clinical trials (human 
subjects, sponsors, and investigators) and how their interests align or collide in the face 
of the need to balance three traditional healthcare competing paradigms:  access, cost, 
and quality.  
(iv) Chapter Four deals with the concerns raised by the globalization of clinical trials, 
building on one of the most renowned contributions in the field of clinical trials’ ethics 
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literature by Emanuel et al.12 The chapter presents concrete legal formulations and 
examples of implementation of the relevant ethical principles, expanding with the 
addition of a supplementary ethical principle applicable to international clinical trials. 
(v) Chapter Five presents a comparative analysis of the European Union and United 
States clinical trial legal frameworks. While the chapter adopts a narrow view and focuses 
on the core legislative provisions applicable in the two jurisdictions, rather than touching 
also upon the guidance tools provided by local authorities, it nevertheless allows to 
identify points of contacts and similarities and to detect divergences and differences 
between the two systems, providing detailed information about the most challenging 
elements for clinical trials stakeholders.   
(vi) Chapter Six focuses on the issue of clinical trials data transparency. The “case for 
registration” is taken into consideration because the global dimension of the issue is 
particularly relevant and the development of an in international set of standards in this 
context has been successfully achieved thanks to synergy between different stakeholders. 
The chapter presents an overview of the competing interests that stand behind the 
creation of clinical trial registries, of the history and functional characteristics of the 
principal registries, and some of the challenges that are still unresolved in this context. 
(vii) Finally, Chapter Seven adopts a more “practical” approach. It introduces the results 
of several interviews conducted with clinical trials sponsors, patients’ and consumer 
organizations, and investigators and presents the findings of a simple empirical analysis 
focused on recruitment-dynamics, conducted on the basis of a sample of 394 clinical 
trials. Through its practical approach, the chapter aims at providing up-to-date figures 
and insights on which clinical trials’ literature and stakeholders may want to rely. 
To conclude, through the above-described chapters, this thesis aims at representing an 
original contribution in the field of clinical trials law and policy at the international level.   
In addition to what introduced above, we briefly introduce some potential future research 
steps and expansions of scope of the research presented in this thesis.   
Regarding the comparative analysis introduced in Chapter Five, we plan to expand the 
research to account for the significant amount of guidance issued by European and United 
                                                 
12 Emanuel, Ezekiel J., et al. “What makes clinical research in developing countries ethical? The 
benchmarks of ethical research.” The Journal of Infectious Diseases 189.5 (2004): 930-937. 
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States authorities, which often contribute to increase the proximity of the two legal 
systems in the field of clinical trials. Depending on the timeline of the European Union 
Clinical Trials Regulation’s implementation, as well as on the political challenges that 
may impact it in some parts of Europe (that is, e.g.: Brexit), the research may need to be 
expanded to take into account further fragmentation and divergences at the European 
level. In addition, we expect that, in the long term, the comparative approach adopted in 
Chapter Five could be applied also to other jurisdictions as well as to joint/international 
regulatory efforts (such as those promoted in the context of the International Council for 
Harmonisation).  
In line with the above, we also plan to run an updated empirical analysis, building on the 
one introduced in Chapter Seven. Based on a series of scoping searches conducted 
following the thesis defense, we expect the updated empirical analysis to reflect the most 
recent dynamics in the field of international clinical trials, including an increased reliance 
on international clinical trials and the popularity of certain jurisdictions as clinical trials 
hosts. A further research step, in relation to this topic, could entail assessing the result of 
the empirical analysis in light of the most relevant regulatory choices made by each 
jurisdiction (e.g., in terms of clinical trials data transparency obligations, marketing 
authorization application requirements, informed consent standards, and post-marketing 
pharmacovigilance duties). This research angle could allow to establish to what extent 
regulatory challenges and opportunities might have influenced the choices of the relevant 
clinical trials stakeholders in each jurisdiction.  
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CHAPTER ONE: REVIEW OF THE LITERATURE 
 
I. Introduction 
This chapter will present a comprehensive review of the literature in the field of law and 
policy relating to clinical trials. Its scope is a double-sided one: on the one hand, to 
provide the reader with an introduction to the field of clinical trials-related research; on 
the other hand, to lay the groundwork for the following chapters, explaining how the 
research questions raised in this contribution fit into the current stream of clinical trials 
literature.  
As the field of clinical trials research is a niche one – especially when the focus of the 
research touches upon law and policy – the literature is not extremely vast. Nevertheless, 
this chapter attempts to present and organize it. In order to do so, it refers to legal-political 
as well as medical-pharmaceutical contributions. 
The following paragraphs will define the topic under consideration, will draw a picture 
of the most relevant approaches and contributions in the field, and will finally present 
some conclusions.   
II. Preliminary Notes 
First, this review focuses on the literature produced on the conduction and regulation of 
clinical trials with an international dimension and connotation. It should be noted at this 
juncture that the term “international dimension” is used here to indicate any clinical trial 
involving sponsors, investigators, and/or human subjects originally based in a variety of 
States. Furthermore, the definition of “clinical trial” upon which this chapter is built, is 
that provided by the World Health Organization (hereinafter, WHO). The latter deems 
the concept of clinical trials to comprise “any research study that prospectively assigns 
human participants or groups of humans to one or more health-related interventions to 
evaluate the effects on health outcomes.”13 
Second, four identifiable strands of literature can be identified in the research devoted to 
clinical trials with an international dimension. The structure of this chapter reflects such 
                                                 
13 “Clinical trials.” WHO, World Health Organization (2017) www.who.int/topics/clinical_trials/en/.  
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consideration, despite the fact that many of the issues that each strand touches upon are 
common and overlapping. Each strand can be identified on the basis of its focus. The 
four strands, therefore, can be seen to adopt: (i) the description as the focus; (ii) ethics 
and law as the focus; (iii) identity as the focus; and (iv) geography as the focus. The 
general interest in providing the audience with insights and inputs regarding the scope of 
a reform of the current clinical trials legal regime is the fils rouge that bounds the four 
approaches – especially (ii)-(iv) – within this contribution.  
III. Strands of Literature 
The following paragraphs will present the principal contributions developed within each 
of the four strands described above.  
(1) Description as the Focus 
The first strand relies on the description of clinical trials as the focus of its research. This 
strand is the most technical in nature, and includes all of the literature produced with the 
aim of describing how clinical trials work and how they are structured when they adopt 
an international dimension. It comprises a mixture of legal-political and medical-
pharmaceutical literature. It can be deemed relevant for the scope of this contribution, to 
the extent that it provides reliable figures in terms of e.g. the number of clinical trials 
conducted in the past decades, percentages of clinical trials conducted with an 
international dimension, and the nature and incidence of any risk factor involved in the 
organization of clinical trials, whether they are being conducted in an exclusively local 
or in an international dimension.  
(2) Ethics and the Law as the Focus 
The second strand of clinical trials literature identified here has ethics and the law as its 
focus. The literature produced in this context can be seen as dealing with four sub-
strands: (a) morality; (b) binding legal instruments; (c) other regulatory tools; and (d) the 
outcomes of existing litigation.  
(a) With regard to morality, the contributions that belong to the first sub-strand tend to 
observe the regulation of clinical trials (or lack thereof) as a choice with deep moral 
implications. They trace aspects of the regulation and conducting of clinical trials that 
are not legal per se, but that precede or accompany the legal choices taken in the field. 
The concern conveyed by some of the contributions that fall within this field regards the 
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risk that clinical trials conducted “abroad” – in particular, when sponsors based in 
developed economies recruit investigators and human subjects in developing economies 
– pose in terms of “colonialism”. The latter term is used, for example, by Treadaway to 
describe the issues that arise when a population that is vulnerable both in terms of access 
to healthcare and economic resources is recruited by sponsors based in developed 
countries to serve as clinical trial participants in developing countries.14 As Fidler – 
exploring the “geographic morality” of clinical trials – aptly described, authors that focus 
on the moral implications of clinical trials tend to join one of three approaches borrowed 
from the international relations discourse: realism, where morality is not deemed to have 
a role in the relations among States;15 rationalism, where States can structure their 
relations according to common moral grounds to pursue peaceful relations;16 and, finally, 
revolutionism, where international relations are seen as the means for achieving the unity 
– even the moral one – of mankind.17 
(b) The second sub-strand comprises one of the most relevant genres for this contribution, 
and focuses on the study of the legal instruments that regulate clinical trials. 
Traditionally, literature belonging to this category considers legal certainty as a value.18 
It entails one of the following aims: (i) to describe purely national legislation, especially 
that which aims at informing practitioners in the field of clinical trials or advocating for 
reforms of such national legislation. For example, Brunts and Rusczek focused on the 
United States (US) regulation of clinical trials and covered its implications in different 
fields of their national law, including civil liability and commercial litigation.19 (ii) To 
describe the relevant international legal instruments, once again with the purpose of 
informing practitioners and/or  advocating for reforms, as undertaken, for example, by 
Traynor.20 Finally, (iii) comparing existing legal instruments, to facilitate the 
                                                 
14 Treadaway, Lauren. “Big Pharma’s Heart of Darkness: The Alien Tort Statute and Preventing Clinical 
Trial Colonialism.” Georgetown Journal of International Law 43 (2011): 1419. 
15 Fidler, David P. “Geographical Morality Revisited: International Relations, International Law, and the 
Controversy over Placebo-Controlled HIV Clinical Trials in Developing Countries.” Harvard 
International Law Journal 42.2 (2001): 316-320.  
16 Ibid.  
17 Ibid. 
18 Cf. Treadaway, op. cit. 
19 Brunts, Hermes and Andrew P. Rusczek. “The International Clinical Trials Roadmap: Steering Clear of 
Legal and Practical Roadblocks.” Journal of Health & Life Sciences Law 5.3 (2012): 1.  
20 Traynor, Michael, “Emerging Issues Regarding Globalization of Pharmaceutical Research, Insurance, 
Informed Consent, Securities Litigation, and Public Policy.” written for ALI-ABA, Emerging Issues in 
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interpretative exercise of the subjects that conduct clinical trials in more than one State 
and/or to assess the feasibility of a harmonization of the applicable legal standards. 
Notably, one of the most developed comparative approaches focuses on the divergences 
and similarities between the legislation in force in the US and that in force in the 
European Union (EU). This is the case of the contributions developed, among others, by 
Trubek, Westergren, and Choi.21 
(c) The third sub-strand is often blended with the second and analyzes all of the relevant
sources in the field of clinical trials regulation; however, these are not strictly binding on
states and private stakeholders. In practical terms, this sub-strand deals with the
regulatory tools produced by non-governmental actors or by States (yet without a
compelling legal value). An exemplary tool observed in this field is the Nuremberg Code,
central in Shtilman’s contribution.22 The literature produced in this context has a peculiar
value, as it often provides insights on the work and opinion of working groups that
represent sponsors and investigators, and that may serve as basis for prospective
legislative reforms. For example, Malinowski, and Gautreaux have engaged in the
description of a well-known law and policy reform proposal. 23
(d) Finally, the fourth sub-strand aims at discerning the outcome of existing litigation.
While litigation that regards clinical trials – both at national and international level – is
not particularly developed in all legal systems, relevant cases have emerged in the past
years. Studying their procedural and substantive aspects offers a chance to test national
and international norms in the field. This has been, for example, one of the focuses of
Treadaway’s research.24 The literature that focuses on such litigation provides insights in
Biotechnology Law (2007) accessed on LexisNexis, www.lexisnexis.com/ (Lexis reference: SN014 ALI-
ABA 73). 
21 Respectively, Trubek, Louise, et al. “Improving Cancer Outcomes through Strong Networks and 
Regulatory Frameworks: Lessons from the United States and the European Union.” Journal of Health 
Care Law & Policy 14 (2011): 119. Westergren, Amy. “The Data Liberation Movement: Regulation of 
Clinical Trial Data Sharing in the European Union and the United States.” Houston J. Int’l L. 38.3 
(2016). And Choi, Rebecca. “Increasing Transparency of Clinical Trial Data in the United States and 
the European Union.” Washington University Global Studies Law Review 14 (2015): 521. 
22 Shtilman, Yevgenia. “Pharmaceutical Drug Testing in the Former Soviet Union: Contract Research 
Organizations as Broker-Dealers in an Emerging Testing Ground for America’s Big Pharma.” Boston 
College Third World Law Journal 29 (2009): 425. 
23 Malinowski, Michael J., and Grant G. Gautreaux. “All That is Gold Does Not Glitter in Human Clinical 
Research: A Law-Policy Proposal to Brighten the Global Gold Standard for Drug Research and 
Development.” Cornell International Law Journal 45 (2013): 185. 
24 Treadaway, op. cit.  
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terms of the susceptibility of wrongdoings to redress in the field of clinical trials, and, 
despite its specific nature, provides the reader with important elements of analysis, 
especially to the extent that it highlights the operational virtues and vices of current 
regulatory regimes.  
In sum, authors that pose ethics as core of their analysis tend to it to take a stand in the 
debate over the morality of clinical trials – especially when they have an international 
dimension – to analyze the way in which clinical trials are regulated both through binding 
legal provisions and through other soft-law tools, and/or to study the shape that clinical 
trials-related litigation has taken in recent times. 
(3) Identity as the Focus 
The third strand of literature presented here focuses on the identity – but also the interests 
and concerns – of the actors involved in clinical trials (especially those conducted with 
an international dimension). In this context, regulating clinical trials means finding the 
optimal balance between the interests and concerns of three main stakeholders: 
patients/participants (i.e. the human subjects that take part in clinical trials), investigators, 
and sponsors.  
Many authors focus on those “players”, while maintaining a balanced approach, and aim 
at describing the interests that belong to each category, as Bard has done in drawing her 
“taxonomy” of clinical trials’ dynamics.25 Other authors tend to focus on a single 
category and to advocate for the prevalence of its particular interests; for example, 
Hathaway’s work is centered on the decisional and precautionary steps that sponsors and 
investigators willing to conduct clinical trials in a third country ought to consider.26 With 
regard to contributions to clinical trials literature that advocate for the promotion of a 
specific goal – which often corresponds to the interest of one category of stakeholders – 
the case for or against the goal of centralizing clinical trials registration is worth 
observing. Contributions developed to support the creation and implementation of 
centralized clinical trials registries – such as the work of Galbraith, Francer and Turner, 
                                                 
25 Bard, Jennifer S. “A Taxonomy for Analyzing Legal and Ethical Issues Arising When Conducting 
Human Subject Research Outside the Borders of One’s Own Country.” Houston Journal of 
International Law 37 (2015): 1. And Hathaway, Carolyn R., et al. “Looking Abroad: Clinical Drug 
Trials.” Food and Drug Law Journal 63. 3 (2008): 673.  
26 E.g. as a case of study that advocates for an increased role of integrated networks of doctors, patients, 
and hospitals: Trubek, op. cit. 
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and Cohen at al. – tend to be grounded in the idea that they contribute to the 
empowerment of patients and increase the quality of and lack of biases in clinical trials’ 
results.27  
In general terms, the following are some of the issues that are commonly presented as 
grey areas at the intersection of the interests of the three main stakeholders: the existence 
and scope of a right to access to treatments – often declined in terms of right to health, 
right to life, and clinical trials’ as public goods;28 the existence and scope of a right to 
information – often analyzed within the debate over the creation and enforcement of 
centralized (i.e. supra-national) clinical trials registries or within the debate over the 
nature and content of the participants’ informed consent;29 the legality and scope of 
placebo clinical trials;30 and the existence and scope of a right to the so called “Best 
Proven Diagnostic and Therapeutic Method” (i.e. best available treatment).31  
(4) Geography as the Focus 
The fourth and final identifiable strand of literature relies on geography as its focus. 
Similarly to the third strand, it allows authors to structure their research in terms of 
potentially conflicting interests and categories of actors. However, while in the third 
strand, the factor that sets “players” apart is the role that they play in the organization 
and carrying out of clinical trials, in the fourth strand, geography constitutes the 
discerning factor.  
In particular, authors active in this field tend to focus their research on one or more of 
the following objects – either adopting a descriptive super partes approach or advocating 
                                                 
27 Respectively, Galbraith, Christine D. “Dying to Know: a Demand for Genuine Public Access to Clinical 
Trial Results Data.” Mississippi Law Journal 78 (2008): 705. Jeffrey K. Francer and Natalie A. Turner. 
“Responsible Clinical Trial Data Sharing: Medical Advancement, Patient Privacy, and Incentives to 
Invest in Research.” Journal of Health & Life Sciences Law 8.1 (2014): 63. And Cohen, Katherine et 
al. “Predictable Materiality: A Need for Common Criteria Governing the Disclosure of Clinical Trial 
Results by Publicity-Traded Pharmaceutical Companies.” Journal of Contemporary Health Law and 
Policy 29 (2012): 201. 
28 E.g. Lemmens, Trudo, and Candice Telfer. “Access to Information and the Right to Health: the Human 
Rights Case for Clinical Trials Transparency.” American Journal of Law and Medicine 38 (2012): 63. 
29 E.g. Doherty, Joan M. “Form over Substance: The Inadequacy of Informed Consent and Ethical Review 
for Thai Injection Drug Users Enrolled in HIV Vaccine Trials.” Pacific Rim Law & Policy Journal 15.1 
(2006): 101. And McGregor, Molly. “Uniformed Consent: The United Nations’ Failure to Appropriately 
Police Clinical Trials in Developing Nations.” Suffolk Transnational Law Review 31/1 (2007): 103.  
30 Fidler, op. cit. 
31 Shtilman, op. cit.  
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for the centrality of the role of one of them: single States belonging to the category of 
developed economies, single States belonging to the category of developing economies 
or economies in transition, and/or clusters of States and international organizations. For 
example, contributions that belong to this strand have been developed by Schuster and 
Ourso.32 The allegation that the interests of different States can be described on the basis 
of a line dividing developed and developing economies is not free from controversies.33 
However, while admittedly, it should not be seen as a clear-cut line, in the context of 
clinical trials regulation, it may become relevant to the extent that it allows for a more 
precise identification of the interests and concerns of different legislators and 
“prospective legislators” on the international scenario. In particular, it provides for a 
chance to not underestimate the need for measures tailored to the risks and opportunities 
that in the case of developed and developing economies have different shades.  
Sub-issues addressed in this context overlap with those addressed by the literature which 
adopts an ethical focus. For example, they regard concerns for the scarce efficacy of the 
inspection-procedures in place in host-States, the increased risks of fraud and abuse in 
certain States, as well as of the risk of exploitation of vulnerable populations.34  
IV. Preliminary Conclusions  
To conclude, the literature produced in the field of clinical trials regulation and 
specifically with a focus on clinical trials that adopt an international dimension is highly 
specific and often fragmented. Nevertheless, four – often overlapping – focuses can be 
identified, and will be taken into consideration in the following chapters of this thesis. 
Namely, the approach that focuses on a descriptive analysis, that which focuses on ethical 
and purely legal aspects of clinical trials, that which focuses on the identity and interests 
of the stakeholders involved in the conduction of each clinical trial, and, finally, that 
                                                 
32 Schuster, Breanne M. “For the Love of Drugs: Using Pharmaceutical Clinical Trials Abroad to Profit 
Off the Poor.” Seattle Journal for Social Justice 13 (2014): 1015. And Ourso, Andre. “Can the FDA 
Improve Oversight of Foreign Clinical Trials: Closing the Information Gap and Moving Towards a 
Globalized Regulatory Scheme.” Annals of Health Law 21 (2012): 493.  
33 While authors often do not describe on the basis of which criteria they distinguish the two categories, 
within this contribution the categorization provided by the UN, World Economic Situation and 
Prospects 2017 (New York, 2017) 153-154, will be relied on.  
34 Schuster, op. cit. and McGregor, op. cit. 
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which focuses on the – sometimes divergent – interests of the States involved in the 
regulation of clinical trials.  
This thesis aims at providing a set of specific contributions in the context of several of 
the strands of literature described above. For example, it will present an analysis of the 
major rights involved in clinical trials regulation, a discussion of clinical trials ethics in 
context, and updated comparative analysis of the existing legal instruments in force at 
the national level in the US and the EU – an exercise that belongs to the second strand 
identified here; and an analysis of the interaction between the interests of different 
stakeholders involved in clinical trials – which belongs to the third strand identified here. 
Incidentally, it will provide an empirical analysis focusing on the international dimension 
of clinical trials and its prevalence in the case of some countries’ action – which belongs 
to the fourth strand identified here. 
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CHAPTER TWO: THE PROTECTION OF HUMAN SUBJECTS IN CLINICAL 
TRIALS – RELEVANT ISSUES IN THE RIGHT TO HEALTH AND RIGHT TO 
INFORMATION DISCOURSES 
 
I. Introduction 
This chapter will describe the main rights touched upon by the carrying out of and 
participation in clinical trials. In general, the observations developed in this chapter can 
be seen as essential to allowing readers to better understand the challenges faced by 
legislators willing to regulate clinical trials and protect human subjects. Furthermore, the 
identification and analysis of such rights and of some of their principal practical 
applications and implications is propaedeutic to the development of other chapters in this 
thesis. 
In particular, this chapter provides notions relevant for the understanding: (i) of the 
contribution on the three competing paradigms in clinical trials policy and legislation – 
access, quality, and cost;35 (ii) of the ethical considerations upon which this thesis 
relies;36 and (iii) of the elements that are at the core of the comparative analysis presented 
herein.37 In particular, the second section of this chapter will revolve around the right to 
health discourse, while the third will revolve around the right to information discourse.  
II. Right to Health 
Discussing clinical trials regulation in the context of international law and, specifically, 
the protection of human subjects entails the opening of a dialogue concerning the nature 
and scope of the right to health. Therefore, this section will provide the reader with some 
introductory notions in terms of definition, legal sources, and the nature of the right to 
health. It will then move to discuss the implications of the right to health in the context 
of clinical trials policy and regulation touching upon a series of specific issues – including 
the issue of sample tailoring, subject recruitment, placebo-controlled clinical trials, and 
standards of care.  
                                                 
35 See Chapter III in this thesis. 
36 See Chapter IV in this thesis. 
37 See Chapter V in this thesis. 
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(1) The Right to Health: Introductory Notions 
The nature and scope of the right to health is the object of a flourishing literature, both 
within the borders of single countries – be they developed or developing economies – 
and in the general international law and policy discourse.38 First, with regard to the 
definitional issue, it is worth noting that there seems to be a widespread consensus 
concerning the core elements in the definition of the right to health. The latter consists of 
the enjoyment of a certain standard of health. Where this standard ought to be placed, 
who the institutional subject in charge of establishing it is, and towards which audience, 
remain arguments of debate among researchers.39 Some insights, however, can be derived 
from the interpretation of both international legal instruments and comparative studies 
that focus on state practice. In general, in terms of international law, there are two main 
sources that are relevant with regard to the right to health: obligations deriving from 
international legal instruments and those deriving from customary international law.  
The most relevant international legal instruments that directly or indirectly refer to the 
right to health are: the WHO Constitution, which touches upon it in its Preamble 
(Preamble), stating that “[t]he enjoyment of the highest attainable standard of health is 
one of the fundamental rights of every human being without distinction of race, religion, 
political belief, economic or social conditions”;40 the International Covenant on 
Economic, Social and Cultural Rights which at Article 12 (1) affirms that “[t]he States 
Parties to the present Covenant recognize the right of everyone to the enjoyment of the 
highest attainable standard of physical and mental health”;41 the United Nations 
Convention on the Rights of the Child, which at Article 24 (1) states that “States Parties 
recognize the right of the child to the enjoyment of the highest attainable standard of 
                                                 
38 See e.g. Farmer, Paul. “Pathologies of Power: Rethinking Health and Human Rights.” American Journal 
of Public Health 89.10 (1999): 1486-1496. Sen, Amartya. “Why and How is Health a Human Right?” 
The Lancet 372.9655 (2008): 2010. And Leary, Virginia A. “The Right to Health in International Human 
Rights Kaw.” Health and Human Rights 1.1 (1994): 24-56 and the contributions cited in the following 
footnotes. 
39 Cf. Toebes, Brigit. “The Right to Health as a Human Right in International Law.” Refugee Survey 
Quarterly 20.3 (2001). And Mann, Johnathan. “Health and Human Rights.” American Journal of Public 
Health 96.11 (2006). 
40 Constitution of the World Health Organization (Geneva: World Health Organization, 1948). 
41 Article 12 (1), UN General Assembly, International Covenant on Economic, Social and Cultural Rights, 
16 December 1966, United Nations, Treaty Series, vol. 993, p. 3. 
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health”;42 and the Convention on the Elimination of All Forms of Racial Discrimination, 
which at Article 5 (e)(iv) provides that States Parties undertake to prohibit and eliminate 
racial discrimination in the enjoyment of “the right to public health, medical care, social 
security and social services.”43 
As of today, 194 States have ratified the United Nations (UN) Convention on the Rights 
of the Child,44 177 States have ratified the International Convention on the Elimination 
of All Forms of Racial Discrimination,45 and 164 States have ratified the International 
Covenant on Economic, Social and Cultural Rights.46   
As can be noted by the wording of the abovementioned provisions, the most common 
term used to refer to the standard of health which is to be promoted by States is the 
“highest.” With regard to the customary nature of the right, as it is well known, customary 
international law can be identified on the basis of a two-prong test under which two 
elements are to be assessed: opinio iuris and state practice.47 In the context of the right 
to health, Kinney has provided a comprehensive study of the customary nature of the 
right, noting that, as of 2000, 83 states had ratified at least a regional treaty 
acknowledging the right to health, and 109 had recognized it in their own constitution.48 
Backman et al. have developed a study of national approaches and standards to the right 
to health, assessing its status in 194 countries.49 Despite the availability of such data, 
                                                 
42 Article 24 (1), UN General Assembly, Convention on the Rights of the Child, 20 November 1989, United 
Nations, Treaty Series, vol. 1577, p. 3. 
43 Article 5(e)(iv),  UN General Assembly, International Convention on the Elimination of All Forms of 
Racial Discrimination, 21 December 1965, United Nations, Treaty Series, vol. 660, p. 195. 
44 UN, UN Treaty Collection.  
https://treaties.un.org/pages/viewdetails.aspx?src=ind&mtdsg_no=iv-11&chapter=4&clang=_en. 
45 UN, UN Treaty Collection.  
https://treaties.un.org/Pages/ViewDetails.aspx?src=IND&mtdsg_no=IV-2&chapter=4&clang=_en. 
46 UN, UN Treaty Collection.  
https://treaties.un.org/Pages/ViewDetails.aspx?src=IND&mtdsg_no=IV-3&chapter=4&clang=_en. 
Additionally, it is worth recalling that the 1948 Universal Declaration of Human Rights, at Article 25, 
reads: “Everyone has the right to a standard of living adequate for the health and well-being of himself 
and his family, including (…) medical care.” Article 25, UN General Assembly, Universal Declaration 
of Human Rights (Paris, United Nations, 1948). 
47 Malcom N. Shaw, International Law, 7th edition (Cambridge University Press, 2014).  
48 Kinney, Eleanor D. “The International Human Right to Health: What Does This Mean for Our Nation 
and World.” Indiana Law Review 34 (2000): 1457-1465. 
49 Backman, Gunilla et al. “Health Systems and the Right to Health: an Assessment of 194 Countries.” The 
Lancet 372/9655 (2008): 2047-2085. 
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attributing a customary value to the right to health is not an exercise free of challenges, 
but ultimately the right-to-health provisions included in the ICESCR can be deemed to 
be customary in nature, or at least at the core thereof.50 With regard to the challenges to 
the enforceability of the right to health, Backman et al. suggested that “[c]ountries have 
a legal obligation to progressively realise the right to the highest attainable standard of 
health and therefore to improve their health systems progressively.”51  
In this context, two main challenges follow the life of the right to health: First, both 
“highest” and “progressively” remain subjective standards as far as States have different 
political attitudes and preferences as well as unequal stages of economic development, 
and face a variety of challenges in terms threats to the health of their citizens. Second, 
consequently and in any event, implementation and enforcement challenges remain 
extremely complex; not only because they depend on the definition of the right but also 
because they are complicated by the absence of a clear chain of responsibilities.  
General Comment 14 presents the UN Committee on Economic, Social, and Cultural 
Rights’ interpretation of Article 12 of the International Covenant on Economic, Social, 
and Cultural Rights and helps to partially clarify those issues.52 Despite its lack of binding 
force, it represents a reliable and authoritative source. Two key findings built into the 
Comment are the following: core obligations are not subject to progressive realization 
and resource availability, and States “have an obligation to ensure that their actions as 
members of international organizations take due account of the right to health”. As of the 
role of supra-national institutions, a strand of literature has developed over time to 
address the challenges which the WHO, as an international organization entrusted with 
the aim of promoting global health, faces.53  
This chapter does not aim at solving the dilemma over the legal nature of the right to 
health; rather, it agrees with Fidler’s intuition that “[n]either international law nor global 
                                                 
50 Kinney, op. cit.  
51 Backman, op. cit. 
52 Committee on Economic, Social and Cultural Rights, General Comment No. 14: The Right to the Highest 
Attainable Standard of Health (Art. 12), (UN Committee on Economic, Social and Cultural Rights, 
Twenty-second session, 2000), U.N. Doc. E/C.12/2000/4 (2000), reprinted in Compilation of General 
Comments and General Recommendations Adopted by Human Rights Treaty Bodies (U.N. Doc. 
HRI/GEN/1/Rev.6, 2003): 85. 
53 Cf. Taylor, Allyn Lise. “Making the World Health Organization Work: a Legal Framework for Universal 
Access to the Conditions for Health.” American Journal of Law and Medicine 18.4 (1992): 301.  
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health jurisprudence provides a magic bullet against the public health problems in the 
world today.”54 Nevertheless, it aims at providing readers with some insights into the 
connections between the right to health and the conduction and regulation of clinical 
trials at the international level. It also aims at contributing to structuring a discussion that 
is still considered underdeveloped.55 In this sense, it seems pragmatic to follow the path 
chosen by other authors, such as Kinney herself. The latter suggested that “[d]efining the 
content of a right to health is a formidable challenge. But the challenge should not impede 
the recognition and development of a human right to health in international human rights 
law.”56 This observation is particularly apposite in the context of clinical trials in which 
the concreteness of the matter often makes it easier to understand which choices a 
legislator – being it a national or an international one – is facing. Hence, to overcome the 
risks associated with tackling the definitional challenges of the right to health and while 
keeping the formulation that international provisions have given it over time, the next 
paragraphs will focus on its aspects “in the field” (of clinical trials).   
(2) Right to Health in the Context of Clinical Trials 
The discourse on the existence, nature, and scope of the right to health meets the interests 
and concerns of clinical trials policy and regulation in two specific respects. The first 
regards the dichotomy right-duty to participate and tailored access: a case of balancing 
public and private interests in restricting or promoting access to clinical trials vis-à-vis 
the costs – both in terms of public health and material monetary costs – and effects on 
quality of the results of such restrictions and promotions. The second is potentially the 
more challenging and specific issue, and concerns the use of placebo-controlled studies 
and the role of local standards of care.  
(a) The Dichotomy Right-Duty to Participate: Sampling and Tailoring in Clinical Trials 
This section will address three sources of concern in the context of the right to health and 
clinical trials: small samples, coercion, and over- or underrepresentation of certain 
portions of the population. The acknowledgment that they must be addressed in the 
debate concerning the regulation of clinical trials should ensure that legislators and the 
                                                 
54 Fidler, David P. “International Law and Global Public Health.” Kansas Law Review 48 (1999): 1. 
55 Cf. Lemmens, and Telfer, op. cit. 
56 Kinney, op. cit. 
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stakeholders involved will not underestimate the risk and opportunities connected with 
such issues.  
First of all, in general, and especially in case of potentially life-saving protocols, many 
patients advocate for increased access to clinical trials as a declination of their right to 
health (and access to healthcare). For example, a strand of service-industry has developed 
to favor patients’ access to clinical trials, Flatiron being one of the leading companies in 
the field.57 The patients’ motivation is clear and is often coupled with the feeling that 
they are not provided with the opportunity to participate due to their lack of 
information.58 While the issues connected with the right to information will be addressed 
later in this chapter, it can preliminarily be noted that a trade-off between costs (either 
public or private) and access to clinical trials exists. In particular, this seems to be one of 
the issues on which sponsors and legislators are aligned: there would be no point in 
enlarging samples of participants beyond what needed for scientific purposes. This would 
merely increase the cost for sponsors and put at risk a larger sample of patients, in case 
of unsuccessful protocols. In fact, limitations on the size of the samples are one of the 
key considerations in clinical trials planning as sample size estimation and the need to 
avoid over- and under-estimation are extremely important in the development of solid 
clinical trials.59 As a result, clinical trials conducted on small samples are increasingly 
popular as – while they may be seen as restricting access to participants willing to take 
part in the studies – they present procedural advantages in terms of enrollment, review 
of records, and timing.60 One aspect that makes them particularly attractive for 
investigators and sponsors is that they require the participation of few centers, and this 
makes it easier to obtain ethical and institutional approval.61  
                                                 
57 Flatiron, Flatiron Health, www.flatiron.com. See also Abernethy, Amy and Sean Khozin. “Clinical Drug 
Trials May Be Coming to Your Doctor’s Office.” The Wall Street Journal (12 Sept. 2017) 
 www.wsj.com/articles/clinical-drug-trials-may-be-coming-to-your-doctors-office-1505256988. 
58 Ibid. 
59 Sakpal, Tushar. “Sample Size Estimation in Clinical Trial.” Perspectives in Clinical Research 1.2 
(2010): 67. 
60 Hackshaw, Allan. “Small Studies: Strengths and Limitations.” European Respiratory Journal 32 (2008): 
1141-1143. 
61 Ibid. 
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On the opposite spectrum of the right to health-related concerns are the clinical trials that 
potential participants may see as unattractive, and the clinical trials that, by design, would 
benefit from a better-tailored sample.  
The first issue is connected with the existence of a potential “duty to participate” in 
clinical trials.62 While enrollment in clinical trials has a deeply voluntary basis, as noted 
by Spencer B. King, “[n]ot every trial is worthy of patients’ and physicians’ duty to 
participate. Some trials have little game-changing potential and are designed to support 
minor changes in the approval of devices, procedures, or therapies.”63 While per se this 
concern belongs to investigators, it enters the realm of regulation, to the extent that 
recruitment strategies cross the line between incentives and coercion (or undue 
influence). Financial incentives are common in clinical trials recruitment but they 
increase the concerns that they may assume a coercive nature directed at people who have 
limited financial resources.64 Strategies to overcome that risk encompass the general goal 
to “improve the effectiveness of methods for informing prospective research volunteers 
about experimental studies, thereby enhancing the protection of their interests”65 and 
specific provisions dedicated to mandatory reviewing by ethical boards and training 
sessions for recruitment professionals.66  
The second issue regards the composition of the sample, namely the characteristics of 
the participants in the clinical trial. According to Caplan and Friesen, in the case of 
clinical trials conducted in the US, minorities tend to be overrepresented in Phase I 
studies – where risks are higher and the likelihood of benefits is lower, compared to more 
advanced trials – and underrepresented in Phase II studies and Phase III trials.67 Similar 
                                                 
62 Schaefer, G. Owen et al. “The Obligation to Participate in Biomedical Research.” Journal of the 
American Medical Association 302/1 (2009): 67-72. And  Spencer, B. King III, “Is Participation in 
Clinical Research a Duty?.” Journal of the American College of Cardiology: Cardiovascular 
Interventions 7.4 (2014): 450. 
63 Spencer, ibid. 
64 Groth, Susan W. “Honorarium or Coercion: Use of Incentives for Participants in Clinical Research.” 
Journal of the New York State Nurses’ Association 41.1 (2010): 11. 
65 Lavori, Philip W., et al. “Improving Informed Consent in Clinical Trials: a Duty to Experiment.” 
Controlled Clinical Trials 20.2 (1999): 187-193. 
66 Groth, op. cit., 11. 
67 Caplan, Arthur, and Phoebe Friesen. “Health Disparities and Clinical Trial Recruitment: Is There a Duty 
to Tweet?” Public Library of Science Biology 15.3 (2017). See also Hussain‐Gambles, Mahvash, et al. 
“Why Ethnic Minority Groups are Under‐Represented in Clinical Trials: a Review of the Literature.” 
Health & Social Care In The Community 12/5 (2004): 382-388. For specific conditions, see: Heiat, 
Asefeh, et al. “Representation of the Elderly, Women, and Minorities in Heart Failure Clinical Trials.” 
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concerns apply to the participation of women.68 In both cases, there is a widespread 
agreement circa the benefits of a better-tailored access to clinical trials: samples of high 
quality (in terms of representation of the population) will guarantee that results will be 
more easily generalized and therefore used to produce an outcome more beneficial for 
the general public. Good tailoring of the samples, in this context, represents a bridge 
between the goals of access and quality in clinical trials. In particular, as noted by Murthy 
at al., “appropriate” representation of specific patient subpopulations is “necessary to 
further understanding of race/ethnicity–based differences in presentation, prognosis, and 
response to therapy.”69 In response to such concerns, for example, the US Congress has 
implemented measures to foster a more diverse participation.70 Unfortunately, those 
provisions have not conclusively proven to be effective. In fact, while enrollment in 
clinical trials in the US has grown by almost 50% between 1996 and 2002, the proportion 
of minorities, women, and elders has declined.71 Nowadays, potential strategies to foster 
the access of underrepresented portions of the population and build more “participant-
friendly” trials include establishing community partnerships, designing study protocols 
based on the knowledge of participants’ life context, and representing diverse 
populations in the members of research teams.72  
In sum, it seems clear that if a clear-cut line can be drawn, it is between well- and badly-
designed and conducted trials. In this context, well-designed regulation – to the extent 
that it can foster well-designed trials – can do much. The common goal and compass in 
terms of balance of interests should not be increasing access to clinical trials in 
                                                 
Archives of Internal Medicine 162/15 (2002) and El-Sadr, Wafaa, and Linnea Capps. “The Challenge 
of Minority Recruitment in Clinical Trials for AIDS.” Journal of the American Medical Association 
267/7 (1992): 954-957. 
68 Cf. e.g. Gurwitz, Jerry H., et al. “The Exclusion of the Elderly and Women from Clinical Trials in Acute 
Myocardial Infarction.” Journal of the American Medical Association 268.11 (1992): 1417-1422. And 
Heiat, Asefeh, et al., op. cit. 
69 Murthy, Vivek H., et al. “Participation in Cancer Clinical Trials: Race-, Sex-, and Age-Based 
Disparities.” Journal of the American Medical Association 29.22 (2004): 2720-2726. 
70 US Congress, National Institutes of Health Revitalization Act of 1993. Subtitle B – Clinical Research 
Equity Regarding Women and Minorities (1993) sections 131-133. 
71 Murthy, et al., op. cit. 
72 The three strategies are discussed in Killien, Marcia, et al. “Involving Minority and Underrepresented 
Women in Clinical Trials: the National Centers of Excellence in Women’s Health.” Journal of Women’s 
Health & Gender-Based Medicine 9.10 (2000): 1061-1070. The term “participant-friendly” has been 
introduced by Swanson, G. Marie, and Amy J. Ward. “Recruiting Minorities into Clinical Trials toward 
a Participant-Friendly System.” Journal of the National Cancer Institute 87.23 (1995): 1747-1759. 
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quantitative terms (i.e. enlarging the pool of patients that they actually involve), rather 
increasing access to clinical trials in qualitative terms.  
Therefore, while regulating clinical trials, legislators should: in general, foster the 
prospective identification of barriers to enrollment;73 and, more specifically take into 
consideration the potential issues connected with sample size estimation, coercion, and 
under- and over-representation of minorities.  
(b) Placebo-controlled Trials and Local Standards of Care 
In the context of international clinical trials, in addition to the concerns described above, 
two practices controversially touch upon the right to health: placebo trials and local 
standards of care. For the subjects that take part in clinical trials, such practices represent 
two examples of potential trade-offs between access as quality, as they tend to correspond 
to an increase in access but also to a decrease in term of the quality (or, better, expected 
quality) of the treatment provided. They are discussed here because they can be seen as 
belonging to the discourse concerning the right to health, but they are also connected 
with the quality paradigm (both in terms of quality of care and quality of scientific 
results) and the cost paradigm (to the extent that placebo trials are deemed to be efficient). 
Furthermore, they are impregnated with ethical concerns and they represent a few of the 
issues traditionally addressed by the literature that focuses on the ethics of clinical trials.  
As a preliminary note, it should be observed that clinical trials are placebo-controlled 
when a portion of the participants in the study receive the product that is thereby tested, 
and a portion of the participants in the study receives a placebo substance.74 Placebo 
substances are designed to look like the tested product, in order to prevent participants 
understanding of which group they belong to, but are made of inert substances such as 
cellulose or lactose.75 Alternatively to placebo-controlled trials, investigators may choose 
                                                 
73 Cf. Lara Jr, Primo N., et al. “Prospective Evaluation of Cancer Clinical Trial Accrual Patterns: 
Identifying Potential Barriers to Enrollment.” Journal of Clinical Oncology 19.6 (2001): 1728-1733. 
And Gaspar, Nathalie, and Lorna Fern. “Increasing Access to Clinical Trials and Innovative Therapy 
for Teenagers and Young Adults with Cancer – A Multiple Stakeholders and Multiple Steps Process.” 
Tumors in Adolescents and Young Adults 43 (2016): 38-49. 
74 Chiodo, Gary T. et al. “Placebo-controlled trials: good science or medical neglect?” Western Journal of 
Medicine 172.4 (2000): 271. 
75 Blease, C. R., et al. “Informed Consent and Clinical Trials: Where Is the Placebo Effect?” British 
Medical Journal (Online) vol. 356 (2017). 
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to perform active-control trials, meaning trials in which the tested product is compared 
to the best available treatment.76 
The general debate surrounding placebo trials revolves around two basic questions: are 
placebo-controlled trials appropriate, i.e. ethical? And, what are the considerations and 
actions that can be put in place in order to tackle the risks connected with placebo-
controlled trials? These issues have been at the core of many contributions to clinical 
trials literature.77 This section of the chapter aims to offer an overview of the risks and 
opportunities connected with placebo-controlled trials, both in general terms and in the 
context of international trials. In doing so, it follows two of the core issues identified by 
Benjamin Freedman et al.78 – the existence of harm to subjects, and the role of the 
Declaration of Helsinki– but adds one extra element – the role of local standards of care, 
following Angell.79 In the final paragraph, some considerations connected with 
regulatory choices will be presented.  
First, it is worth acknowledging that placebo-controlled trials carry some risk of harm. 
Precedents of clinical trials – conducted both in developed economies and developing 
ones – that produced controversial effects on subjects matched with a placebo treatment 
exist. Examples of controversial uses of placebo-controlled trials include: the Tuskegee 
Study of Untreated Syphilis during which, for 40 years, patients affected by syphilis were 
observed but not administered any treatment, despite the availability of penicillin-based 
treatments and the lack of the subjects’ informed consent;80 a placebo-controlled trial of 
fluphenazine decanoate, which relied on a group of placebo-controlled patients affected 
by schizophrenia, in which 66 percent of the placebo group relapsed, compared with 8 
percent of the treatment group;81 and several clinical trials on the vertical transmission of 
human immunodeficiency virus (HIV) infection which took place in developing 
                                                 
76 Spławiński, Jacek, and Jerzy Kuźniar. “Clinical Trials: Active Control Versus Placebo – What Is 
Ethical?” Science and Engineering Ethics 10.1 (2004): 73-79. 
77 See e.g. Hill, A. Bradford. “The Continuing Unethical Use of Placebo Controls.” New England Journal 
of Medicine 331.6 (1994): 394-398.  
78 Freedman, Benjamin, et al. “Placebo Orthodoxy in Clinical Research II: Ethical, Legal, and Regulatory 
Myths.” The Journal of Law, Medicine & Ethics 24.3 (1996): 252-259.  
79 Angell, Marcia. “The Ethics of Clinical Research in the Third World.” New England Journal of Medicine 
337.12 (1997): 847-9. 
80 “U.S. Public Health Service Syphilis Study at Tuskegee.” Centers for Disease Control and Prevention, 
US Department of Health & Human Services (30 Aug. 2017) www.cdc.gov/tuskegee/timeline.htm. 
81 Freedman, et al., op. cit. 
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economies and employed placebo-treated control groups, “despite the fact that 
zidovudine has already been clearly shown to cut the rate of vertical transmission greatly 
and is now recommended in the US for all HIV-infected pregnant women.”82 These 
examples can be seen as pointing not only at the fact that placebo-controlled trials may 
carry risks for the placebo-treated patients, but also at the fact that informed consent, 
protection of vulnerable subjects, and presence of specific risks connected with 
international trials should be taken into consideration. 
Second, from the regulatory point of view, the rule of thumb applicable to placebo-
controlled trials is included in the Declaration of Helsinki.83 Article 33 of the Declaration 
of Helsinki reads:  
“[t]he benefits, risks, burdens and effectiveness of a new intervention must 
be tested against those of the best proven intervention(s), except in the 
following circumstances: Where no proven intervention exists, the use of 
placebo, or no intervention, is acceptable; or Where for compelling and 
scientifically sound methodological reasons the use of any intervention less 
effective than the best proven one, the use of placebo, or no intervention is 
necessary to determine the efficacy or safety of an intervention and the 
patients who receive any intervention less effective than the best proven one, 
placebo, or no intervention will not be subject to additional risks of serious 
or irreversible harm as a result of not receiving the best proven intervention. 
Extreme care must be taken to avoid abuse of this option.”84  
The Declaration has been object of extensive reforms in the past years, and many have 
discussed its role in the context of placebo-controlled clinical trials’ regulation.85 In a 
nutshell, the rule foreseen in the Declaration prescribes that placebo-controlled trials 
should be conducted only when no “best proven intervention(s)” i.e. treatment exists, 
with two exceptions: (a) the presence of “compelling and scientifically sound 
methodological reasons” or (b) subjects assigned to the placebo treatment, would not be 
subject to “additional risks of serious or irreversible harm.” 
                                                 
82 Angell, op. cit. 
83 World Medical Association (WMA). Declaration of Helsinki. Ethical principles for Medical Research 
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last amended in October 2013. 
84 Ibid. 
85 See e.g.  Lewis, John A., et al. “Placebo-Controlled Trials and the Declaration of Helsinki.” The Lancet 
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While the standard set by the Declaration has been considered the most relevant by many 
authors,86 Lie et al. have developed an insightful comparative study, trying to assess the 
existence and content of an “international consensus opinion.”87 According to the study, 
such consensus opinion would be based on three elements – valid science, social benefits, 
and favorable individual risk-benefit ratio – and could be seen as emerging from the 
positions taken over time by the Council for International Organization of Medical 
Sciences (CIOMS), the European Group on Ethics in Science and New Technologies 
(EGE), the National Bioethics Advisory Commission (NBAC), and the UN Program on 
HIV/AIDS (UNAIDS).88 While adjudicating between the Declaration of Helsinki and the 
“international consensus opinion” as identified by Lie et al. goes beyond the scope of this 
contribution, the two standards are worth being taken into consideration. In fact, 
especially in the context of international clinical trials, a narrow interpretation of the 
Declaration of Helsinki would seem to exclude the legality of placebo-controlled trials 
when a better standard of care would otherwise be available (even in countries in which 
such standard of care would not be the regularly available one); on the contrary, the 
reliance on ethical standards different than the Declaration’s ones could allow for the 
legitimation of international trials conducted respecting local standards of care for 
placebo-patients.  
Third, an increased vulnerability in placebo-controlled trials exists in the case of trials 
conducted in developing economies; in particular, due to the fact that in the case of those 
trials subjects may belong to communities that otherwise would have no access to any of 
the treatments available worldwide.89 As noted by Angell, those who justify the 
conducting of clinical trials in developing countries e.g. on the vertical transmission of 
HIV, as described above, do so for two reasons: first, the placebo-patients in those areas 
would not receive treatment anyway so “investigators are simply observing what would 
happen to the subjects’ infants if there were no study;”90 and second, a placebo-controlled 
study is the most efficient way to obtain results, from which also the patents’ community 
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will benefit.91 Those who, instead, express concerns for placebo-controlled studies, do so 
relying on the standard set in the abovementioned Declaration of Helsinki: as the wording 
of the declaration clearly refers to the “best standard of care” test, substituting it with the 
best locally available standard of care would merely be an exercise of ethical relativism.92  
Fourth, in clinical trials’ regulation and literature, several instruments and authors have 
attempted to clarify why and how the two positions described above should be balanced 
in practice. In general, they tend to depart from the acknowledgment that while placebo-
controlled trials – especially when taking place in developing countries – remain 
controversial, there is no univocal way of labeling them as unethical or per se illegal. For 
example:  
(a) Guideline n. 5 of the International Ethical Guidelines for Health-related Research 
Involving Humans advises host (developing) countries to take precautions in the context 
of international placebo-controlled trials.93 The two pieces of advice consist of: seeking 
expert opinion “as to whether use of placebo may lead to results that are responsive to 
the needs or priorities of the host country” and “ascertain whether arrangements have 
been made for the transition to care after research for study participants (…), including 
post-trial arrangements for implementing any positive trial results, taking into 
consideration the regulatory and health care policy framework in the country.”94  
(b) Some authors place emphasis on the efficacy of placebo-controlled trials and the 
concept of harm. According to those authors, valid scientific reasons support the use of 
placebo-controlled trials vis-à-vis active-control trials.95 Furthermore, the rule of thumb 
to be applied when deciding whether placebo-controlled trials are appropriate depends 
on the risk of harm for the participating subjects. In this context, some conclude that 
placebo-controlled trials should be deemed acceptable when patients are not absolutely 
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harmed.96 However, some suggest that best-available therapy control groups should not 
be preferred to placebo-groups as far as the risk of harm for participants is small and the 
trial “offers potential benefit to the subjects.”97 
(c) Finally, other authors place emphasis on the need for balancing of different interest 
and the concept of favorable risk-benefit ratio. In this context, clinical trials that lack an 
immediate or obvious benefit for local populations should be addressed on a case-by-
case basis.98 Furthermore, in particular, the risk-benefit ratio should be assessed “by 
comparing the net risks of the research project with the potential benefits derived from 
collaborative partnership, social value, and respect for study populations.”99 
To conclude, the right to health meets the technical and regulatory aspects of clinical 
trials in many connection points, including within the debate over ethical and legal 
standards to be applied to placebo-controlled trials. In this context, legislators should take 
into consideration at least three challenging aspects: the existence of harm to subjects, 
the role of international guidelines and ethical standards such as the Declaration of 
Helsinki, and the dichotomy between the “best standard” rule and the “local standards” 
option. As of their regulatory options, binding rules at the international level could be 
introduced to ensure that: a clear standard to assess when placebo-controlled trials should 
be deemed appropriate is established and corollary rules to guarantee the protection of 
the clinical trials subjects’ interest in their right to health.  
III. Right to Information 
The second set of concerns related to the protection of human subjects in clinical trials 
belongs to the right to information discourse. Therefore, the following sections will 
provide the reader with, first, some introductory remarks concerning the right to 
information in the healthcare context, in general; and second, with some a discussion of 
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the most relevant issues connected with the right to information in the clinical trials 
context.  
(1) Right to Information: Introductory Notions 
In the context of healthcare law and policy, the right to information can be seen as 
touching upon two main issues: the rules to be applied to the information that concerns 
individuals and that is entered in the system (e.g. medical records) and the rules to be 
applied to the information that is transmitted by the system to the patient (e.g. informed 
consent). Furthermore, there is a general understanding within healthcare law and policy 
literature that regulatory decisions taken concerning the field of right to information 
entail an exercise in balancing two interests: the benefit in terms of public health, and the 
autonomy of the patient.100 The balancing exercise becomes clear in practical terms when 
one – following Gostin et al. – puts, for example, at one end of the spectrum interests 
such at the social good of the collection of health data, and at the other end, the individual 
good of privacy protection.101 
First, with regard to the treatment to be reserved to the information that regards 
individuals and is entered into the system, healthcare literature expresses two recurring 
concerns: one for data management regulations, and another for the scope of publicity of 
healthcare data.102 In a nutshell, the first concern is related to the measures to be 
implemented in order for private patients’ information to remain private, while the 
second concern is associated with the balancing of privacy interests with the general 
public interest in access to patients’ information e.g. in the context of communicable 
diseases’ control. Second, with regard to the rules to be applied to the information that is 
transmitted by the system to the patient, the main concern revolves around the nature and 
scope of the notion and the practical operation of informed consent.103 Within the 
discussion of informed consent, following Faden and Beauchamp, it is not uncommon to 
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adopt either a pragmatic-legal approach – where the focus lies on the duty of the 
physician to ask for the patients’ consent and the consequent liability – or a philosophic-
moral approach – where the focus is on the patients’ right to make autonomous 
choices.104 
Both in the context of access to medical records and informed consent, many 
contributions have attempted to list and balance the interests involved. Interests that 
swing the balance towards an increased publicity of healthcare-related information touch 
upon patients’ autonomy and self-determination, as well as on the general public interest 
in health services research and public health.105 Contributors that advocate for an increase 
in the access to information also claim that it is connected with an increased productivity 
on the part of healthcare providers, a low error rate, an increased quality of care, an 
increased level of trust in the doctor-patient relationship, increased positive competition 
among healthcare providers, and an improvement in terms of public participation in 
healthcare policy decisions.106 On the other hand, some have noted how increasing the 
access to information in healthcare would result in adverse effects on the protection of 
privacy interests and an increment in costs (especially those related to compliance).107 
While presenting a possible interpretation of the balancing exercise between those 
interests and concerns in the general context of healthcare law and policy goes beyond 
the scope of this contribution, it is nevertheless important to take note of those elements, 
as they can also be found in the field of clinical trials. 
(2) Right to Information in the Context of Clinical Trials 
The following paragraphs of this section will discuss how the interests of stakeholders in 
clinical trials interact in the context of two core regulatory issues related to the right to 
information in healthcare: the publicity of data and the nature and scope of informed 
consent. While the issue of publicity of data can be seen as intrinsically connected with 
the role, creation, and implementation of clinical trial registries (which will be addressed 
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later in this thesis – within Chapter Six), the section dedicated to informed consent will 
address both the issue of the practical collection of the informed consent and that of 
organizing a fair and transparent recruitment process (and will be presented in the 
following paragraphs, within this chapter).  
(a) Clinical Trials Registries 
Clinical trials registries are databases of privately- and publicly-funded clinical studies 
conducted within single countries or worldwide. Understanding their rationale, history, 
and functioning is particularly interesting in the context of this thesis. Therefore, Chapter 
Six in this thesis is entirely dedicated to an analysis of clinical trials registries. 
(b) Informed Consent 
At the time of writing, the latest wave of debate over informed consent in clinical research 
is hitting the US, partially due to the new-found popularity of the story of Henrietta 
Lacks. A sample tissue taken from Ms. Lacks, a young black woman, in 1951 – was used 
to create the first immortal human cell line and, as of today, is still pervasively used in 
laboratories over the world.108 The story of Henrietta Lacks raised several questions 
regarding the right of information in clinical research and several contributors have 
touched on it to address issues related to informed consent, commercialization and 
compensation, privacy and confidentiality, race, poverty, and health disparities, familial 
implications of genetic information, and trust in biomedical research.109 Despite the fact 
that her contacts with clinical research did not directly concern clinical trials, the 
considerations applicable to it tend to be easily transferable to the context of clinical 
trials.  
In the context of clinical trials regulation, informed consent is one of the pivotal elements 
that need to be addressed. Patients’ participation in clinical trials should be informed and 
voluntary.110 Therefore, for the purpose of this section, the issue will be divided into two 
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sub-topics: first, the concerns that specifically touch upon the collection and 
understanding of the agreement that conveys participants’ informed consent. Second, the 
concerns that apply to voluntariness (particularly in the phase of recruitment). They 
regard not only the tailoring of the sample and the underrepresentation of certain portions 
of the population but also – and more specifically – the issues emerging from the risk of 
coercion and the role of remuneration in clinical trials. 
(i) Informed Consent Per Se 
First, as noted by Beauchamp and Childress, informed consent in the context of clinical 
research can be seen as a process that encompasses five steps.111 Lavori et al. summarized 
the steps as follows:  
“1. Assessing the decision-making capacity or competence of the prospective 
research volunteer. 2. Disclosing relevant information about the proposed 
research. 3. Ensuring that the prospective volunteer understands the 
information. 4. Ensuring that the prospective volunteer be positioned to make 
a voluntary choice. 5. Authorizing a decision by the prospective volunteer 
and, if affirmative, having him or her sign a consent form.”112  
In a nutshell, the goal of informed consent is to inform the patient about the 
treatment/procedure, to present benefits, risks, and alternative treatments/procedures 
with the intent of allowing him or her to make an autonomous decision.113  
Second, reliance on those steps and the prevalence of the idea that informed consent 
represents both a right for patients and a duty for investigators is a modern 
phenomenon.114 In the 1980s and 1990s, research conducted by Taylor et al. and 
Williams and Zwitter, highlighted both concerns expressed by physicians and the results 
of those concerns in practical terms (in European countries).115 The main concerns of 
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physicians related to their role – when they considered their definition of the medical 
profession as incompatible with the regulation of informed consent –, their autonomy – 
when they perceived informed consent as a loss of their own – and their relationship with 
patients.116 The practical result of those concerns was a low rate of use of written consent, 
the use of information without authorization, a high rate of reliance on verbal consent 
only, and in cases in which the consent was sought and obtained, a tendency not to share 
all potentially relevant information.117 Nowadays, a shift can be observed from the focus 
on the concerns expressed by physicians to the focus on patient protection.118 
Consistently, in many contexts, detailed informed consent procedures and information 
constitute integral tenets of the process of approval of clinical trials.119 Nevertheless, it 
is worth noting that physicians’ concerns regarding the goal of advancing medical 
knowledge still exist,120 that physicians still experience difficulties in conciliating their 
role of caring professional and that of experimenter,121 and that there are de facto means 
for obtaining informed consent that discourage participation more than others.122 
Therefore, it is important to note that regulating informed consent entails an exercise in 
balancing the need to provide patients with information to preserve their autonomy and 
the need to balance physicians’ concerns that touch upon the possible effects of informed 
consent collection procedures on the recruitment rate.123 
Third, there are recurring issues that affect the practical result of informed consent. 
Scholars consistently attempt to provide solutions to those issues, in order to allow 
legislators to better structure their informed consent regulation in clinical trials. Among 
the main issues often identified in literature, are the three discussed by Brown et al.: (i) 
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the risk of patients that do not understand the rationale for trials, (ii) the risk of patients 
poorly recalling the information obtained, and (iii) physiological and psychological 
impairing patients from making an informed decision.124 Brown’s findings are consistent 
with other contributions, such as that of Joffe et al., who found that while 90% of the 
participants in their study considered themselves well informed, 63% did actually not 
recognize the potential for incremental risk from participation and 70% did not recognize 
the unproven nature of the treatment.125 Many studies have tested means to obtain 
informed consent in order to assess whether some increase the quality of patients’ 
understanding – when possible, without decreasing the chances of recruitment. For 
example, despite the widespread idea that the use of multimedia and enhanced consent 
forms (e.g. condensing their length, revising content or form to make them more 
readable, adding graphics, etc.) may contribute to a better understanding on the side of 
patients, empirical research has established that they do not correspond to any 
improvement. Instead, it is useful to note that increased knowledge in patients is 
associated with: the introduction of a neutral educator to talk one-to-one to 
participants,126 not signing the consent form at the initial discussion, the presence of a 
nurse, and the careful reading of the consent form.127  
Fourth, in the case of international clinical trials, especially if conducted in developing 
economies, specific concerns arise in addition to those listed above. Concerns are 
connected, first, with the difference in the effectiveness of informed consent procedures 
between clinical trials that take place in developed and developing economies and, 
second, with the specific challenges that emerge for clinical trials conducted in 
developing economies.  
With regard to the first category of concerns, for example, Marshall et al. observed the 
differences between pools of participants who took part in clinical trials respectively in 
the US and in Nigeria.128 99% of respondents in the US but only 72% of Nigerian 
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respondents reported being told the study purpose. 97% of participants in the US reported 
that they could withdraw, compared with only 67% in Nigeria.129  
With regard to the second category of concerns, Hyder and Wali, following their study 
on the practical approaches used by researchers in developing economies, found that 66% 
of them considered the informed consent process to be too focused on the individual 
rather than the family/community and in 35% of cases local staff shortened or simplified 
the informed consent procedure compared with the original protocol.130 Interestingly, 
their study also showed that only 50% of researchers the participants in their clinical 
trials understood the concept of placebo and that only 84% of researchers participants 
were usually aware that they were in a research study.131  
The goal, in those contexts, is not only that of obtaining truly informed consent but also 
of obtaining “culturally relevant” consent.132 Bhutta compiled a useful list of “areas of 
disagreement” in which merely exporting standards and concerns arose in developed 
economies may not be in the best interest of clinical trials participants’ in other countries. 
In particular, those areas regard: (i) the focus on written consent which is traditionally 
used in developed economies but may not represent a guarantee of protection of 
participants’ interests in other areas of the world; (ii) the complex language used in 
written documentation, the length of consent forms, the alternative means to be used in 
case of illiterate populations; and (iii) the role of consent in traditional societies 
(communal, familiar, and/or individual).133 Consistently, Marshall noted pointed out that 
“[s]ociocultural influences on comprehension of information, perceptions of risk, and 
beliefs regarding decisional authority” are to be considered when approaching the issue 
of informed consent in international clinical trials.134  
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Stakeholders willing to express an opinion on the regulation of international clinical trials 
should take into consideration the concerns derived from these data. Possible strategies 
to address such issues entail using innovative materials and processes, using alternative 
processes for documentation, and involving senior staff and communication express in 
the obtainment of informed consent.135 More specific suggestions regard the goal of 
tailoring informed consent to the sex and developmental age of participants as well as 
using local languages and involving community leaders and local cultural representatives 
in the process.136  
 
(ii) The Issue of Payment in the Recruitment Process 
Recruitment represents one of the pivotal moments in any clinical research study. In 
general terms, it can be defined as the “dialogue which takes place between an 
investigator and a potential participant prior to the initiation of the consent process.”137 
The recruitment-phase entails two goals: recruiting a sample that adequately represents 
the target population and recruiting a sufficient number of participants to meet the 
targeted sample size.138 The main concerns that arise in connection with recruitment tend 
to focus on the role of payment of clinical trials subjects.139 When assessing the ethical 
appropriateness, effectiveness, and legality of payment policies in clinical trials, practice 
varies significantly.  
First, in general, investigators and sponsors are divided. Some see the use of payment in 
clinical trials as “wrong” and coercive per se, some see it as a potentially effective tool.140 
On the one hand, concerns often focus on the potential risk of coercion, undue 
inducement, a disproportionate burden on participants with financial problems, and 
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commodification.141 The challenge with assessing such risks is often dependent upon 
subjective factors. On the other hand, supporters of the use of payment highlight the value 
that it may have in encouraging participation and promoting the goal of achieving ethnic 
and gender diversity within the sample of participants.142 They also see payment as “an 
indication of respect for the time and contribution that research subjects make.”143 The 
complexity of the issue increases in the case of clinical trials involving children, where 
the need to obtain consent from parents and the challenge of structuring payment as a 
“token gesture of appreciation” represent pervasive concerns.144 
Second, in practical terms, it is unclear how common the practice of economically 
rewarding participants is. Grady noted that there is some variation depending on medical 
subspecialties.145 Furthermore, data are hard to collect, given that few organizations have 
written policies on payment and review boards often decide with little specific 
guidance.146 Practice also varies, as to how investigators and sponsors decide to present 
payment to research subjects: in some cases payment serves as an incentive, in some as 
compensation (i.e. wage-payment), in some as reimbursement and in some as a sign of 
appreciation (i.e. “mere” reward).147  
Third, while there seems to be no clear-cut ethical rule allowing or prohibiting reliance 
on payments in order to incentivize recruitment, it may be relevant to list some of the 
potential strategies implementable to avoid the risk of coercion and undue inducement. 
Concerns may be addressed by (i) carefully tailoring eligibility criteria,148 (ii) 
establishing mechanisms to calculate payments on the basis of criteria e.g. the level of 
risk entailed in the study,149 and also (iii) addressing via full disclosure the potential 
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conflicts of interest posed not only by the remuneration of participants but by the 
remuneration of medical personnel for patient recruitment.150  
To conclude, relevant concerns exist and apply both during the recruitment-phase and at 
the moment of the collection of informed consent. Being aware of such issues and of the 
different interests involved in their solution is important for any legislator wishing to 
structure a clinical trials regulation.  
IV. Preliminary Conclusions 
To conclude, with regard to the right to information – whether seen as an autonomous 
right in the healthcare context or as sub-stratum of the general right to health –, it can be 
noted that it represents a relevant lens through which the regulation of clinical trials can 
be observed and promoted. In the specific context of clinical trials, risk and opportunities 
related to the right of information can be analyzed studying the evolution of clinical trials 
registries as well as the issue of informed consent. In both contexts, different stakeholders 
have sometimes aligned and sometimes competing interests. Nevertheless, legislators can 
rely on a wide range of inputs produced by different stakeholders, both to identify issues 
to be regulated and ways in which effectively address them.  
At the same time, while the status of the definition, scope, and binding nature of the right 
to health in international law remain controversial, its role in the framework of clinical 
trials regulation raises several practical issues. In particular, relevant challenges emerge 
in the context of sampling and tailoring goals and techniques as well as in the context of 
placebo trials and standards of care. While prospective legislators should not 
underestimate those issues, either at the national or international level, they confirm to a 
certain extent the need for a global perspective on clinical trials regulation. In fact, while 
some challenges to the right to health in the context of clinical trials can be effectively 
regulated at the national level e.g. the issue of sample sizing, other depend on the 
international dimension of contemporary clinical trials e.g. the relevance of standards of 
care in placebo-controlled trials and can therefore be better addressed at the international 
level. 
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CHAPTER THREE: COMPETING PARADIGMS IN CLINICAL TRIALS POLICY 
AND REGULATION 
 
I. Introduction 
As noted by Gostin et al., studying the law and the health system requires acknowledging 
that three pulling and pushing forces need to be balanced: the pursuit of access, cost, and 
quality.151 They can be seen as competing paradigms and as shadows under which the – 
often competing – interests of the stakeholders involved in clinical trials meet. Instead, 
their definition will tend to vary on the basis of the stakeholder entrusted with the role of 
defining them.  
With regard to the three competing paradigms, in the general context of healthcare 
regulation, it can be noted that the paradigm of access concerns both the access of 
healthcare users (patients) to treatment and the access of healthcare providers (primarily 
physicians but – in privatized healthcare systems – also intermediaries such as 
insurances) to the healthcare market; the paradigm of quality chiefly concerns the level 
of quality of the care provided; and the paradigm of costs mainly concerns the quality 
and quantity of healthcare costs – where “quality” pertains to the choice of level of public 
intervention in healthcare expenditure and “quantity” pertains the sheer economic cost of 
treatments. Tradeoffs between those concepts are inevitable when attempting to regulate 
healthcare systems.152 In fact, regulatory interventions affecting any of those paradigms 
will likely produce results on one or more of the others. For example, expanding the pool 
of subjects with access to free healthcare will increase the pressure on the societal cost 
of healthcare.153  
In the context of clinical trials, as will be shown later in this contribution, access, cost, 
and quality cannot be univocally defined, but one of the aims of this contribution is to 
provide for an application of such paradigms to the study of clinical trials regulation. 
Given that the three paradigms are no more than a means of reading the interests and 
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concerns of the stakeholders involved in clinical trials, each section of this chapter will 
provide the reader with an analysis of the three paradigms specifically focused on the 
characteristics that they assume in the face of those interests and concerns. This activity 
will shed some light on what those paradigms mean for the different stakeholders 
involved in clinical trials regulation.  
As for the relevant stakeholders, within clinical trials literature, there is no uniform 
identification of their definition and identity. However, broad interpretations of the 
concept encompass the following categories among the stakeholders: participants in 
clinical trials, funders and sponsors of trials, regulatory agencies, investigators, research 
institutions and universities, journals, and professional societies.154 On the one hand, this 
contribution departs from such a broad categorization of clinical trials’ stakeholders and 
narrows its perspective, focusing on three of them. The focus on three stakeholders is a 
result of two considerations: first, journals, investigators, research institutions, and 
professional societies can all be seen as falling within a broadened definition of 
investigators – a definition that focuses on seeing all of them as members of the scientific 
community. Second, in our opinion, encompassing regulatory agencies among the 
stakeholders risks portraying them as one of the parties interested in the regulation of 
clinical trials. On the contrary, regulatory agencies, as well as any institutional player, 
should not be seen as one of the weights in the balancing activity but as the weight scale 
entrusted with the role of conducting such balancing activity. On the other hand, this 
contribution marginally expands the definition of human subjects, pairing the focus on 
participants in clinical trials with that on patients. The latter category encompasses both 
the pool of subjects potentially interested in becoming participants in clinical trials and 
those who will potentially consume the products that obtained approval for use and 
commercialization following successful clinical trials.  
Therefore, the next paragraphs will focus on human subjects, sponsors, and investigators 
as stakeholders. In this context, as noted above, human subjects encompass clinical trials 
participants, perspective participants, and consumers of post-clinical trials marketed 
products. Sponsors encompass all the subjects that are involved in commissioning and 
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funding clinical trials, both when they belong to the pharmaceutical industry and when 
they constitute public and nonprofit organizations. Investigators primarily encompass the 
clinicians involved in any stage of clinical trials; subjects that belong to this category are 
both the designers of clinical trials, the infrastructures (study-sites) and the professionals 
involved in the administration of the protocol created for the clinical trial (e.g. the 
physicians and nurses that will follow participants during the clinical trial), the secondary 
users that rely on clinical trial data for purposes different than the original one, the 
professional organizations that represent those professionals, and the scientific journals 
that publish the results of clinical trials.  
To conclude, this chapter aims at describing what the paradigms of quality, cost, and 
access represent in the context of clinical trials regulation. For the purpose of this chapter, 
human subjects, sponsors, and investigators, will be considered as the relevant 
stakeholders. 
II. The Paradigm of Access 
Within the paradigm of access, different stakeholders manifest different – sometimes 
competing – interests.  
First, the interest in access for human subjects is a double-folded one.  
On the one hand, the patients interested in taking part in clinical trials have an interest in 
open and transparent recruitment practices.155 In general terms, this translates as an 
interest in recruitment standards that impose a prospective rigid identification of the 
recruitment criteria.156 In more specific terms, for example, patients that belong to a 
population that has traditionally been more challenging to recruit and underrepresented 
in clinical trials have an interest in policies implemented to increase their access to 
clinical trials.157 Those policies in principle would be capable of inducing positive results 
                                                 
155 Gelinas, Luke, et al. “When Clinical Trials Compete: Prioritising Study Recruitment.” Journal Of 
Medical Ethics (2017): medethics-2016. 
156 Lovato, Laura C., et al. “Recruitment for Controlled Clinical Trials: Literature Summary And Annotated 
Bibliography.” Controlled Clinical Trials 18.4 (1997): 328-352. And Hunninghake, Donald B., et al. 
“Recruitment Experience in Clinical Trials: Literature Summary and Annotated Bibliography.” 
Controlled Clinical Trials 8.4 (1987): 6-30. 
157 Ford, Jean G., et al. “Barriers to recruiting underrepresented populations to cancer clinical trials: a 
systematic review.” Cancer 112.2 (2008): 228-242. And Murthy, Vivek H., et al. “Participation in 
cancer clinical trials: race, sex-, and age-based disparities.” Journal of the American Medical 
Association 291.22 (2004): 2720-2726. 
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at the level of the quality of outcome of the clinical trials. Therefore, they represent an 
interest in which increased access (in qualitative terms) may translate into increased 
quality of the output. However, this reaction would also entail higher costs, given that 
measures to increase the recruitment of traditionally underrepresented populations would 
require higher investments in pre-recruitment advertisement and in compensation to 
participants.  
On the other hand, participants in clinical trials – both prospectively and retrospectively 
– as well as the general public (prospective consumers) have an interest in access to 
information and data pertaining to clinical trials. The interest in the availability of such 
information has a value both in the context of the informed decision that prospective 
clinical trial participants must take before enrolling in a trial and in the context of the 
informed decision that prospective consumers can take.158 On this issue, a partial 
alignment can be observed between the participants’ interest and the investigators’ 
interest, to the extent that transparency in clinical trials registration can be seen as a tool 
to reward participants’ trust and altruism and guarantee that communities will repeatedly 
commit to voluntarily participate in clinical research.159 However, the possibility of 
misalignment exists in situations in which clinicians have observed the risk of a 
decreased enrollment rate proportional to the increase in the amount of information 
provided to prospective participants.160 Also, among pulling factors in the context to 
access to information, the concerns of sponsors for the costs of divulging potentially 
valuable data can be observed, together with the interest of participants in the protection 
of personal and private sensitive data.161  
                                                 
 
158 Flory and Emanuel, op. cit. 
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C., et al., op. cit. 
161 The Pharma Letter. “Concern Over US FDA Disclosure Plans.” TPL, 
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Second, the interest of investigators in access has two concrete contexts of application. 
The first is the access to information and data mentioned above. The first regulatory battle 
fought in this field has been one for mandatory trial registration. Within it, the interests 
of the general public and of scientific investigators have traditionally been aligned, to the 
point that it is following a decision of the International Committee of Medical Journal 
Editors (which mandated prospective registration of the clinical trials aiming at being 
published) that registration rates have steeply increased.162 Access to information, from 
the perspective of investigators, has both the advantage of fostering a better relationship 
with prospective participants in the trial and the advantage of preventing the risks 
associated with selective publication.163 It also increases the potential for the conduction 
of secondary investigations, based on meta-data obtained by the primary ones.164  
The second category of access-related concerns for investigators regards the access to 
sponsors and to the  system of credentials, when one is in place.165 In many legal systems, 
access to the role of investigators is limited by the rate at which funding is available (both 
in the public system and in the private market), as well as by barriers to entry to the 
investigators’ “market”, e.g. minimum training requirements, accreditation 
infrastructures, etc. Such barriers, as with any traditional compliance tool, are correlated 
with a general interest in guaranteeing a good quality of clinical trials, but have an effect 
on their cost. Therefore, in this context, the investigators’ concerns are often aligned with 
those of the sponsors. 
Third, as stated above, sponsors share some of the investigators’ concerns with regard to 
barriers to access and compliance.  
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At the same time, certain concerns are unique to the sponsors. This is the case for 
disclosure-related concerns that apply to information and data-sharing policies. In that 
context, sponsors – specifically, pharmaceutical companies that promote and organize 
clinical trials – tend to be reluctant to support and implement measures that will 
incentivize the disclosure of information garnered via clinical trials. Their position seems 
to emerge from the combination of three sub-concerns. The first relates to the protection 
of trade secrets – to the extent that information pertaining to their clinical trials is 
produced at a cost, and its divulgation may result in other sponsors taking advantage of 
it;166 the second is related to any liability derived from breaches of the participants’ right 
to privacy;167 while the third relates to the potential negative effects on the company’s 
reputation from any publicity regarding clinical trials that produce negative results.168 
Intuitively, a reduction in efforts to expand access e.g. to information garnered from 
clinical trials would lower the economic burden of compliance on sponsors and therefore 
result in lower costs, but this could negatively affect both the interests of investigators 
and human subjects to access as well as the paradigm of quality (to the extent that 
transparency is considered to produce positive effects on the quality, especially with 
regard to the safety of the results). 
To conclude, the paradigm of access is a relevant one in clinical trials regulation and 
policy, and can assume different shapes, depending on the stakeholder in question. In 
some cases, stakeholders have aligned interests and concerns, while in others, their 
positions diverge. Nevertheless, policies that aim at expanding or restricting the influence 
of the paradigm of access or clinical trials regulations will produce results – be they 
negative or positive – on the competing paradigms of cost and quality.  
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III. The Paradigm of Cost 
Similarly to what was observed above with regard to the paradigm of access, the 
paradigm of cost can be seen as a field of interaction of the three stakeholders’ interests 
and concerns. 
The paradigm of cost, for human subjects interested in clinical trials, encompasses two 
categories of costs. First, the cost of participation for patients involved in clinical trials.169 
This cost can be seen as the combination of direct and indirect expenses. Although some 
legal systems prevent sponsors from transferring these costs onto participants in clinical 
trials, direct expenses relate to the products that participants purchase in order to 
participate in clinical trials e.g. auxiliary medicinal products and medical devices used 
for the administration of the primary treatment. Indirect expenses may relate both to 
material indirect costs – e.g. travel expenses to reach the clinical trials site – and 
psychological costs, connected with the fact that taking part in trials is often an action 
dictated by trust in and altruism towards scientific progress. Often, sponsors implement 
financial mechanisms to reward participants for taking part in clinical trials;170 this can 
be seen as an example of how, within the same paradigm, namely the paradigm of cost, 
the burden can actually be transferred from one subject to another.  
The second cost of clinical trials falls on the general public, i.e. taxpayers. This cost can 
be seen as a function of both the public investment in medical research and development 
spent in publicly funded clinical trials and in the public investment in compliance 
measures such as inspections and auditing involving sponsors and investigators.171  
In the case of investigators, the paradigm of cost has mainly to do with the costs of 
compliance e.g. with accreditation and credentialing procedures. As noted above, 
restrictions to access to the cadre of investigators are dictated by quality- and safety-
related concerns, but result in an increase in terms of costs. Sponsors share similar 
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concerns, as they are often responsible for the compliance of the investigators that they 
hire with clinical trials regulation.172  
In the case of sponsors, in addition to the costs of compliance that simultaneously affect 
sponsors and investigators, the former often have to deal with the direct organizational 
and material costs of clinical trials.173 These costs can be seen as a combination of the 
costs related to the materials necessary for the clinical trial (the treatment studied in the 
trial, auxiliary treatments, and administering tools), the costs for the recruitment of 
participants in clinical trials, and the costs for the investigation-personnel (medical and 
administrative) and facilities.  
In sum, the paradigm of cost remains a relevant one in the context of clinical trials, and 
is connected with the actions and preferences of all three stakeholders. Actions taken to 
affect the paradigm of cost will often produce effects on the other two competing 
paradigms.  
IV. The Paradigm of Quality 
Finally, clinical trial dynamics often deal with the paradigm of quality. As in the case of 
the other paradigms, quality can have different meanings and focuses depending on the 
interested stakeholder.  
Human subjects have a specific interest in two aspects of quality. First, the quality of 
clinical trials in terms of safety of the process that they entail. Prospective participants 
and patients who take part in clinical trials value rights that, when expanded, have an 
effect on the paradigm of quality. Amongst those rights, the right to informed consent, 
that to withdrawal from clinical trials, and the right to post-trial treatment may be 
identified.174 Informed consent mainly relates to the need for patients to make an 
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informed decision at the recruitment stage. While participants have an interest in this 
value, investigators and sponsors often advocate for simplified procedures because 
complex informed consent procedures have effects on the cost of recruitment and on the 
access – in terms of enrollment rate – to participants. 
Second, the paradigm of quality intersects with the interests of human subjects in terms 
of the outcome of the process, namely, with regard to the quality of the treatment that is 
approved for administration and commercialization following the positive conclusion of 
a clinical trial.175 In principle, clinical trials conducted in compliance with the highest 
quality standards of design and administration produce better results, and better results 
can contribute to the commercialization of more effective products. However, increases 
in terms of quality may be correlated with increased compliance cost and may eventually 
result in less clinical trials being conducted therefore causing reduced access to the latter 
or reduced outputs in terms of commercialized products. 
Investigators share with human subjects the common interest in the quality of the output 
of clinical trials.176 For the scientific community, in particular, the results of high-quality 
trials, i.e. those that are derived through scrupulous scientific methodologies and absent 
any procedural biases and data falsification, represent a stronger contribution to the 
advancement of scientific innovation. Even trials with negative results, in this sense, have 
the potential to positively influence further research.177 Related the general goal of 
producing and receiving results of a high quality, are certain sub-interests of 
investigators, such as an interest in the quality of the materials and facilities to which 
they have access. as well as an interest in the quality of the pool of prospective 
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participants to which they have access (in terms of correspondence with the ideal subjects 
on which the treatment ought to be tested). 
Finally, sponsors can be seen as having their main quality-related interest in the quality 
of the outcome of the clinical trials. Considering that the sponsor is often the subject that 
has a direct interest in the profits deriving from the approval of any tested treatment – be 
they “social” profits when the clinical trial is publicly funded or sheer financial profits 
when the treatment tested is approved for commercialization on the market. The case for 
absolute quality – and thus, safety – of the outcome of clinical trials is a strong one as, in 
principle, any stakeholder and legislator share an interest in introducing only safe and 
effective products to the market.  
To conclude, the paradigm of quality is pivotal in the context of clinical trials. However, 
in this context, it is important to observe that even the promotion of absolute values is 
influenced by competing paradigms and triggers different dynamics of which legislators 
should be aware. For example, in any system that decides to exclusively and absolutely 
focus on the paradigm of quality (namely, on the quality of the products commercialized 
following successful clinical trials), the effects of the cost paradigm will materialize, 
making it more expensive for investigators and sponsors to conduct clinical trials; this 
may result in investors pulling out of the clinical trials market or, in any event, on fewer 
clinical trials being promoted and conducted. 
V. The Three Paradigms and Clinical Trials gone Global  
The considerations presented thus far in this contribution aim at providing prospective 
reformers and legislators with some insights on the dynamics of clinical trials regulation. 
They stand independently from which institutional standpoint they are observed – being 
it that of a national legislator or an international organization. Nevertheless, it is worth 
noting that the existence of the three pulling-and-pushing paradigms and the interaction 
of the three relevant stakeholders may also be used to better understand clinical trials 
dynamics – and especially – in a moment in which clinical trials have become a global 
phenomenon.  
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The past decades have been characterized by a globalization of clinical trials.178 The latter 
is the result of the “increased geographic dispersion of drug development operations.” In 
practical terms, it results in sponsors – more often than not based in developed economies 
– commissioning clinical trials in centers based in developing economies.179 Although 
the phenomenon should not be confused with the tendency to conduct multi-centered 
clinical trials, global trials often involve research centers based in more than one 
country.180 This trend has pushed both legislators and commentators to act and participate 
in the dialogue over the risks and opportunities of global clinical trials. Legislators have 
focused on regulatory challenges, such as those related to overseas inspections and 
credentialing;181 commentators often analyze the scientific and ethical issues that can be 
raised when observing the globalization of clinical trials.182  
In this context, this contribution does not aim at identifying the risks and opportunities 
connected with the globalization of clinical trials, or at suggesting possible solutions to 
the main regulatory challenges that they pose. Instead, it encompasses among its purposes 
that of suggesting how the three-paradigm model can also be applied in the context of 
global clinical trials. 
The first way in which the model becomes relevant is explanation. This, in the context 
of global clinical trials, concerns more specifically the action of national and macro-
regional policymakers and legislators. In particular, the tendency of clinical trials to go 
global may be seen as a “relief valve” for situations in which the three paradigms are out 
of balance and excessive pressure is exercised on one of them. For example, two of the 
main pushing forces that move sponsors to run clinical trials in developing economies 
are the difficulty in recruiting patients in developed economies and general economic 
advantages (in terms of the sheer cost of clinical care and operational compliance-related 
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costs).183 The first factor can be seen as a function of the interest of investigators in data 
garnered from clinical trials; the second can be seen as a function of the interest of 
sponsors in cost-reduction. In a global context in which running clinical trials in 
developed economies represents an available option, understanding that when 
stakeholders perceive excessive pressure placed on one of the paradigms, they may 
choose to outsource clinical trials abroad, is an important notion for legislators based in 
developed economies.  
The second way in which the three paradigms can be used in the context of global clinical 
trials is application. In fact, the three paradigms exist and represent pulling and pushing 
forces, also in the dynamic of global clinical trials. Understanding them – and the fact 
that they also exist at the global level – may serve international organizations interested 
in clinical trials regulation to better plan and structure their action. In this sense, the 
existence of the three competing paradigms and the shape that they take in the globalized 
industry of clinical trials is something of which international institutional actors should 
be aware.  
 
VI. Preliminary Conclusions 
To conclude, the paradigms of access, cost, and quality identified by Gostin et. al 
represent a useful tool to understand the background of clinical trials policy and 
legislation.  
Table 1 provides an overview of the main interests and concerns that are relevant in this 
context.  
 
Table 1 
Competing Paradigms in clinical Trials Policy and Regulation 
  Access Cost Quality 
Human 
Subjects 
(1) Access of 
participants to clinical 
trials  
(1) Cost of participation  (1) Safety of clinical 
trials 
    
                                                 
183 Ayalew, op. cit. 
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(2) Public access to 
clinical trials data  
(2) Cost of compliance (2) Safety and 
effectiveness of the 
clinical trials’ outcome 
Investigators 
(1) To sponsors and to 
credentialing systems 
(when existing) 
(1) Costs of compliance (1) Of clinical trials 
data 
  
(2) To clinical trials 
data 
(2) Safety and 
effectiveness of the 
clinical trials’ outcome 
Sponsors 
(1) To sponsors and to 
credentialing systems 
(when existing) 
(1) Costs of clinical 
trials per se 
(1) Of clinical trials 
data 
   
(2) Disclosure-related 
concerns  
(2) Costs of compliance (2) Safety and 
effectiveness of the 
clinical trials’ outcome 
 
Understanding how pulling and pushing on each of those competing paradigms will 
produce effects on the other two paradigms is an essential exercise that legislators should 
use, in order to better predict the results of clinical trials regulations and reforms. 
Furthermore, analyzing the way in which each stakeholder – human subjects, 
investigators, and sponsors – develops specific concerns and interests within each 
paradigm provides us with a better understanding of the dynamics of clinical trials, both 
at local and at international-global levels. Finally, the three paradigms can be used not 
only to better appreciate global clinical trials dynamics but also to better understand how 
the development of a global dimension of clinical trials represents a “relief valve” when 
the three paradigms are unbalanced at the local level.  
This chapter aimed at providing an original taxonomy of the major clinical trials’ 
stakeholders and at reading them in the light of the competing interests of access, cost, 
and quality.  
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CHAPTER FOUR: CLINICAL TRIALS ETHICS IN CONTEXT 
 
I. Introduction 
Clinical trials raise several ethical concerns.184 Those concerns become more intense in 
the case of global clinical trials.185 While many within the scientific and legal literature 
have contributed to defining and testing the ethical rules that are relevant in the field of 
clinical trials, this contribution follows the seven ethical principles identified by Emanuel 
et al. in the renowned contribution “What makes clinical research in developing countries 
ethical? The benchmarks of ethical research.”186 In particular, the eight ethical principles 
identified in the latter are the following: collaborative partnership, social value, scientific 
validity, fair selection of study population, favorable risk-benefit ration, independent 
review, informed consent, and respect for recruited participants and study 
communities.187  
The next sections of this chapter will aim at (i) presenting concrete legal formulations in 
which the eight ethical principles could be “translated” and implemented into normative 
documents; (ii) when possible and appropriate, presenting examples of specific projects 
that follow (or are coherent with) the eight ethical principles; and (iii) expand the eight 
ethical principles suggesting how their “agenda” could be completed by the addition of 
an eight principle.  
II. Legal Formulas and Examples 
The seven ethical principles identified by Emanuel et al. have the advantage of being 
comprehensive and concise. However, the article that introduced them does not provide 
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for concrete indications as to how to translate them into specific legal provisions. For 
example, the principle of informed consent is acknowledged and affirmed but “only” four 
benchmarks – described as “practical measures” by the authors – are presented to the 
reader as explanatory tools; the four benchmarks suggest “involv[ing] the community in 
establishing recruitment procedures,” utilize “culturally appropriate” formats, etc. The 
same explanatory mechanism based on principles and benchmarks is used for the other 
six ethical principles.  
However, the benchmarks are numerous (31 in total) and are expected to be balanced in 
a “process that requires judgment.”188 This mechanism risks putting legislators in front 
of a balancing exercise that they may not be willing to conduct, and leaves them without 
a practical suggestion as to how to concretely implement such principles.   
Therefore, the following paragraphs will try to present potential concrete formulations 
that legislators willing to fully implement the seven ethical principles could rely on. Some 
of the formulations are autonomously developed, while some are modeled on the basis 
of the findings of a National Bioethics Advisory Commission report (NBAC Report).189  
Conscious of the fact that legislative reform requires widespread political support and 
that not every national legislator may have an interest in implementing such ethical 
principles, the following paragraphs will also try to provide the readers with some 
concrete examples of projects that have put in practice each of the ethical principles. 
Listing those examples may offer to clinical trials stakeholders (in particular, 
investigators and sponsors) inputs as of which aspects of their action could be improved 
and through which practices. 
Therefore, the next paragraphs, for each of the seven principles, will first provide a 
description, second, provide a legal formulation that could be of interest for prospective 
legislators, and third, provide an example of practical implementation.  
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(1) Collaborative Partnership  
Collaborative partnership is the first ethical principle listed in Emanuel et al.’s 
contribution. This ethical principle is the most peculiar in the framework of global 
clinical trials conducted in developing countries, in fact, it is the only principle added by 
Emanuel et al. in the passage from the first contribution (i.e. “What Makes Clinical 
Research Ethical?”)190 to the second one (i.e. “What makes clinical research in 
developing countries ethical? The benchmarks of ethical research.”)191 
The explanatory benchmarks associated with this principle concern the development of 
partnerships that involve partners in sharing responsibilities (and benefits) and 
simultaneously ensure the respect of local cultures. Amongst the goals of the principle 
are: fostering mutual respect and minimizing disparities between the role, contribution, 
and profit-sharing of the partners based in developed economies and those based in the 
host country.192 While many authors have addressed the topic of collaborative 
partnership, Lau et al. noted that the activity encompasses the need to assess needs and 
build sustainable capacity, to engage all stakeholders, to invest in leadership and strategic 
planning, and to practice cultural awareness.193 
An example of collaborative partnership in global clinical trials fostered in part by private 
stakeholders is the Yale School of Medicine partnership to promote clinical trials and 
training in Puerto Rico.194 The partnership provides for community training and shared 
services for multisite clinical trials in Puerto Rico.195 Also, Yale-staff members, under 
the partnership agreement, will travel to Puerto Rico to provide support and training to 
local researchers and will perform monitoring of the Puerto Rican sites as needed.196 
Another example of collaborative partnership, established by private as well as 
institutional stakeholders on a larger scale is the European and Developing Countries 
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Clinical Trials Partnership.197 Under the partnership, the EU will provide a contribution 
of up to € 683 million between 2014 and 2024 and the program involves 14 African and 
14 European countries as full and equal members.198 Both examples seem to respect and 
foster the ethical principle of collaborative partnership, especially to the extent that they 
involve partners in sharing responsibilities and promote the development of the capacity 
of local researchers.  
One way in which legislators can support collaborative partnership is, for example, by 
providing support for the financial cost of compliance. Consistently with the NBAC 
Report’s finding, countries willing to implement the ethical principle of collaborative 
partnership should include provisions in their legislation to “provide financial support for 
the administrative and operational cost of host country compliance with requirements of 
oversight of research involving human participants.”199 
(2) Social Value  
Social value is the second ethical principle listed in Emanuel et al.’s contribution. The 
principle is based on the notion that scientific research is rooted in the need to produce 
results that will benefit the community. This is especially true in a context in which social 
benefits for host countries take different shapes, varying from indirect medical benefits 
to payments for subjects and local investigators.200 However, in the context of the ethical 
principle of social value, the main concern regards the need to specify who will benefit 
of the research and to connect it with the community that hosts any specific clinical 
trial.201 
An example of private-actors action that follows those concerns can be found in the 
policy adopted by the pharmaceutical company GlaxoSmithKline (GSK). The latter, 
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when conducting global clinical trials that involve developing economies as hosts, 
pledges to respect the following rule:  
“GSK-sponsored clinical trials are only conducted in countries where the 
medicines are likely to be suitable for the country’s wider community. 
Furthermore, clinical trials of investigational medicines are not conducted in 
countries when it is known at the outset that there is no intent to pursue 
registration and make the medicine available for use in that country.”202  
In this context, GSK’s pledge can be seen as a positive attempt to respect the ethical 
principle of social value or at least to take into consideration the prospective value of 
research for the community hosting clinical trials. An additional and more concrete 
example of partnership that complies with the goal of respecting social value – and, 
specifically, with the goal of not supplanting local healthcare infrastructures – is the US-
Liberia partnership, established during the Ebola outbreak in 2015.203 The partnership 
makes global resources available locally and acknowledges the importance of not 
running operations that are completely foreign to the host-communities.204  
Legislators willing to fully prevent private stakeholders from disregarding the ethical 
principle of social value could implement more precise provisions. For example, they 
could affirm that “clinical trials conducted in developing countries should be limited to 
those studies that are responsive to the health needs of the host county.”205  
(3) Scientific Validity  
The third ethical principle identified by Emanuel et al. is scientific validity. In general, 
scientific validity deals with the design of the study – i.e. correct assessment and choice 
of randomisation, allocation concealment, blinding, and sample size – and with the 
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necessity for the trial to produce results that can be generalized to the prospective users’ 
population.206 In the context of global clinical trials, these concerns stand but are also 
coupled with concerns for the quality of the data produced.207 Furthermore, additional 
specific concerns regard the goal of “guaranteeing research participants the health-care 
intervention to which they are entitled.”208 This issue falls within the widespread debate 
over the use of placebos in clinical trials conducted in developing countries. The 
controversy over the use of placebo treatments, in particular, concerns the practice of 
administering placebo treatments to subjects who, in developing countries, would not 
have had access to the treatment available for subjects in developed countries in any 
event, despite the existence, at a global level, of a best available treatment that could be 
administered as active-control.209  
First, an example of project that focuses on the prevention of data falsification to comply 
with the ethical concern for scientific validity, concerns the use of blockchain protocols 
in clinical trials. Blockchain is the database connected with Bitcoins and other 
cryptocurrencies and promoters of its use in the context of healthcare claim that it could 
guarantee a better public-like supervision of data-entry in clinical trials, significantly 
reducing the risk of data inaccuracy and falsification.210 Second, with regard to the use 
of placebo vs. active-control treatments, concrete cases of policies implemented by 
private stakeholders seem to be limited. For example, the pharmaceutical company 
Novartis pledged to always justify its choice of comparator (between placebo and active 
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treatment) on both scientific and ethical grounds.211 However, policies of this kind do not 
specify how the balance between scientific and ethical concerns ought to be conducted. 
Therefore, it seems particularly important to promote the implementation of clear 
legislative standards in this context. Some institutional commentators suggest that 
placebo-controlled trials should be completely banned.212 However, given that placebo-
controlled trials may be acceptable or useful under certain scientific considerations, 213 a 
ban on placebo-treatments per se may set a standard that would stray too far from the 
needs and expectations of the scientific community and sponsors of major clinical trials. 
Nevertheless, to prevent different local standards of care from being be the decisive factor 
in choosing how to conduct clinical trials, uniform standards should be considered, 
independently from the location. A norm implemented to fulfill this goal could read as 
follows: “Clinical trials participants assigned to a control-group shall be provided with 
the best available active treatment, independently from whether the letter is available as 
default option in the host country.”214 Legislators willing to provide for an exception to 
the rule should add formulae consistent with that stated in Recommendation 2.2 in the 
NBAC Report i.e. “[a]ny study that would not provide the control group with an 
established effective treatment should include a justification for using an alternative 
design. Ethics review committees must assess the justification provided, including the 
risk to participants, and the overall ethical acceptability of the study design.”215 
(4) Fair Selection of Study Population 
The fourth ethical principle listed by Emanuel et al. is the fair selection of the study 
population. The principle, as the benchmarks associated with it suggest, derives from two 
kinds of concerns: first, the one for selecting the study population “to ensure scientific 
                                                 
211 Novartis Public Affairs, “Novartis Position on Clinical Trials in Developing Countries”, August 2011, 
https://www.novartis.com/sites/www.novartis.com/files/clinical-trials-developing-markets.pdf 
212 See, for example, the report “Clinical trials in developing countries and Swissmedic’s role in protecting 
vulnerable participants” edited by the Berne Declaration, an independent Swiss non‐governmental 
organization, 
https://www.publiceye.ch/fileadmin/files/documents/Gesundheit/1309_SWISSMEDIC_Final_Report_
ENG.pdf 
213 Temple and Ellenberg, op. cit. 
214 Cf. Recommendation 2.2, NBAC Report. 
215 Ibid.  
 59 
validity of the research”216 and, second, the one for the protection of vulnerable 
populations that have traditionally been subjected to high-risk research studies.217 The 
first concern has been addressed within the section dedicated to scientific validity in this 
contribution. The second concern, however, remains at the core of the “fair selection of 
study population” ethical principle. In that context, the identification of vulnerable 
populations in developing and developed countries has vastly overlapping results. In fact, 
in both cases, a broad definition of vulnerable subjects can be seen as including the 
following categories of subjects: children, pregnant women, prisoners, terminally ill, 
physically and intellectually challenged individuals, institutionalized individuals, elderly 
individuals, and ethnic minorities.218 Concerns for those subjects’ participation in clinical 
trials regard mainly the risk of coercion and non-autonomous informed consent decision-
making.219  
In the context of fair selection (and above all, treatment) of study population, two 
examples seem to be particularly interesting. The first one regards the role of potentially 
vulnerable populations and their involvement in the evaluation of the ethical challenges 
connected with clinical research. The project – called TRUST – involves 13 international 
partners and aims at generating an online tool for “fair research contracting.”220 Its role 
– among others – will be to provide standard contracts that vulnerable communities will 
be able to access at no cost to better negotiate their involvement in scientific research.221 
Furthermore, as a concrete result of TRUST’s efforts, local indigenous communities have 
already been supported in drafting specific ethical codes to specify their position towards 
clinical trials conducting in their local community.222 The second example of a specific 
project adopted to better achieve full compliance with the ethical principle of fair 
selection of study population, with a specific focus on the protection of vulnerable 
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subjects in the informed-consent phase, is the Global Health Trials website. The latter is 
part of a wider set of projects which have received conspicuous funding from the Bill 
and Melinda Gates Foundation starting in 2010.223 Concretely, the website provides free 
access to a variety of templates for e.g. informed consent forms, which researchers that 
have already worked in developing countries can share with both researchers based in 
developed countries planning to conduct global clinical trials and researchers based in 
host developing countries.224 
As to the possible steps that legislators willing to protect the ethical principle of fair 
selection of study population and, specifically, to implement rules that will better protect 
vulnerable subjects in the informed-consent phase, two insights can be provided. The 
first regards the possibility to implement a broad set of norms to establish a protection 
mechanism. Hurst developed a comprehensive analysis of the fragmented legal and 
ethical standards applicable to those subjects, but also highlighted how it is possible to 
address vulnerability through a four-step process.225 The steps require: (i) identifying the 
presence of a potential risk; (ii) assessing whether the risk-rate is higher in the case of 
some portions of the population; (iii) identifying who shares the duty to minimize such 
risk; and (iv) assessing how the risk can be minimized.226 Possibly, to overcome the risk 
of an impasse related to the difficulty in prospectively listing vulnerable subjects in 
normative documents, legislators should consider asking subjects who apply to conduct 
clinical trials to present an answer to the four above-listed questions.   
The second consideration is more specific and regards the suggestion to implement in 
normative documents specific provisions aimed at containing the risks connected with 
the participation of subjects that are arguably vulnerable. In this context, provisions could 
be established on the basis of two concerns: the role of community representatives in the 
process of acquiring informed consent and the risk of coercion in subjects’ recruitment 
and acquisition of informed consent. Following the first concern, a provision similar to 
the following could be implemented: “sponsors and investigators shall be sensitive to 
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local customs requiring that a local community representative gives permission to 
approach perspective participants.”227 The rule should, however, be balanced, by taking 
into consideration the second concern. Hence, a complementary rule should be 
implemented entailing that “sponsors and investigators shall ensure that individuals agree 
to participate in research without coercion or undue inducement from community 
representatives.”228 
(5) Favorable Risk-Benefit ratio 
The fifth ethical principle listed by Emanuel et al. is the presence of a favorable risk-
benefit ratio. In general, the latter refers to a balance in which the benefits for participants 
outweigh the risks.229 Traditionally, the benefits associated with the participation in 
clinical trials regard the fact that participants will be given access to the new treatment 
or – at least – to a standard-treatment, to medical supervision, and to the possibility to 
contribute to the advancement of scientific knowledge.230 On the other hand, the risks 
associated with the participation in clinical trials encompass the material and 
psychological cost of participating and the fact that the tested treatment may not result to 
be “better than the current standard care” and may present side effects.231  
The three core goals in the risk-benefit ratio evaluation are quality, consistency, and 
transparency of the assessment.232 A concrete way in which sponsors and investigators 
can quantify and convey the risk-benefit ratio associated with any clinical trial entail the 
choice and mastering of a descriptive or quantitative framework. Describing such 
frameworks – which, in substance, represent protocols for the definition and description 
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of the risk and benefit balance in any clinical trial – goes beyond the scope of this 
contribution. However, by way of an example, it can be noted that at least eight 
descriptive frameworks233 and nine quantitative frameworks234 exist and that it may 
beneficial for to prospectively identify which framework on which they wish sponsors 
and investigators to rely.  
Provisions aimed at increasing transparency in the context of the risk-benefit ratio 
assessment could read as follows: “Sponsors and investigators should present and justify 
the research design to be used, including the consistent description and application of (i) 
the descriptive and quantitative protocols and (ii) the procedures to be used to assess and 
minimize risks to participants.”235 Furthermore, looking at which provisions could be 
implemented taking into consideration concerns related specifically to the case of global 
clinical trials conducted in developing countries, the recourse to the ethical principle of 
favorable risk-benefit ratio could be used to supplement the rules suggested in the context 
of the ethical principle of social value (addressed earlier). Hence, for example, legislators 
should consider implementing corollary provisions similar to last part of 
Recommendation 4.2 of the NBAC Report, which reads as follows: “In cases in which 
investigators do not believe that successful interventions will become available to the 
host country population, they should explain to the relevant ethics review committee(s) 
why the research is nonetheless responsive to the health needs of the country and presents 
a reasonable risk/benefit ratio.”236 
(6) Independent Review 
Independent review is the sixth ethical principle listed by Emmanuel et al. The general 
concerns behind such an ethical principle are the need to identify potential conflicts of 
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interests and to foster public accountability.237 More specifically, the benchmarks 
associated with the ethical principle of independent review regard the need to ensure 
independence, competence, and public accountability of the reviews.238 Although this 
does not amount to an example of best practice in the field of independent review, it can 
be noted that recently a tendency has developed under which for-profit review boards are 
taking over for hospitals, at least in the US market.239  
As for the concrete provisions that a legislator may implement – especially in the context 
of the regulation of global clinical trials – some remarks can be presented. First, approval 
to clinical trials should be granted only following a prior ethical review conducted by an 
ethical committee. Second, such a review should take into consideration all the ethical 
principles analyzed so far in this contribution, as well as those that will be addressed in 
the following sections. Third, focusing specifically on the case of global trials a double 
ethical review system should be established. Hence, legislators should require clinical 
trials to “receive prior approval by both an ethical review committee based in their county 
and in the host country, unless the ethical review mechanism of the host country is found 
to respect the same principles and procedures of their one.”240  
(7) Informed Consent
Informed consent is the seventh ethical principle identified by Emanuel et al. Informed 
consent is an issue transversal to all eight ethical principles because it is often in the 
informed-consent phase that the human subjects’ freedom of choice is protected. The 
benchmarks connected with this ethical principle deal with the need to involve local 
communities in establishing recruitment procedures, the need to utilize the most 
appropriate formats, and the need to ensure freedom to withdraw from clinical trials. 
Given the multiple issues connected with informed consent, the section about the fair 
selection of study participants (above in this contribution) has already partially touched 
237 Emanuel, et al. (2004) op cit. 
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on it. Nevertheless, it is important to highlight that the aim of informed consent is to 
acquire a voluntary consent based on a solid understanding of information.241 
As of the current status of informed consent as an ethical principle in the context of global 
clinical trials, it can be noted that, following the strand of litigation tied to the Pfizer 
scandal regarding the trials conducted in Kano (Nigeria)242 some commentators suggest 
that the informed consent requirement is sufficiently “(i) universal and obligatory, (ii) 
specific and definable, and (iii) of mutual concern,” to be considered a customary 
international law norm.243  
On the one hand, practical examples of effective means to administer inform consent 
procedures encompass tailoring informed consent forms to the sex and developmental 
age of prospective participants, while associating counseling to traditional formal 
procedures.244 Furthermore, a common recommendation regards the use of social 
language and the involvement of local leaders, when useful.245 In this context, the Global 
Health Trials website described in the “fair selection of study participants” section of this 
contribution may represent a useful tool.246 
On the other hand, legislators willing to introduce measures to protect and implement the 
ethical principle of informed consent should consider introducing the following 
provisions. First, clinical trials shall not be approved, unless they recruit participants on 
the basis of their voluntary informed consent. Second, “researchers shall adopt culturally 
appropriate ways to disclose information that is necessary for adherence to the 
substantive ethical standard of informed consent and shall describe in their protocols and 
justify to the ethics review committee(s) the procedures they plan to use for disclosing 
such information to participants.”247 Third, “in order to obtain participants’ informed 
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consent, researchers shall present – both to ethics review committees, prospectively, and 
prospective participants, on-site – information about benefits available to participants 
when the participation in the study has ended.”248  
(8) Respect for Recruitment Participants and Study Communities 
The eighth and final ethical principle identified by Emanuel et al. focuses on the respect 
for host study communities in which participants are recruited. It focuses on the conduct 
of researchers following the obtainment of informed consent.249 There are five 
benchmarks connected with this ethical principle and they principally regard goals such 
as the protection of confidentiality of enrolled participants, and the right to withdraw 
from clinical trials, the divulgation of information that arises during clinical trials to 
participants and to their community.250 Common practices associated with the 
achievement of these goals encompass the development of consistent contacts between 
the research staff and participants, the scheduling of numerous updates for contacting 
participants about progress, and the encouragement of contacts from participants and 
their community.251  
Examples of private commitments to achieve the implementation of the ethical principle 
of respect for recruitment participants and study communities include the pledge 
presented by the pharmaceutical company Roche. The latter affirms its intention to keep 
the records of its clinical trials confidential and protected from disclosure to third parties 
also after the conclusion of the studies. In addition, it is committed to “provide the 
investigational medicinal product free for the duration of the study” and “continued 
access to the investigational medicinal product that they [participants] received after trial 
completion, when appropriate.”252 Furthermore, private stakeholders willing to comply 
with the benchmark related to the need to communicate with patients and their 
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communities have access to a variety of services available on the market; for example, 
PAREXEL’s Clinical Communications group – which, inter alia, has recently become a 
partner of Microsoft in the field of clinical trials services253 – develops contents uniquely 
tailored to diverse audiences that sponsors and investigators can use both before and after 
the recruitment of participants.254  
Legal formulae that legislators may want to introduce to protect and foster the ethical 
principle of respect for recruitment participants and study communities in context of 
global clinical trials, for example, could read as follows: “Sponsors and investigators 
shall consult with community representatives to establish effective means to 
communicate necessary information in a manner that is understandable to prospective 
participants – before recruitment –, to enrolled participants – following recruitment –, 
and their community.”255 Consistently with the NBAC Report’s Recommendation 3.5, in 
case of lack of involvement of community representatives, “the protocol presented to the 
ethics review committee should justify why such involvement is not possible or 
relevant.”256 
III. Expanding Emanuel et al.’s Ethical Principles 
From the perspective of this contribution, the ethical principles identified by Emanuel et 
al. are extremely helpful in orienting the everyday action of clinical trials stakeholders 
and the regulatory efforts of legislators. However, the list does not provide stakeholders 
or legislators with an additional principle as to how to allocate the responsibility to 
comply with such principles. Therefore, it seems appropriate and useful to include a ninth 
principle to accompany the eight ethical principles described above and better support 
their implementation: the principle of subsidiarity.  
To present the suggestion regarding the inclusion of the principle of subsidiarity as ninth 
principle – and corollary principle – to the eight discussed in Emanuel et al., the following 
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paragraphs will address the following issues: (i) the definition of subsidiarity, (ii) why 
the principle can be considered also as an ethical tool, (iii) why the principle should be 
considered as relevant in the ethical discourse about clinical trials, (iv) how the principle 
can be usefully applied in the field of clinical trials (ethical) regulation, and (v) the 
limitations of the suggestion here presented and how they can be addressed.  
(i) Subsidiarity is a principle used to assess how to allocate decision-making powers 
among different actors. According to the principle of subsidiarity, decision-making 
powers should be exercised at the lowest level of governance, provided that their exercise 
is equally effective.257 In the international framework, it is mainly utilized in the 
allocation of powers in the context of the EU,258 but its value in the field of international 
law and human rights is often discussed.259 Notably, subsidiarity has a two-fold 
application, namely vertical (between different institutional levels) and horizontal 
(between different actors, institutional and non-institutional, at the same level).260 These 
are the two applications on which the following paragraphs will rely. It is worth noting 
that in the specific context of scientific research, subsidiarity is and has been utilized also 
with a different meaning; this meaning utilizes subsidiarity to assess when scientific 
experiments should be conducted.261 This contribution will not discuss such possible 
application of the principle of subsidiarity; instead, it will focus on the value of 
                                                 
257 Feichtner, Isabel. “Subsidiarity.” Oxford Public International Law, 6 June 2017,  
    opil.ouplaw.com/view/10.1093/law:epil/9780199231690/law-9780199231690-
e1477?rskey=CFTYtA&result=1&prd=EPIL and “EUR-Lex Access to European Union law.” Glossary 
of summaries - EUR-Lex, eur-lex.europa.eu/summary/glossary/subsidiarity.html. 
258 In the context of the EU, specifically, subsidiarity is “the principle whereby the EU does not take action 
(except in the areas that fall within its exclusive competence), unless it is more effective than action 
taken at national, regional or local level. It is closely bound up with the principle of proportionality, 
which requires that any action by the EU should not go beyond what is necessary to achieve the 
objectives of the Treaties.” Glossary of summaries - EUR-Lex, op. cit.   
 
259 See, among others, Carozza, Paolo G. “Subsidiarity as a Structural Principle of International Human 
Rights Law.” American Journal of International Law 97.1 (2003): 38-79. Alvarez, José E. International 
organizations as Law-makers. vol. 586 (Oxford University Press, 2005). And Kumm, Mattias. “The 
Legitimacy of International Law: a Constitutionalist Framework of Analysis.” European Journal of 
International Law 15.5 (2004): 907-931. 
260 Feichtner, op. cit. 
261 See, for example, the application of the principle of subsidiarity to the subsidiarity principle to establish 
that “research on embryos should only be conducted if no suitable alternatives exist.” Pennings, Guido, 
and André Van Steirteghem. “The Subsidiarity Principle in the Context Of Embryonic Stem Cell 
Research.” Human Reproduction 19.5 (2004): 1060-1064. 
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subsidiarity in its more traditional legal meaning, as a principle to assess how to allocate 
decision-making powers in the field of clinical trials.  
(ii) Subsidiarity, in the context of this contribution, is relied upon not solely for its legal 
value but also for its ethical one. In fact, subsidiarity can be seen not only as a mechanism 
to regulate the allocation of power, but also as a cooperative principle. As suggested by 
Carozza, subsidiarity also represents the “principle that each social and political group 
should help smaller or more local ones accomplish their respective ends without, 
however arrogating those tasks to itself.”262 Therefore, subsidiarity can also be seen as a 
corollary value that could accompany a better protection and implementation of the rights 
of human subjects, to the extent that it hands such protection and implementation to a 
clear institutional subject on the basis of the appropriateness of its action and the interest 
of citizens therein.  
(iii) Furthermore, the application of the principle of subsidiarity in the specific context 
of clinical trials regulation would be particularly useful, considering the globalization 
through which the clinical trials framework is currently evolving. In this context, national 
legislation can do much to affect clinical trials, but their global dimension often reduces 
the impact of national norms alone can have. At the same time, some specific aspects of 
the implementation of clinical trials standards – even when they have an international 
nature and scope – cannot be managed solely at the international level. Hence, keeping 
in mind the goal of fully implementing the eight ethical principles identified by Emanuel 
et al., reliance on the principle of subsidiarity could guarantee a more effective 
development and implementation of clinical trials regulation.  
(iv) Specifically, the principle of subsidiarity could be applied in the context of clinical 
trials regulation on three levels. To follow the structure chosen by Emanuel et al., these 
three levels could be seen as representing the three benchmarks associated with the 
principle. In particular, the three levels can be described as: (a) horizontal subsidiarity – 
to better assess whether an issue can be better addressed through the private action of the 
stakeholders (sponsors, investigators, human subjects) or through the public action of 
institutions; (b) sub-horizontal subsidiarity – when the issue can be better addressed 
through the private action of the stakeholders and there is a need to assess which category 
                                                 
262 Carozza, op. cit. 
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of stakeholders can better address it (e.g. sponsors, investigators, and/or human subjects); 
and (c) vertical subsidiarity – when the issue can be better addressed through the public 
action of institutions and there is a need to assess which level of power should have the 
competence to act (e.g. supra-national level, national level, local-community level, etc.). 
Examples of how the mechanism provided by the principle of subsidiarity could represent 
a necessary and structural corollary of the eight ethical principles listed by Emanuel et 
al., can be easily identified. For example, first, one of the benchmarks associated with 
the ethical principle of fair selection of study population is “select the study population 
to ensure scientific validity of the research.”263 With the latter being such a concrete issue, 
it is likely that applying horizontal subsidiarity would bring the conclusion that private 
stakeholders are the actors that could more effectively implement the benchmark. 
Applying sub-horizontal subsidiarity may then result in the identification of sponsors as 
investigators as the two stakeholders with a higher chance of effectively protecting the 
benchmark. Second, one of the benchmarks associated with the ethical principle of social 
value is to “prevent supplanting the extant health system infrastructure and services.”264 
Given that healthcare is a matter that relies mainly on decisions taken at the national 
level, applying horizontal subsidiarity as well as vertical subsidiarity may result in the 
allocation of the decision-making power in the context of the protection of that aspect of 
social value to national governments. Third, similarly, the protection and implementation 
of the benchmark “disclose information in culturally and linguistically appropriate 
formats,” associated with the “informed consent” ethical principle,265 may effectively be 
left to the level of the local community, following the application of vertical subsidiarity. 
Fourth and finally, decision-making powers regarding the benchmark “ensure public 
accountability through transparency and review by other international and 
nongovernmental bodies, as appropriate,” associated with the “independent review” 
ethical principle,266 would be better exercised if allocated to the international level (e.g. 
to the WHO).  
(v) Finally, it is worth noting that some shortcomings may affect the current expansion 
of the model ideated by Emanuel et al. The most valuable concern regards the possibility 
                                                 
263 Feichtner, op. cit. 
264 Emanuel, et al. (2004) op cit. 
265 Ibid. 
266 Ibid. 
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that the principle of subsidiarity, applied alone, would guarantee a completely successful 
implementation of the other eight ethical principles. A possible way of addressing such 
concerns could entail the inclusion of other three principles next to the subsidiarity one 
– either as autonomous expansions of the eight original principles or as benchmarks 
associated with the subsidiarity principle. The three additional principles could represent 
some of the core principles at the base of the international legal system i.e. the principle 
of international legality, the principle of adequate participation and accountability, and 
the principle of achieving outcomes that are not violative of fundamental rights and are 
reasonable.267 
IV. Preliminary Conclusions 
This contribution has built on the cornerstone findings of leading authors in the area. In 
particular, first, it identified and presented examples of best practices with regard to the 
protection and implementation of the eight ethical principles listed by Emanuel et al. This 
activity aimed at clarifying what the eight principles may signify in concrete terms as 
well as at providing private stakeholders with examples of ways in which they can impact 
the respect of ethical principles in their daily activity. Second, it provided some legal 
formulae that legislators might consider implementing when regulating clinical trials in 
accordance with the eight ethical principles. Third, it suggested a possible expansion of 
the model established by Emanuel et al. Such an expansion focuses on the addition of a 
ninth principle – the principle of subsidiary – which represents a necessary and structural 
element for the full and effective implementation and protection of the other eight 
principles.  
  
                                                 
267 For the identification of the principles see Kumm, op. cit. 
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CHAPTER FIVE: COMPARATIVE ANALYSIS – CLINICAL TRIALS 
REGULATION IN THE EUROPEAN UNION AND THE UNITED STATES 
 
I. Introduction 
This chapter presents a comparative analysis of the EU and US clinical trial legal 
frameworks. The aim of such analysis is twofold: to identify points of contacts and 
similarities in the two sets of provisions and to detect divergences and differences 
between the two systems. This exercise will provide: (i) in terms of policy – for national 
and international legislators –, useful insights in terms of assessment of the standards 
applicable in two of the most advanced clinical trials legal frameworks (that often serve 
as models for other legal systems); and (ii) in terms of compliance – for actors willing to 
operate under both legal frameworks –, detailed information about the most challenging 
differences between the two systems. In this context, it is worth noting that a comparative 
analysis of the size proposed in this contribution does not already exist in the literature. 
Furthermore, the conclusions presented here are particularly original as one of the main 
items taken here into consideration is a recent EU legislative document, which has not 
yet been the object of extensive analysis. 
The main sources for the regulation of clinical trials taken into consideration in this 
contribution are the following: for clinical trials in the EU legal framework, Regulation 
No. 536/2014 of the European Parliament and of the Council on clinical trials on 
medicinal products for human use (the “Clinical Trials Regulation,” hereinafter: EU 
CTR), adopted on 16 April 2014 and published in the Official Journal on 27 May of the 
same year.268 Due to some delays, the Regulation is not yet in force; it is expected to 
come into full application in 2019.269 Until then, Directive 2001/20/EC of the European 
Parliament and of the Council of 4 April 2001 on the approximation of the laws, 
regulations and administrative provisions of the Member States relating to the 
                                                 
268 Regulation (EU) No. 536/2014 of the European Parliament and of the Council of 16 April 2014 on 
clinical trials on medicinal products for human use, and repealing Directive 2001/20/EC (Text with EEA 
relevance). Hereinafter within the references “EU CTR 536/2014.” 
269 “Clinical Trial Regulation.” European Medicines Agency - Clinical trials - Clinical Trial Regulation, 
www.ema.europa.eu/ema/index.jsp?curl=pages%2Fregulation%2Fgeneral%2Fgeneral_content_00062
9.jsp.  
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implementation of good clinical practice in the conduct of clinical trials on medicinal 
products for human use (the “Clinical Trials Directive”) will still apply. However, this 
contribution will not focus on it – both because being a directive it includes less specific 
and directly applicable obligations than the Clinical Trials Regulation, and because it is 
nevertheless destined to lose its legal value and relevance in the short term.  
For clinical trials in the US legal framework, a variety of sources are relevant. We might 
begin with the Code of Federal Regulations (hereinafter: US CFR), as it has been dubbed 
“the codification of the general and permanent rules published in the Federal Register by 
the departments and agencies of the Federal Government produced by the Office of the 
Federal Register (OFR) and the Government Publishing Office.”270 In particular, the 
most relevant provisions taken into consideration belong to Title 45 US CFR 46 (The 
Common Rule) which is a core set of regulations defining protection of Human Subjects 
in clinical research;271 and to Title 21 US CFR, which applies when research is being 
conducted to develop a medical product that will be licensed for sale in the US.272 
With regard to international standards and guidelines, documents that will be taken into 
consideration, when appropriate, include, for example, the guidelines produced by the 
International Conference on Harmonisation (ICH).  
II. Comparative analysis  
As noted above, the core aim of this chapter is to build a comparative analysis of the EU 
and US clinical trial legal frameworks. In order to achieve this aim, the next sub-sections 
will focus on five specific clinical trials aspects that both legal frameworks address and 
regulate. First, the fundamental preliminary elements established in clinical trials 
regulations. Second, the scope and technical aspects of the applications that sponsors are 
required to submit to governmental authorities in order to obtain an authorization to 
conduct clinical trials in the EU or in the US territories – or outside such territories, but 
                                                 
270 ECFR — Code of Federal Regulations, US Government Publishing Office,  
www.ecfr.gov/cgi-bin/ECFR?page=browse.  
271 “How Is Clinical Research Governed?” Duke School of Medicine, 
medschool.duke.edu/research/clinical-and-translational-research/duke-office-clinical-research/about-
clinical-research-0.  
272 Ibid. And Center for Devices and Radiological Health. “Medical Device Databases - Code of Federal 
Regulations - Title 21 - Food and Drugs.” US Food and Drug Administration Home Page, Center for 
Devices and Radiological Health, 
www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/Databases/ucm135680.htm.  
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subject to the EU or US legal standards. Third, the mechanisms on the basis of which 
such applications for authorization are scrutinized in each system. Fourth, some specific 
concerns that both legislators address in their clinical trials-related provisions – such 
concerns are de facto addressed when applications are assessed, but given the fact that 
they particularly focus on concerns connected with the protection of human subjects in 
clinical trials, they are analyzed here in a dedicated sub-section. Finally, fifth, the ways 
in which the EU and the US systems regulate the monitoring of approved clinical trials. 
(1) Fundamental Elements 
This section will present the fundamental elements established in the EU and US legal 
frameworks on the matter of clinical trials regulation. Their identification and description 
is propaedeutic to a deep understanding of the following sub-sections included in this 
chapter. The elements analyzed and compared here concern the most relevant definitions 
used by each legislator, the general principles on the basis of which the EU and the US 
systems develop clinical trials norms, and the division of competences applicable in the 
context of clinical trials regulation and their enforcement.  
(a) Definitions 
The most important definition in the context of this analysis is that of clinical trials. 
Additionally, it is germane to provide a limited yet essential definition of other recurring 
terms often used by both the EU and the US legislator. Therefore, this section will 
analyze the definition – the nature and scope – of the following terms: (i) clinical trials 
(investigations, in the US framework) and (ii) sponsor, investigator, and subject.  
(i) Definition of Clinical Trials  
The first item that can be compared when looking at clinical trials regulation is the 
definition of clinical trials adopted by different legal systems.  
At the EU level, the Clinical Trials Regulation provides for a two-tier test to define 
clinical trials to which the Regulation applies. The first tier focuses on the aim of clinical 
studies. There, clinical studies are defined as investigation in relation to humans intended  
“(a) to discover or verify the clinical, pharmacological or other 
pharmacodynamic effects of one or more medicinal products; (b) to identify 
any adverse reactions to one or more medicinal products; or [emphasis 
added] (c) to study the absorption, distribution, metabolism and excretion of 
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one or more medicinal products; with the objective of certaining the safety 
and/or efficacy of those medicinal products.”273  
The second tier focuses on the conditions to be fulfilled by any clinical study to be 
considered a clinical trial. A clinical trial is any clinical study (which passed the test 
established in the first tier) which additionally fulfills one of the following three 
conditions:  
“(a) the assignment of the subject to a particular therapeutic strategy is 
decided in advance and does not fall within normal clinical practice of the 
Member State concerned; (b) the decision to prescribe the investigational 
medicinal products is taken together with the decision to include the subject 
in the clinical study; or [emphasis added] (c) diagnostic or monitoring 
procedures in addition to normal clinical practice are applied to the 
subjects.”274  
With regard to the US, the CFR does not directly provide a definition of clinical trials. 
Instead, it focuses on the definition of “clinical investigation.” 21 US CFR 56.102 (c) 
reads as follows:  
“[c]linical investigation means any experiment that involves a test article and 
one or more human subjects, and that either must meet the requirements for 
prior submission to the Food and Drug Administration under section 505 (i) 
or 520 (g) of the act, or need not meet the requirements for prior submission 
to the Food and Drug Administration under these sections of the act, but the 
results of which are intended to be later submitted to, or held for inspection 
by, the Food and Drug Administration as part of an application for a research 
or marketing permit.”275  
It is worth noting that “the act” to which the provision refers is the Federal Food, Drug, 
and Cosmetic Act (FD&C Act) which is included in the US Code (USC) in Title 21.276 
Section 505 refers to new drugs and Section 505 (i) specifically refers to exemptions of 
drugs for research and discretionary and mandatory conditions.277 Similarly, Section 520 
                                                 
273 Article 2.2 (1), EU CTR 536/2014. 
274 Article 2.2 (2), EU CTR 536/2014. 
275 21 CFR 56.102 (c). 
276 21 USC § 355. Note that a conversion table of the position of the provisions from the FD&C Act to the 
USC is available at: “FD&C Act Chapter V: Drugs and Devices.” US Food and Drug Administration 
Home Page,  
www.fda.gov/RegulatoryInformation/LawsEnforcedbyFDA/FederalFoodDrugandCosmeticActFDCAct/
FDCActChapterVDrugsandDevices/default.htm. In this contribution, provisions will be cited according 
to their position in the USC.  
277 21 USC § 355 (i).  
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refers to general provisions respecting control of devices intended for human use, and 
Section 520 (g) specifically refers to exemptions for devices for investigational use.278  
Three additional definitions of clinical trials can be observed and considered useful to 
better interpret and understand the choices of the EU and US legislators. First, the ICH 
defines clinical trials within its E6 Guideline on Good Clinical Practice. In particular, 
section 1.12 defines a clinical trial/study as  
“[a]ny investigation in human subjects intended to discover or verify the 
clinical, pharmacological and/or other pharmacodynamic effects of an 
investigational product(s), and/or to identify any adverse  reactions  to  an  
investigational  product(s),  and/or  to  study  absorption,  distribution, 
metabolism, and excretion of an investigational product(s) with the object of 
ascertaining its  safety and/or efficacy.”279  
It is worth noting that as of October 2017, the guideline has already been implemented 
in the European framework280 and its implementation in the US is still to be notified.281 
Second, the definition provided by ClinicalTrials.gov, the US clinical trials registry. 
According to ClinicalTrials.gov, “[i]n a clinical trial, participants receive specific 
interventions according to the research plan or protocol created by the investigators. 
These interventions may be medical products, such as drugs or devices; procedures; or 
changes to participants’ behavior (…).”282 
                                                 
278 21 USCS § 360j (g). 
279 ICH Harmonised Guideline, Integrated Addendum to ICH E6 (R1): Guideline for Good Clinical 
Practice, E6(R2), Current Step 4 version dated 9 November 2016. The definition specifies also that 
“[t]he terms clinical trial and clinical study are synonymous.” 
280 Adopted by CHMP, 15 December 2016, issued as EMA/CHMP/ICH/135/1995 where CHMP stands for 
Committee for Human Medicinal Products cf. “ICH E6 (R2) Good clinical practice.” European 
Medicines Agency - ICH E6 (R2) Good clinical practice,  
www.ema.europa.eu/ema/index.jsp?curl=pages%2Fregulation%2Fgeneral%2Fgeneral_content_001251.j
sp.  
281 “Efficacy Guidelines.” ICH, www.ich.org/products/guidelines/efficacy/article/efficacy-
guidelines.html.  
282 “Learn About Clinical Studies.” ClinicalTrials.gov, clinicaltrials.gov/ct2/about-studies/learn#WhatIs. 
The definition follows specifying that “[c]linical trials may compare a new medical approach to a 
standard one that is already available, to a placebo that contains no active ingredients, or to no 
intervention. Some clinical trials compare interventions that are already available to each other. When 
a new product or approach is being studied, it is not usually known whether it will be helpful, harmful, 
or no different than available alternatives (including no intervention). The investigators try to determine 
the safety and efficacy of the intervention by measuring certain outcomes in the participants. For 
example, investigators may give a drug or treatment to participants who have high blood pressure to see 
whether their blood pressure decreases.”  
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Third, the WHO – and, by extension, the International Clinical Trials Registry Platform 
– defines clinical trials as  
“any research study that prospectively assigns human participants or groups 
of humans to one or more health-related interventions to evaluate the effects 
on health outcomes. Interventions include but are not restricted to drugs, cells 
and other biological products, surgical procedures, radiological procedures, 
devices, behavioural treatments, process-of-care changes, preventive care, 
etc.”283 
Comparing the two definitions introduced in each context, it is possible to draw some 
conclusions. First, all the observed definitions focus on clinical trials as studies 
investigational in nature and involving human subjects.   
Second, the two main aspects in which the US approach and the EU one diverge – while 
however not reaching a contradiction – regard: 
(i) The choice of the object to be defined. While the EU CTR distinguished between 
clinical studies ad one of their sub-category, clinical trials – clashing with the ICH 
definition, according to which the two terms are synonyms –, the US CFR focuses on 
clinical investigations, without even touching upon the term “clinical trials.” While the 
US definition can be deemed to have the benefit of being more generic and therefore 
capable of covering more situations, the EU’s one has the benefit of setting a precisely 
applicable two-tier test.  
(ii) The role of a study’s aim within the definition. While the EU CTR relies on the aim 
of a study to assess whether it falls within the “clinical study” definition provided in the 
first tier of the test. In the EU definition, the end-scope of commercialization is not 
prominent (assessing safety and efficacy of a treatment are). On the other hand, the US 
definition is completely focused on the aim of the clinical investigation; in fact, clinical 
trials fall within the US CFR basically any time they have the aim of testing a treatment 
that aims at obtaining the FDA approval for commercialization.  
 
                                                 
283 “Clinical trials.” WHO, World Health Organization, www.who.int/topics/clinical_trials/en/.  
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(ii) Additional Definitions 
There are other three core concepts to be defined in the context of clinical trials 
regulation. They coincide with the three main stakeholders involved in clinical trials: 
sponsors, investigators, and human subjects.  
Within the EU CTR, a sponsor is defined as “an individual, company, institution or 
organisation which takes responsibility for the initiation, for the management and for 
setting up the financing of the clinical trial.”284 The US CFR reads as follows: “[sponsor] 
means a person who takes responsibility for and initiates a clinical investigation. The 
sponsor may be an individual or pharmaceutical company, governmental agency, 
academic institution, private organization, or other organization.”285  
It can be noted how, on the one hand, the US set of definitions related to the concept of 
sponsors also provides for the figure of sponsor-investigator,286 which is not envisaged 
within the EU legislation. On the other hand, the EU definition is an “open” one, which 
does not list for specific categories of sponsors while the US pre-identifies a list of 
subjects traditionally deemed to fall within the definition of sponsor.  
An investigator, under the EU CTR, is “an individual responsible for the conduct of a 
clinical trial at a clinical trial site.”287 The Regulation provides also for an additional 
definition for the concept of “principal investigator” being it “an investigator who is the 
responsible leader of a team of investigators who conduct a clinical trial at a clinical trial 
site.”288 Under the US CFR investigator means “an individual who actually conducts a 
clinical investigation (i.e. under whose immediate direction the drug is administered or 
dispensed to a subject).”289 As to the hierarchy between investigators, the CFR clarifies 
that “[i]n the event an investigation is conducted by a team of individuals, the investigator 
                                                 
284 Article 2.2 (14), EU CTR 536/2014. 
285 21 CFR 312.3. 
286 See 21 CFR 312.3 according to which “Sponsor-Investigator means an individual who both initiates 
and conducts an investigation, and under whose immediate direction the investigational drug is 
administered or dispensed. The term does not include any person other than an individual. The 
requirements applicable to a sponsor-investigator under this part include both those applicable to an 
investigator and a sponsor.”   
287 Article 2.2 (15), EU CTR 536/2014. 
288 Article 2.2 (16), EU CTR 536/2014. 
289 21 CFR 312.3. 
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is the responsible leader of the team. ‘Subinvestigator’ includes any other individual 
member of that team.”290  
Therefore a slight yet potentially confusing difference between the approaches in the two 
legal systems can be observed: while in the US system, an investigator as a default option 
is the team leader (and team members are “subinvestigators”), in the EU system, an 
investigator as a default option is a team member (and the team leader is the “principal 
investigator”).  
Finally, within the EU CTR, a subject is “an individual who participates in a clinical trial, 
either as recipient of an investigational medicinal product or as a control.”291 
Interestingly, the EU CTR provides for corollary definitions of “minor”292 and 
“incapacitated subject,”293 unlike US clinical trials rules. In the US CFR, subject means 
“a human who participates in an investigation, either as a recipient of the investigational 
new drug or as a control.”294 The CFR specifies that “[a] subject may be a healthy human 
or a patient with a disease.”295 
Definitions in this field are extremely similar and, interestingly, they both introduce the 
option of participation in clinical trials with control groups. The EU definition is then 
expanded through reference to sub-categories of subjects, while the US one refers to the 
distinction between healthy and unhealthy patient.  
(b) General Principles 
The EU CTR includes an article dedicated to stating a “general principle.” The aim of 
the article is to set the two basic conditions that must be cumulatively met for a clinical 
trial to be conducted. Those are: “(a) the rights, safety, dignity and well-being of subjects 
are protected and prevail over all other interests; and (b) it is designed to generate reliable 
                                                 
290 21 CFR 312.3. 
291 Article 2.2 (17), EU CTR 536/2014. 
292 Article 2.2 (18), EU CTR 536/2014 where minor “means a subject who is, according to the law of the 
Member State concerned, under the age of legal competence to give informed consent.” 
293 Article 2.2 (19), EU CTR 536/2014 where incapacitated subject “means a subject who is, for reasons 
other than the age of legal competence to give informed consent, incapable of giving informed consent 
according to the law of the Member State concerned.” 
294 21 CFR 312.3. 
295 21 CFR 312.3. 
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and robust data.”296 The US CFR provides for a longer description of the principles 
behind the assessment of clinical trials appropriateness.297 For now, it is worth noting 
that safety and rights of the subjects are the core principles that the FDA will protect in 
all phases of clinical trials and quality of the scientific evaluation (seen as a function of 
effectiveness and safety) are the primary objectives of the FDA’s action in phase 2 and 
3 of clinical trials.298 Hence, the protection of human subjects and the interest in scientific 
validity are common principles affirmed by both legislators.  
(c) Competences  
With regard to the delegation of competences which stands behind the implementation 
of the EU CTR and the US CFR (in the portions addressed in this contribution), it is 
worth noting that, within the EU system, competences on the matters addressed in the 
EU CTR are awarded to the supra-national level on the basis of the principle of 
subsidiarity and the principle of proportionality. Under the principle of subsidiarity, it is 
deemed appropriate for the EU to regulate clinical trials, as the goal of fully 
implementing the principles described above “cannot be sufficiently achieved by the 
Member States but can rather, by reason of its scale, be better achieved at Union level.”299 
Under the principle of proportionality, however, the EU CTR “does not go beyond what 
is necessary in order to achieve that objective.”300 
Simultaneously, the federal competence to intervene in clinical trials regulation descends 
from the interstate commerce nature of clinical investigations – where the US use of 
“investigations,” as clarified above, corresponds to the European use of “trials”. 
Specifically, (i) in general, drugs must be the subject of an approved marketing 
application before being transported or distributed across state lines; (ii) before drugs 
obtain such approval, sponsors are likely to need to ship the investigational drug to 
clinical investigators in many states; (iii) therefore, sponsors willing to do so must seek 
an exemption from the legal requirement described under (i); (iv) to obtain such 
                                                 
296 Article 3, EU CTR 536/2014. 
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298 Ibid.  
299 Premable (85), EU CTR 536/2014. 
300 Ibid. 
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exemption – which is awarded by the FDA – sponsors file an Investigational New Drug 
(IND) Application.301 
(2) Application for Authorization
The analysis of the provisions that regulate the application process for stakeholders 
interested in the conducting of clinical trials in the EU or US context encompasses 
considerations on two aspects: the procedural one and the one of content.  
First, procedure-wise, sponsors willing to conduct clinical trials must file an application 
to competent authorities. At the US level, as clarified above, the competent authority to 
file an IND application is the FDA.302 At the EU level, the identification of the competent 
authority/authorities is more complex. In fact, while applications to conduct clinical trials 
must be filed by sponsors through an EU portal,303 the competence to assess whether the 
clinical trial applied for falls within the scope of the EU CTR and whether the application 
filed is complete in accordance with the EU CTR belongs to one EU Member State.304 
There are three main rules that can help sponsors to assess which Member State will be 
the competent one (i.e. the “reporting Member State): (i) it is generally up to the sponsor 
itself to propose one reporting Member State; (ii) if that Member is willing to be the 
reporting one or if the clinical trial involves only one Member State, that one shall be the 
reporting Member State; (iii) if more Member States are concerned with a clinical trial 
and there is no agreement among the Member States concerned as of which one should 
serve as reporting Member State, the proposed reporting Member State shall be the 
reporting one.305 
Second, content-wise, applications submitted within the EU context and the US one 
present similar elements. The two legislators often use different terms to define such 
elements and often require applicants to provide the necessary contents under different 
301 Center for Drug Evaluation and Research. “Investigational New Drug (IND) Application.” U S Food 
and Drug Administration Home Page, Center for Drug Evaluation and Research, 
www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalA
pplications/InvestigationalNewDrugINDApplication/default.htm.  
302 See e.g. 21CFR 312.20 which reads as follows: “[a] sponsor shall submit an IND to FDA [emphasis 
added] if the sponsor intends to conduct a clinical investigation (…)” 
303 Article 5 (1) and Article 80, EU CTR 536/2014. 
304 Article 5 (3), EU CTR 536/2014. 
305 Article 5 (1), EU CTR 536/2014. 
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sections of their applications. However, five basic sections of the applications required 
in the two systems will be taken into consideration in this analysis. They are the 
following: (a) cover letter/sheet, introductory information, and application forms; (b) 
protocols; (c) the investigator’s brochure; (d) chemistry, manufacturing, and control 
information; and (e) subject information, the informed consent form, and the informed 
consent procedure. 
(a) Cover Letter/Sheet, Introductory Information, and Application Forms 
Under the EU CTR, the letter, amongst other elements, should specify: the EU trial 
number and the universal trial number,306 whether the clinical trial in question is 
considered to be a low-intervention clinical trial, whether the trial is expected to obtain 
informed consent from participants through simplified means.307  
In this context, it is important to clarify that a “low-intervention clinical trial” within EU 
legislation means a clinical trial which cumulatively meets the following requirements:  
“(a) the investigational medicinal products, excluding placebos, are 
authorised; (b) according to the protocol of the clinical trial, (i) the 
investigational medicinal products are used in accordance with the terms of 
the marketing authorisation; or (ii) the use of the investigational medicinal 
products is evidence-based and supported by published scientific evidence 
on the safety and efficacy of those investigational medicinal products in any 
of the Member States concerned; and (c) the additional diagnostic or 
monitoring procedures do not pose more than minimal additional risk or 
burden to the safety of the subjects compared to normal clinical practice in 
any Member State concerned.”308  
Despite the fact that the US CFR does not rely on the same concept of “low-intervention 
clinical trial,” it is worth noting that some of the cases in which sponsors are exempted 
from the duty to file an IND application are similar to those listed under the “low-
intervention clinical trial” category in the EU CTR. In particular, under the US CFR 
exceptions apply when: a clinical investigation involves the use of a placebo but does not 
                                                 
306 Furthermore, in the case of a resubmission, “the cover letter shall specify the EU trial number for the 
previous clinical trial application, highlight the changes as compared to the previous submission and, if 
applicable, specify how any unresolved issues in the first submission have been addressed.” Annex 
I.B.12, EU CTR 536/2014. Note that applicants are required to submit a clinical trial number also under 
US legislation, certifying that the study is registered in the national database of clinical trials through 
FDA Form 3674. 
307 Annex I.B, EU CTR 536/2014. 
308 Article 2 (3), EU CTR 536/2014. 
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otherwise require the submission of an IND; the clinical investigation regards a drug 
product that is lawfully marketed in the US, when certain conditions apply regarding no 
prospective change of labelling or advertising; and no significant increase of the risk is 
entailed.309 In this sense, the exceptions identified in the US CFR and those that define a 
low-intervention clinical trial in the EU CTR are extremely similar. However, an 
important caveat should be noted: while the exceptions listed in the US CFR are 
technically exempted from the duty to file an IND application, the trials that meet the 
low-intervention standard in the EU are not exempted from the duty to file an application 
but are “merely” subjected to “less stringent rules.”310 
The US equivalent of the EU cover letter is the “Cover sheet (Form FDA-1571).” The 
latter is expected to include the following elements: the identification of the sponsor, or 
the phases of the clinical trial to be conducted, a commitment to await for the outcome 
of the IND application process, a commitment that an Institutional Review Board (IRB) 
will be responsible for the review of the study, the identification of monitoring subjects 
and of the contract research organization (CRO) if one is used.311  
Preliminarily, two observations can be made. First, the US CFR – unlike the EU CTR – 
already addresses on its cover sheet the issue of applicants based outside the US. In fact, 
the US CFR specifies that if the applicant resides outside the US, the IND must be 
countersigned by an agent who resides or maintains a place of business within the US.312 
Second, sponsors that file their application in the EU are not required to provide 
information regarding ethical review and monitoring in the cover letter, while applicants 
in the US are required to do so on the cover sheet. This aspect, however, merely has 
superficial value, as applicants in the EU are bound to address such issue in the EU 
application form in any event, while the latter must be submitted in addition to the cover 
letter. Currently the form is a 15 page document, which requires sponsors to provide 
some basic information and to check some boxes to describe the trial under standard 
                                                 
309 21 CFR 312.2(b)(1). 
310 See Preamble(11), EU CTR 536/2014 which reads as follows “[t]hose clinical trials should be subject 
to less stringent rules, as regards monitoring, requirements for the contents of the master file and 
traceability of investigational medicinal products. In order to ensure subject safety they should however 
be subject to the same application procedure as any other clinical trial.” 
311 21 CFR 312.23(a)(1). 
312 21 CFR 312.23(a)(1)(ix). 
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categories e.g. information useful to identify the sponsor and its legal representative, the 
sponsor’s status, the status of the products to be used in the clinical trial and its 
characteristics, information on the use of placebo, general information on the scope and 
the design of the trial, as well as on the targeted participants, prospective investigators, 
and ethical review authorities.313 On the other hand, applicants in the US must 
accompany the cover letter with a bundle of introductory information, which is not 
expected under the EU CTR. The US table of “introductory statement and general 
investigational plan” includes – inter alia – information pertaining to the following 
elements: a brief introductory statement giving the name of the drug, the broad objectives 
and planned duration of the trial as well as other elements; a brief summary of previous 
human experience with the drug and – interestingly – “to investigational or marketing 
experience in other countries that may be relevant to the safety of the proposed clinical 
investigation(s);”314 and information regarding e.g. risks of particular severity anticipated 
on the basis of the toxicological data in animals.315 Therefore, while there seems to be a 
partial overlap in the information expected to be provided by applicants in the EU cover 
letter and the US cover sheet, it can be noted how applicants in the EU are also required 
to fill the EU application form, and applicants in the US are also required to provide 
general introductory information (which touches already upon the matter of products 
already tested abroad).  
(b) Protocols  
Annex I.D to the EU CTR describes the content of the clinical trial protocol to be included 
in the application. 11 sub-provisions regulate the content of the protocol and one of them 
(Annex I.D.17) lists 38 elements that represent the minimum content of the protocol. 
Given how extensive the norms are, this contribution will refrain from listing all of them. 
Nevertheless, it is useful to highlight how the elements expected to be addressed in the 
                                                 
313 A copy of the form – in a 2009 version – is available in “EudraLex - Volume 10 - Clinical trials 
guidelines - Public Health - European Commission.” Public Health, 10 Sept. 2017,  
  ec.europa.eu/health/documents/eudralex/vol-10_en.  
 
314 Including information regarding the following: “[i]f the drug has been withdrawn from investigation or 
marketing in any country for any reason related to safety or effectiveness, identification of the 
country(ies) where the drug was withdrawn and the reasons for the withdrawal.” 21 CFR 
312.23(a)(3)(iii). 
315 21 CFR 312.23(a)(3). 
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protocol are “the objective, design, methodology, statistical considerations, purpose and 
organisation of the clinical trial.”316 As a result of this, protocols include details about 
design and safety procedures, lists of the products to be used and of the scientific findings 
that support the organization of the clinical trial, a description of the criteria to be used 
to select participants and of the monitoring procedures, and a description of the risk 
management strategies to be implemented especially in the case of adverse events.317  
Similarly, the US CFR requires applicants to file a protocol with technical information 
presented. The requirements set for in the US CFR are different than the EU ones in two 
ways. First, the list provided for in the US CFR is more concise. Unlike the EU rules, 
e.g. it does not require sponsors to address the issue of procedures to be implemented in 
case of adverse effects. Second, unlike the EU CTR, it requires applicants to include the 
name and address of each reviewing IRB.318 Third, while EU rules provide for a single 
set of requirements for protocols, independently form the phase involved in each clinical 
trials, US rules provide for a distinction on the basis of phases.319 Fourth, US 
requirements included in the content of the protocol the identification of investigators.320 
This is not required within EU protocols, however, applicants in the EU must 
nevertheless provide such information in a different section of the application named 
“suitability of the investigator.” This section aims at identifying “the planned clinical 
trial sites, the name and position of the principal investigators and the planned number 
of subjects at the sites.”321 In the application, the qualification of the investigators must 
be established and potential conflicts of interest must be identified.322 Additionally, 
information must be provided regarding the suitability of the facilities,323 proof of 
insurance cover of indemnification,324 a description of the financial agreements behind 
                                                 
316 Annex I.D.14, EU CTR 536/2014. 
317 Annex I.D, EU CTR 536/2014. 
318 21 CFR 312.23 (a)(6)(iii)(b). 
319 See 21 CFR 312.23 (a)(6)(i) which reads as follows: “protocols for Phase 1 studies may be less detailed 
and more flexible than protocols for Phase 2 and 3 studies.” 
320 21 CFR 312.23 (a)(6)(iii)(b). 
321 Annex I.M.64, EU CTR 536/2014. As of the sites, they must described also under the US FCR, in 
particular through the submission of FDA Form 1572. 
322 Annex I.M.65 and I.M.66, EU CTR 536/2014. 
323 Annex I.N, EU CTR 536/2014. 
324 Annex I.O, EU CTR 536/2014. 
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the conduction of the clinical trial,325 proof of payment of the fee (if applicable),326 and 
proof that data will be processed in accordance with EU law on data protection i.e. 
Directive 95/46EEC.327 
(c) Investigator’s Brochure  
The document has the purpose of reaching prospective investigators, later in the process. 
Therefore, its aim is to provide them with the information necessary to foster their 
understanding and compliance with the clinical trial, if approved.328 The expected content 
of the document is similar under the EU CTR and the US CFR. However, two differences 
can be noted. First, under the US CFR the IB must include a description of “possible 
risks and side effects” of the treatment that is tested;329 the IB described in the EU CTR, 
instead, refers to safety monitoring procedures and risk-benefit assessment but not 
explicitly to risks and side effects. Second, under the EU CTR the information provided 
in the IB shall be presented in a “non-promotional form”330 and a similar caveat about 
the style of the IB is not included in US norms.   
(d) Chemistry, Manufacturing, and Control Information 
Under the EU CTR, sponsors are required to submit an investigational medicinal product 
dossier (IMPD). By definition, the IMPD aims at giving information on “the quality of 
any investigational medicinal product, the manufacture and control of the investigational 
medicinal product, and data from non-clinical studies and from its clinical use.”331 IMPD 
rules are divided into three sub-sections that regard data relating to the investigational 
                                                 
325 Annex I.P, EU CTR 536/2014. 
326 Annex I.Q, EU CTR 536/2014. 
327 Annex I.R, EU CTR 536/2014. 
328 See Annex I.E.26, EU CTR 536/2014 – where IB stands for investigator’s brochure – which reads as 
follows: “[t]he purpose of the IB is to provide the investigators and others involved in the clinical trial 
with information to facilitate their understanding of the rationale for, and their compliance with, key 
features of the protocol, such as the dose, dose frequency/interval, methods of administration, and safety 
monitoring procedures. 
329  21 CFR 312.23 (a)(5)(v) see also “[s]uch information may be distributed to investigators by means of 
periodically revised investigator brochures, reprints or published studies, reports or letters to clinical 
investigators, or other appropriate means”. 21 CFR 312.55 (b). 
 
330 Annex I.E.27, EU CTR 536/2014. 
331 Annex I.G.36, EU CTR 536/2014 note also that following Annex I.H, the IMPD requirements apply 
also to auxiliary medicinal products.  
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medicinal product,332 simplified IMPD by referring to other documentation,333 and IMPD 
in cases of placebo.334 In the context of this contribution, it is interesting to note that the 
section of the EU CTR regarding the IMPD does not solely state EU standards but in 
more than one occasion refers to ICH standards to provide applicants with examples. 
This happens, for example, in the context of provisions on quality data,335 non-clinical 
pharmacology and toxicology data,336 and data from previous clinical trials and human 
experience.337 Additionally to the IMPD, applicants may submit an auxiliary medicinal 
product dossier, a scientific advice and pediatric investigation plan (PIP), and the content 
of the labeling of the investigational medicinal product, and recruitment arrangements.338 
The latter section, in particular, includes copies of the advertising material to be used in 
case of recruitment through advertisement.339 Furthermore, applicants in the EU are 
required to file any documentation relating to compliance with good manufacturing 
practice (GMP) for the investigational medicinal product.340 Two very important 
provisions can be noted in this context because they represent a bridge between the EU 
context and potential connections with global clinical trials. First, the documentation 
should not be submitted “where the investigational medicinal product is authorised and 
is not modified.”341 Interestingly, this exception applies, whether or not the product is 
manufactured in the EU.342 Second, particular conditions are envisaged for products that 
                                                 
332 Annex I.G.37-49, EU CTR 536/2014. 
333  Annex I.G.50-53, EU CTR 536/2014. 
334 Annex I.G.54, EU CTR 536/2014. 
335 Annex I.G.40, EU CTR 536/2014 which reads as follows: “[q]uality data shall be submitted in a logical 
structure such as that of Module 3 of the ICH Common Technical Document format.” Cf. “The CTD 
triangle and M4: The Common Technical Document.” ICH, www.ich.org/products/ctd.html.  
336 Annex I.G.42, EU CTR 536/2014 which reads as follows: “[n]on-clinical pharmacology and toxicology 
data shall be submitted in a logical structure, such as that of Module 4 of the ICH Common Technical 
Document format.” 
337 Annex I.G.46, EU CTR 536/2014 which reads as follows: “[d]ata from previous clinical trials and 
human experience shall be submitted in a logical structure, such as that of Module 5 of the ICH Common 
Technical Document format.” 
338 Annex I.H-K, EU CTR 536/2014. 
339 Annex I.K.60, EU CTR 536/2014. 
340 Annex I.F, EU CTR 536/2014 note also that following Annex I.H, the IMPD requirements apply also 
to auxiliary medicinal products. 
341 Annex I.F.32, EU CTR 536/2014. 
342 Ibid.  
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are not authorized within the EU but have a marketing authorization from a third country 
that is party to the ICH.343 
Similarly, in the US context, applicants are required to provide information regarding the 
composition, manufacture, and control of the drug substance and the drug product as well 
as pharmacology and toxicology information.344 While the list of requirements included 
in the US CFR is less detailed than that included in the EU CTR, it is important to note 
that in the US framework, the case of products already tested and/or commercialized in 
other countries is also foreseen. In particular, US legislation provides that (a) “if the 
investigational drug has been investigated or marketed previously, either in the US or 
other countries, detailed information about such experience that is relevant to the safety 
of the proposed investigation or to the investigation’s rationale”345 and (b) “if the drug 
has been marketed outside the US, a list of the countries in which the drug has been 
marketed and a list of the countries in which the drug has been withdrawn from marketing 
for reasons potentially related to safety or effectiveness.”346 In this sense, provisions 
regarding products tested or commercialized abroad seem more stringent in the US 
context, and in any event, the amount of information pertaining to such products that 
applicants are required to disclose is greater under US standards than under EU standards.  
(e) Subject Information, Informed Consent Form, and Informed Consent Procedure 
Under the EU CTR, applicants must submit information regarding informed consent 
forms,347 procedures in place to protect vulnerable subjects (e.g. incapacitated 
subjects),348 involving witnesses,349 in place in case of emergency situations,350 or for 
cases in which simplified means to obtain informed consent are sought.351 All of these 
elements fall within a specific section of the EU application. On the contrary, US norms 
do not provide for a specific portion of the application to focus on human subjects’ 
                                                 
343 Cf. Annex I.F.33-35 and Article 61, EU CTR 536/2014. 
344 21 CFR 312.23 (a)(7)(i) and 21 CFR 312.23 (a)(8). 
345 21 CFR 312.23 (b)(iii)(9)(i). 
346 21 CFR 312.23 (b)(iii)(9)(iii). 
347 Annex I.I.61, EU CTR 536/2014. 
348 Annex I.I.62, EU CTR 536/2014. 
349 Ibid. 
350 Ibid. 
351 Ibid.  
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guarantees and informed consent. Instead, applicants in the US are expected to address 
the criteria for participants’ selection and protection within the protocol.352 As for their 
duty to address informed consent-related issues, despite the fact that other portions of the 
CFR (outside the context of IND applications) are dedicated to the matter, the only 
reference included in 21 CFR 312.23 regards the need of pre-identification of exception 
from informed consent.353 
(3) Assessment of the Application
Assessment procedures can be compared on the basis of different elements. The 
following paragraphs in this contribution will deal with four specific aspects: the timing 
of the assessment process, the bodies entrusted with the assessment, the criteria to be 
used in the assessment process, and the possible outcomes of the assessment. 
(a) Timing of the Assessment Process
With regard to the timing of the assessment process, the EU CTR provides that sponsors 
and the concerned Member States must be notified by the reporting Member State of the 
assessment report through the EU portal within 45 days from the validation date of the 
application. For the purpose of the regulation, the validation date does not necessarily 
coincide with the date in which the application was filed. Rather, the 45-day term starts 
running from the day in which a sponsor was notified by the reporting Member State that 
the application submitted was (or was not) found to fall within the scope of the EU CTR 
and was (was not) deemed to be complete.354 The notification regarding the pertinence 
and completeness of the application, in any event, must take place within 10 days since 
the application submission.355 Hence, sponsors will receive a response regarding the 
admission or rejection of their clinical trials in the EU within 55 days from the filing of 
the application.  
352 Cf. 21 CFR 312.23 (a)(6)(iii)(c). 
353 21 CFR 312.23 (f). 
354 Article 5 (6), EU CTR 536/2014. 
355 Article 5 (3), EU CTR 536/2014. 
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Within the US framework, applications are technically processed by the Center for Drug 
Evaluation and Research, as part of the FDA.356 Following the submission of the 
application, the will enter into force after 30 days, unless the FDA notifies the sponsor 
that a clinical hold is applied.357 A clinical hold is an order issued “to delay a proposed 
clinical investigation or to suspend an ongoing investigation.”358 If a clinical hold is put 
into place within the 30 days term, the sponsor will receive a written explanation of the 
hold within 30 days after the imposition of the hold.359 (b) Bodies Entrusted with the 
Assessment 
With regard to the bodies entrusted with the assessment, in the EU framework, the 
ultimate decision regarding the authorization of clinical trials is left to the Member States. 
Member States determine autonomously which bodies to involve in the assessment as a 
matter of internal organization.360 The EU CTR, however, refers to such bodies as “ethics 
committees” and specifies some core requirements: the involvement of at least one 
layperson, the involvement of qualified and experienced subjects, the involvement of 
specifically qualifies subjects in specific circumstances,361 the lack of conflicts of interest 
between the members of the committees and any of the stakeholders involved in the 
clinical trials examined.362 In the US, while the ultimate decision regarding any IND 
application lies with the FDA, the assessment of the clinical trials is traditionally assigned 
to Institutional Review Board (IRB). Under the US CFR, clinical trials cannot initiate 
unless they have been reviewed and approved by an IRB.363 While the bodies entrusted 
                                                 
356 Center for Drug Evaluation and Research. “About the Center for Drug Evaluation and Research.” U S 
Food and Drug Administration Home Page, Center for Drug Evaluation and Research, 
www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/default.htm.  
357 21 CFR 312.40(b)(1). See also “Investigational New Drug Application (IND) Process Overview.” 
Investigational New Drug Application (IND) Process Overview | Clinical Trials | Health Care 
Professionals | Dartmouth-Hitchcock,  
    med.dartmouth-hitchcock.org/clinical_trials/ind_process_overview.html.  
358 21 CFR 312.42 (a). 
359 21 CFR 312.42 (d). 
360 Preamble (18), EU CTR 536/2014. 
361 In addition, “[s]pecific expertise should be considered when assessing clinical trials involving subjects 
in emergency situations, minors, incapacitated subjects, pregnant and breastfeeding women and, where 
appropriate, other identified specific population groups, such as elderly people or people suffering from 
rare and ultra rare diseases.” Preamble (19), EU CTR 536/2014. 
362 Preamble (18) and Article 9, EU CTR 536/2014. 
363 21 CFR 56.103 (a). The requirement does not apply to some exceptional cases; in particular, trials 
commenced before July 27, 1981, emergency use of a test article, provided that such emergency use is 
reported to the IRB within 5 working days, some taste and food quality evaluations and consumer 
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with the assessment under the EU CTR are not necessarily the same that will keep 
reviewing over time the clinical trial that they have approved, clinical trials in the US 
remain subject to continuing review by an IRB during the whole length of the trial.364 In 
practical terms, IRBs are bodies – both private and public in nature –, which have 
undergone a registration process through the FDA.365 The US CFR provides with some 
details about the composition of IRBs in a way that is more detailed than the EU CTR. 
In particular, while – similarly to ethics committees in the EU framework –, IRBs’ 
members are expected to be selected on the basis of “experience and expertise,” if 
necessary considering the involvement of specifically qualifies subjects in specific 
circumstances,366 and are expected to have no conflict of interest with the projects 
assessed,367 specific considerations apply to IRBs which are not to be found in the EU 
framework. For example, the US FCR provides that IRBs must: be composed of at least 
5 members and on the basis of diversity-considerations;368 ensure diversity of gender in 
its composition; not consist entirely of members of one single profession; and collectively 
possess the expertise to assess not only the scientific validity of a project but also its 
organizational feasibility and compliance with the law.369 In the US CFR, there is not 
provision similar to Article 6 of the EU CTR requiring laypersons to be involved in the 
assessment process; however, the US CFR provides that “[e]ach IRB shall include at 
least one member who is not otherwise affiliated with the institution and who is not part 
of the immediate family of a person who is affiliated with the institution.”370  
                                                 
acceptance studies, and in cases in which the FDA decides to waive the IRB requirement. See 21 CFR 
56.104 and 56.105.   
364 Cf. 21 CFR 56.103 (a). 
365 The registration requirements are listed in 21 CFR 56.106. 
366 See.21 CFR 56.107 which reads as follows “[i]f an IRB regularly reviews research that involves a 
vulnerable category of subjects, such as children, prisoners, pregnant women, or handicapped or 
mentally disabled persons, consideration shall be given to the inclusion of one or more individuals who 
are knowledgeable about and experienced in working with those subjects.” 
367 21 CFR 56.107. 
368 See 21 CFR 56.107 (a) which reads as follows: “including consideration of race, gender, cultural 
backgrounds, and sensitivity to such issues as community attitudes (…).” 
369 21 CFR 56.107 and, specifically, see section (a) which reads as follows: “[i]n addition to possessing the 
professional competence necessary to review the specific research activities, the IRB shall be able to 
ascertain the acceptability of proposed research in terms of institutional commitments and regulations, 
applicable law, and standards of professional conduct and practice.” 
370 21 CFR 56.107 (d). 
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(b) Criteria to be Used in the Assessment Process 
With regard to the criteria to be used in the assessment process, it is important to note 
that in the EU framework the Member States are provided with a single set of criteria to 
be used in the assessment. Differently, criteria relevant in the US framework can be found 
in two sets of provisions: those regarding the IRB criteria for approval of research and 
those regarding the grounds for the imposition of a clinical hold by the FDA.371  
In the EU framework, the assessment is conducted on the basis of the “anticipated 
therapeutic and public health benefits” and the “risks and inconveniences for the 
subjects.372 Furthermore, compliance with the requirements concerning the 
manufacturing of the products, labeling requirements, and completeness and 
adequateness of the IB is assessed.373 With regard to specific concerns for the protection 
of subjects, assessment criteria focus on compliance with informed consent requirements, 
rewarding/compensation policies, suitability of sites and investigators, and data 
protection requirements.374 EU norms provide also for an additional set of provisions that 
belong to the context of assessment-criteria and do not strictly regard the approval 
process for clinical trials but rather the division of competences between different 
Member States involved in the process.375  
In the US framework, the concerns assessed by IRBs are similar. In order to approve 
research projects, IRBs must consider the following issues: the risks for subjects, with 
one of the concerns being the avoidance of unnecessary risks;376 the risks-benefits 
balance, where, however, two elements are not to be considered: “risks and benefits of 
therapies that subjects would receive even if not participating in the research” and “the 
possible effects of the research on public policy;”377 the equitableness of subjects’ 
selection;378 the quality of informed consent procedures to be implemented;379 the 
                                                 
371 See respectively 21 CFR 56.11 and 21 CFR 312.42. 
372 Article 6.1(b), EU CTR 536/2014. 
373 Article 6.1(c)-(e), EU CTR 536/2014. 
374 Article 7.1, EU CTR 536/2014. 
375 E.g. Article 6.5-8, EU CTR 536/2014. 
376 21 CFR 56.111 (a)(1). 
377 21 CFR 56.111 (a)(2). 
378 21 CFR 56.111 (a)(3). 
379 21 CFR 56.111 (a)(4)-(5). 
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policies implemented for data protection and privacy concerns.380 It is interesting to note 
that both legal systems provide for caveats to be considered in the case of clinical trials 
involving vulnerable subjects. However, the identification of vulnerable subjects, as well 
as the identification of the concerns related to their participation in clinical trials is more 
extensive in the case of US legislation. In fact, under the EU framework, Article 10 CTR 
prescribes that specific considerations shall be given to the assessment of applications 
for clinical trials involving minors, incapacitated subjects, pregnant or breastfeeding 
women, and emergency trials.381 However, the EU CFR does not specifically identify the 
major concerns to be considered in the context of research involving vulnerable subjects. 
On the other hand, the US CFR identifies a longer list of subjects: “children, prisoners, 
pregnant women, handicapped, or mentally disabled persons, or economically or 
educationally disadvantaged persons.”382 It also identifies the specific concern behind the 
need to protect those subjects as being vulnerable to coercion and undue influence.383 
Aside from the IRBs’ assessment, the FDA, in deciding whether to impose a clinical 
hold, will take into consideration the following elements: unreasonable and significant 
risk of illness or injury for participants,384 unqualified clinical investigators, misleading, 
erroneous, or materially incomplete IB, lack of information in the IND application, and 
in the case of projects “not designed to be adequate and well-controlled.”385 Interestingly, 
while the elements listed so far are to be considered for Phase 1 studies; for Phase 2 or 3 
studies, an additional ground for clinical holds is the deficient design of the study to meet 
                                                 
380 Note, however, that the US CFR adds a caveat in the case of data protection and privacy concerns that 
makes the assessment of the IBR more discretionary than for other elements. In facts, the wording of 21 
CFR 56.111 (a)(6)-(7) sets the standard to “when appropriate.” 
381 Article 10, EU CTR 536/2014. in addition, the preamble refers to a concern for economically 
disadvantaged subjects but does not associate any prescription regarding an absolute need for their 
protection. See: “[i]n order to certify that informed consent is given freely, the investigator should take 
into account all relevant circumstances which might influence the decision of a potential subject to 
participate in a clinical trial, in particular whether the potential subject belongs to an economically or 
socially disadvantaged group or is in a situation of institutional or hierarchical dependency that could 
inappropriately influence her or his decision to participate.” Preamble (31), EU CTR 536/2014 
382 21 CFR 56.111 (b). 
383 Ibid. 
384 A more specific concern regards “[t]he IND is for the study of an investigational drug intended to treat 
a life-threatening disease or condition that affects both genders, and men or women with reproductive 
potential who have the disease or condition being studied are excluded from eligibility because of a risk 
or potential risk from use of the investigational drug of reproductive toxicity (i.e., affecting reproductive 
organs) or developmental toxicity (i.e., affecting potential offspring).” 21 CFR 312.42 (b)(v) 
385 21 CFR 312.42 (b). 
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its objectives.386 On the other hand, the EU CTR does not distinguish concerns on the 
basis of the phases that clinical trials are addressing. 
(c) Possible Outcomes of the Assessment 
Finally, with regard to the possible outcomes of the assessment, the US system maintains 
a two-tier process in which clinical trials applications are examined first by an IRB and 
then by the FDA. At the IRB-level, IRBs have the authority to “approve, require 
modifications in (to secure approval), or disapprove all research activities.”387 At the 
FDA level, the agency has the power to approve a clinical trial application or to impose 
a clinical hold in order to delay the proposed investigation or suspend an ongoing one.388 
In the EU framework, the reporting Member State can conclude its assessment report 
finding that the clinical trial project is either acceptable under the EU CTR’s 
requirements, or acceptable but subject to compliance with specific conditions listed in 
the conclusion, or not acceptable under the EU CTR’s requirements.389 Despite the lack 
of specific instructions given by the EU CTR to national ethics review boards, the EU 
CTR adds a further level of review that can be triggered in certain cases. This regards the 
situation in which a concerned Member State may disagree with the conclusions drawn 
be the reporting Member State. The only grounds on which objections may be raised by 
the concerned Member State are the following: when “participation in the clinical trial 
would lead to a subject receiving an inferior treatment than in normal clinical practice in 
the Member State concerned,” when its national law on the use of any specific type of 
human or animal cells or derived products, or considerations regarding subjects safety 
and data reliability and robustness.390   
In conclusion, the approval protocols in the EU and the US framework present both 
several similarities and differences. On the one hand, the main similarities regard the 
timing of the assessment and the criteria to be used in the assessment. On the other hand, 
the main differences, concern three principal points. First, the structure of the assessment 
mechanism in terms of institutional bodies involved. In this context, the EU assessment 
                                                 
386 21 CFR 312.42 (b)(v)(C)(2)(ii). 
387 21 CFR 56.109 (a). 
388 21 CFR 312.42 (a). 
389 Article 6.3 (a)-(c), EU CTR 536/2014. 
390 Article 8.2(a)-(c), EU CTR 536/2014. 
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is principally conducted by national review boards instituted in the Member States but 
under the instructions included in the EU CTR and with the possibility for concerned 
Member States to object the assessment’s outcome. In the US, the assessment has a two-
tier structure in which first IRBs are involved and then the FDA is involved. The second 
point relates to the protection of vulnerable subjects – in which case, the US CFR 
provides for a longer list of subjects and specifies that the main concern for clinical trials 
that involve them regards coercion and undue influence, while the EU CTR provides for 
a shorter list and no identification of specific concerns to be taken into consideration. The 
third point concerns the possible outcome of the assessment process, where, in the US 
system, sponsors may be granted an exception (that de facto will allow them to conduct 
the clinical trial) or be subjected to a clinical hold, while in the EU system sponsors may 
receive a full approval, a conditional one, or a rejection of their application.  
(4) Specific Concerns 
There are two additional issues that this comparative analysis takes into consideration. 
Both regard aspects of clinical trials design and application, which are intrinsically 
connected with concerns for the protection of human subjects: rules applicable to the use 
of placebo in clinical trials and rules applicable to the design and obtainment of informed 
consent. The will be analyzed in this sub-section, as they represent concerns that are 
particularly relevant in terms of the protection of the human subjects who take part in 
clinical trials. One additional issue regards the life of clinical trials following their 
approval and specifically the control procedures to which they are subjected and will be 
addressed in the following sub-section.  
(a) Use of Placebo in Clinical Trials 
As noted earlier, the use of placebo trials is often controversial.391 In the EU CTR context, 
repeated reference to the use of placebo is made. The first regards the definition within 
which placebos fall, which is the “investigational medicinal product” one.392 The second 
one regards the simplified IMPD application within which, if the investigational medical 
                                                 
391 Cf. e.g. Gupta and Verma, op. cit. 
392 Annex I (54), EU CTR 536/2014. 
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product is a placebo, applicants are only required to provide quality data.393 No reference 
is made within the EU CTR to the need for the use of placebo-controlled trials to be 
limited as much as possible. However, good clinical practice standards – to which the 
same EU CTR refers – as well as the European Medicines Agency have over time 
clarified the scope of the use of placebo in clinical trials conducted in the EU. In 
particular, their considerations suggest that the current standard in the EU territory is 
based on two elements. First, the fact that placebo-controlled trials are not per se 
prohibited, even in areas in which proven prophylactic and therapeutic methods exist.394 
Second, ethical considerations should limit the use of placebo-controlled trials. Those 
considerations include (i) concerns for the risk of irreversible harm to the subjects, (ii) 
the need for the obtainment of an adequate informed consent, (iii) the right of subjects to 
withdraw from a clinical trial, but still receive conventional treatment, and (iv) the need 
to apply identical standards to trials conducted outside the EU territory.395    
In the US context, similarly, there is no prohibition of the use of placebo per se. In fact, 
placebo-controlled trials are one of the five categories identified by the FDA in response 
to effectiveness concerns (the five categories being placebo concurrent control, dose-
response concurrent control, no-treatment concurrent control, active treatment 
concurrent control, and historical control).396 However, both under applicable legal 
standards and common clinical practice, reliance upon placebo-controlled trials 
principally arises in the context of add-on treatments to standard therapy or in the case 
of patients refractory to standard treatment.397 Add-on treatments, in particular, are those 
in which “when a placebo is used, standard care, if any, would be given to all subjects, 
with subjects randomized to receive, in addition, the test treatment or a placebo.”398 
Despite the fact that they represent traditional usages of placebo in clinical trials, under 
                                                 
393 Furthermore, “[n]o additional documentation is required if the placebo has the same composition as the 
tested investigational medicinal product (with the exception of the active substance), is manufactured 
by the same manufacturer, and is not sterile.” Article 2.2(6), EU CTR 536/2014. 
394 European Agency for the Evaluation of Medicinal Products, Pre-authorisation Evaluation of Medicines 
for Human Use (London, 28 June 2001) EMEA/17424/01. 
395 Ibid.  
396 61 FR 51498 and Office of the Commissioner. “Search for FDA Guidance Documents - Drug Study 
Designs - Information Sheet.” US Food and Drug Administration Home Page, Office of the 
Commissioner, www.fda.gov/RegulatoryInformation/Guidances/ucm126501.htm.  
397 FDA, “Placebo-controlled Trials: Are They Ethical? Are They Necessary?” Presentation available at 
https://www.fda.gov/ohrms/dockets/ac/00/slides/3641s1d.ppt 
398 61 FR 51498. 
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US legislation they are not necessarily the only cases in which placebo may be used. In 
fact, the US CFR provides that “[a] placebo-controlled study may [emphasis added] 
include additional treatment groups, such as an active treatment control or a dose-
comparison control, and usually includes randomization and blinding of patients or 
investigators, or both.”399 Hence, the use of placebo – even when a better available 
standard of care exists – is not openly prohibited by the FDA but in normal 
circumstances, the agency expects clinical trials to be placebo-controlled mainly in the 
context of add-on treatments. To conclude, neither in the EU nor in the US context is 
reliance on placebo-controlled clinical trials prohibited per se, but ethical and practical 
considerations limit sponsors’ recourse to it where alternative designs are available.400  
(b) Informed Consent Regulation 
Informed consent rules to be applied in the context of clinical trials and set in the EU and 
the US frameworks are similar yet not identical. This section will compare the two sets 
of provisions and identify elements that are unique to each legal system.  
Under the EU CTR, the first caveat regarding informed consent is in included in the 
preamble. It specifies that Member States should cooperate in the assessment of any 
clinical trial authorization, but that aspects of intrinsically national nature (e.g. informed 
consent) are not included in such duty to cooperate.401 Despite the identification of 
informed consent procedures as intrinsically national in nature, the EU CTR addresses 
the issue of informed consent in several ways. First, it identifies informed consent as one 
of the essential requirements supporting the legality of clinical trials. It does so both 
referring to the Charter of Fundamental Rights of the EU and the value of human dignity, 
and listing the technical elements necessary to approve a clinical trial.402 Similarly, 
                                                 
399 21 CFR 314.126 (b)(2)(i). 
400 Cf. “Access Services to Enable Research.” Placebo Controls – Are they Ethically Acceptable in a 
Clinical Trial? | CTSI Services for Researchers, accelerate.ucsf.edu/blogs/ethics/placebo-controls-
%E2%80%93-are-they-ethically-acceptable-clinical-trial.  
401 Preamble (6), EU CTR 536/2014. 
402 See Preamble (27), EU CTR 536/2014: “Human dignity and the right to the integrity of the person are 
recognised in the Charter of Fundamental Rights of the European Union (the ‘Charter’). In particular, 
the Charter requires that any intervention in the field of biology and medicine cannot be performed 
without free and informed consent of the person concerned” and Article 28, EU CTR 536/2014: “A 
clinical trial may be conducted only where all of the following conditions are met: (…) the subjects, or 
where a subject is not able to give informed consent, his or her legally designated representative, have 
been informed in accordance with Article 29(2) to (6).” 
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informed consent is an essential element of clinical trials approval in the US 
framework.403  
The EU CTR requires informed consent to be written, dated and signed by the 
professional conducting the informed consent interview and by the subject.404 
Furthermore, the subject must be given adequate time to consider her decision to take 
part in the research and must be given a copy of the document.405 Similarly, under the 
US CFR, sufficient time must be given to the subject to consider her decision to 
participate,406 the subject must receive a copy of the consent form,407 and the date of the 
signature of the form must be entered.408 It appears like the signatures explicitly relevant 
in the US context are those of the subject and his or her legal representative (if one is 
involved) and that – unlike in the EU system – no signature of an investigator is required. 
As to the availability of means alternative to written consent and language requirements, 
in the EU, audio or video recorders may be used when necessary but a witness must be 
present and interviews with any subject should take place “in a language which is easily 
understood by him or her.”409 It is not clear whether the latter requirements refer to the 
use of technical language vs lay language, or the mother tongue of the participant (e.g. 
for immigrants). In the US context, reliance on has a different meaning to traditional 
written consent. Such a conclusion can be made in two situations: first, when use of a 
short form is allowed and the elements of informed consent are presented orally to the 
subject.410 Alternative methods of obtaining informed consent (e.g. via telephone, email, 
and in general not in face-to-face circumstances) are constantly discussed and monitored 
by the FDA.411 As of the language-concern, US legislation relies on the goal of 
                                                 
403 With the exclusion of some exceptions, “no investigator may involve a human being as a subject in 
research covered by these regulations unless the investigator has obtained the legally effective informed 
consent of the subject or the subject's legally authorized representative.” 21 CFR 50.20.  
404 Article 29.1, EU CTR 536/2014. 
405 Ibid. Note also that the prior interview must be conducted by a “member of the investigating team who 
is appropriately qualified according to the law of the Member State concerned.” Article 29.2(c), EU 
CTR 536/2014. 
406 21 CFR 50.20.  
407 21 CFR 50.27 (a).  
408 Ibid. 
409 Preamble (30), EU CTR 536/2014. 
410 21 CFR 50.27 (b)(2). 
411 FDA, Informed Consent Information Sheet Guidance for IRBs, Clinical Investigators, and Sponsors, 
2014, at p. 17. 
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understandability without specifically referring to non-English speaking participants; 
however, FDA guidelines provide for instructions to be used in case of non-English 
speaking participants.412  
As for the elements of informed consent, the EU CTR lists seven basic requirements. 
Inform consent should enable subjects to understand (i) “nature, objectives, benefits, 
implications, risks and inconveniences of the clinical trial,” (ii) their rights and guarantee, 
in particular in case of refusal to participate and withdrawal, (iii) the conditions of the 
clinical trial (e.g. expected duration), (iv) possible treatment alternatives, and (v) follow-
up measures if the participation in the clinical trial is discontinued.413 Furthermore, 
subjects must be provided with information regarding (vi) the applicable damage 
compensation and (vii) the EU trial number and information on the availability of 
results.414 The goal of the first five elements is strictly tied to the need for participants to 
understand information pivotal to the formation of their free consent, while the last two 
elements regard more widely information that must be provided (without any specific 
focus on the need for subjects to understand it). The EU CTR provides also that informed 
consent procedures shall be kept “understandable to a layperson.”415  
Similar elements can be found in the US CFR requirements, though the latter often appear 
to be more detailed. Under the US CFR, informed consent procedures are expected to 
include (a) a description of the clinical investigation – which encompasses a description 
of the procedures and their purposes, including practical information e.g. about the 
number of clinical visits expected.416 This element is similar to the one identified under 
(i) and (iii) above. (b) A description of “any reasonably foreseeable risk or discomforts
to the subjects.”417 This statement is more precise than the one included under (i) above,
as the threshold is clearly set by the foreseeability of risks in the US system,418 while it
412 Ibid. at p. 30. Note, in any event, that individuals cannot be routinely excluded from participation 
because they do not understand English cf. 21 CFR 56.111 (a)(3). 
413 Article 29.2(a), EU CTR 536/2014. 
414 Article 29.2(d)-(e), EU CTR 536/2014. 
415 Article 29.2(b), EU CTR 536/2014. 
416 21 CFR 50.25 (a)(1) and FDA, Informed Consent Information Sheet Guidance for IRBs, Clinical 
Investigators, and Sponsors, 2014, at p. 7. 
417 21 CFR 50.25 (a)(2). 
418 Except in certain situations in which a statement about unforeseeable risks may be included in informed 
consent forms under 21 CFR 50.25 (b)(1). 
 99 
may entail both foreseeable and unforeseeable risks in the EU. (c) A description of the 
expected benefits,419 as under (i) above. (d) A disclosure of appropriate alternative 
procedures,420 as under (iv) above. It is worth noting that in addition to this, distinct from 
the EU CTR, the FDA recommends that subjects are also informed about the care that 
they would receive if they were to decide not to take part in the research421 and about the 
effect of participation in one trial on eligibility to participate in others.422 (e) A statement 
about the confidentiality policy to be applied to medical records pertinent to the clinical 
trial,423 which appears to be different than the rule on availability of clinical trial results 
under the EU CTR described in (vii) above. (f) An explanation of the compensation 
available in the case of injuries,424 as under (vi) above. A different exists between the two 
legal standards in this context: while under the EU CTR Member States shall ensure for 
damage compensation mechanisms,425 in the US context it is possible to organize clinical 
trials in which no damage compensation is available e.g. due to hospital policies.426 (g) 
The contacts of competent subjects that may be reached to obtain clarifications regarding 
the clinical trial.427 This element is not explicitly present in EU legislation. (h) A 
statement regarding the voluntariness of the participation and the possibility of 
withdrawal,428 as in (ii) above. Differently than EU legislation (point (v) above), the 
fundamental elements identified in the US CFR do not include provisions on the 
involuntary termination of subjects’ participation. Information regarding that case, in the 
US context, are to be included in informed consent documents only when appropriate.429 
Further information that can be presented in the US context (when appropriate) and that 
are not listed in the EU CTR concern: unforeseeable risks, additional costs to subjects, 
                                                 
419 21 CFR 50.25 (a)(3). 
420 21 CFR 50.25 (a)(4). 
421 21 CFR 50.25 (a)(1) and FDA, Informed Consent Information Sheet Guidance for IRBs, Clinical 
Investigators, and Sponsors, 2014, at p. 7. 
422 Ibid., at p. 10. 
423 21 CFR 50.25 (a)(5). 
424 21 CFR 50.25 (a)(6). 
425 Article 76, EU CTR 536/2014. 
426 In that case disclaimers should include statements about e.g. hospital policies in the informed consent 
documents. See FDA, Informed Consent Information Sheet Guidance for IRBs, Clinical Investigators, 
and Sponsors, 2014, at p. 11. 
427 21 CFR 50.25 (a)(7). 
428 21 CFR 50.25 (a)(8). 
429 21 CFR 50.25 (b)(2). 
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consequences of withdrawal, significant new findings and the policy for their disclosure, 
and the number of subjects involved in clinical trial.430  
There are two categories of particular circumstances in which standard norms prescribed 
for informed consent procedures do not entirely apply. They regard cases in which the 
threshold to obtain informed consent is lowered; and cases in which the threshold to 
obtain consent is heightened. They will be analyzed and compared in the following 
paragraphs.  
(i) Lowered Informed Consent Standards 
Both in the EU and the US systems, in certain circumstances, legislators allowed for 
informed consent to be obtained in ways that are procedurally less complex than in the 
standard case. The main case is the one of emergency participation in clinical trials.   
First, under EU legislation, clinical trials in emergency situations result in the need to 
obtain informed consent “only” after the decision to include the subject in the trial 
“provided that this decision is taken at the time of the first intervention on the subject, in 
accordance with the protocol for that clinical trial” and that six conditions are met.431 In 
the US context, the consequence of a finding of emergency situation renders unnecessary 
the obtaining of informed consent.432 The finding is subject to several requirements and 
procedural steps.  
Second, in the US context, the assessment of the presence of an emergency situation is 
left to the investigator and “a physician who is not otherwise participating in the clinical 
investigation.”433 Furthermore, the documentation regarding the assessment of the 
emergency situation is then expected to be submitted to an IRB.434 The EU CTR does not 
clarify which subjects are to be involved in the assessment of emergency situations.  
Third, under the EU CTR, six conditions must be met for a clinical trial in an emergency 
situation to be allowed. They regard the existence of (1) sudden life-threatening or serious 
                                                 
430 21 CFR 50.25 (b). 
431 Article 35, EU CTR 536/2014. 
432 21 CFR 50.23. 
433 21 CFR 50.23 (a). Also, following 21 CFR 50.23 (b), the opinion of the independent physician may be 
obtained ex post under certain circumstances, but within 5 days from the start of the trial on the patient. 
434 21 CFR 50.23 (c). 
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condition that makes the subject incapable of giving informed consent; (2) scientific 
grounds which allow to expect measurable health-improvement for the subject; (3) 
impossibility to obtain informed consent form the subject’s representative within the 
“therapeutic window;” (4) absence of known objections to participate previously 
expressed by the subject; (5) characteristics of the trial that make it possible only in 
emergency situations – it is not clear whether this requirement refers to the subjective 
situation of the participant or to the nature of the trial; (6) minimal risk and minimal 
burden for the subject, in comparison with the standard available treatment.435 Under the 
US CFR, four conditions must exist: (1) life-threatening situation436 – which differs from 
the EU standard to the extent that it must involve a life-threatening situation and not, in 
alternative, a “serious condition;” (2) impossibility to obtain informed consent form the 
subject’s representative,437 as under EU standards; (3) impossibility to obtain informed 
consent form the subject,438 as under EU standards; (4) “no alternative method of 
approved or generally recognized therapy that provides an equal or greater likelihood of 
saving the life of the subject.”439 The last requirement refers directly to a comparison 
between available treatments and the one to be tested in terms of effectiveness, while the 
EU CTR only compares treatments in terms of risks and burden for subjects. An 
additional difference between the two tests lies in the lack of reference to possible 
previous objections of the subject in the US context.  
Fourth, it is worth noting that the EU CTR describes the standard to be applied to clinical 
trials in emergency situations with regard to single subjects. Differently, the US CFR 
provides that lower standards for informed consent can be applied not only in case of 
single subjects but also in the face of military operations and public health 
emergencies.440 Furthermore, the EU CTR provides for the possibility to obtain informed 
consent by simplifies means in case of cluster trials (i.e. that require groups of subjects 
                                                 
435 Article 35.1(a)-(f), EU CTR 536/2014. 
436 21 CFR 50.23 (a)(1). 
437 21 CFR 50.23 (a)(2). 
438 21 CFR 50.23 (a)(3). 
439 21 CFR 50.23 (a)(4). 
440 21 CFR 50.23. The only way in which the EU CTR addresses the issue of public health crisis is by 
stating the following in the preamble: “[i]n the event of a public health crisis, Member States should 
have the possibility to assess and authorise a clinical trial application swiftly. No minimal timelines for 
approval should therefore be established.” Preamble (8), EU CTR 536/2014. 
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rather than single participants, are low-intervention, use products in accordance with 
marketing authorizations, and justify the reliance on informed consent obtained in 
simplified means) when they take place in only one Member State.441 Such option is not 
envisaged in the US context.  
(ii) Heightened Informed Consent Standards 
In certain circumstances, particular concerns arise in the case of participants in clinical 
trials that belong to potentially vulnerable categories. They regard subjects that are 
capable of giving informed consent but in certain conditions may not be able to freely 
exercise that capability i.e. persons performing military service, persons deprived of 
liberty, persons living in residential care institutions, etc., and also subjects that may have 
an impaired consent capacity e.g. incapacitated subjects and minors.  
The EU CTR provides directly for specific norms for informed consent to be applied 
when the following subjects are involved in clinical trials: incapacitated subjects, minors, 
and pregnant or breastfeeding women.442 It also lists some less direct recommendations 
regarding persons performing military service, persons deprived of liberty, persons living 
in residential care institutions, and anyone who belongs to an “economically or socially 
disadvantaged group or is in a situation of institutional or hierarchical dependency that 
could inappropriately influence her or his decision to participate.”443 The US CFR 
provides for specific norms to be applied when children are involved in clinical trials and 
the FDA provides guidelines for cases involving incapacitated subjects. The US CFR 
also lists subjects to which general concerns apply: prisoners, pregnant women, and 
economically or educationally disadvantaged persons.444 Hence, while the general set of 
subjects for which concerns are raised is almost identical in the EU and the US context, 
the subjects for which specific norms are to be applied differ in the two systems. Given 
this, it is only possible to compare the treatment reserved in the two legal frameworks to 
the only two categories for which they both developed specific norms (or, at least, 
                                                 
441 Article 30.3, EU CTR 536/2014. 
442 See respectively Article 31, 32, and 33, EU CTR 536/2014. 
443 Preamble (31) and (33), EU CTR 536/2014. 
444 21 CFR 56.111 (a)(3). 
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guidelines: incapacitated subjects (“mentally disabled persons” in the US framework) 
and minors (children in the US framework).  
As for incapacitated subjects, the EU CTR requires that informed consent is obtained by 
their representative, but that at the same time they are provided with information 
appropriate in view of their capacity.445 More specific prescriptions require that their 
representative does not receive any incentive or financial inducement, that the trial is 
essential to the subject and the same data cannot be obtained through clinical trials 
conducted on subjects capable of giving consent, and that there are scientific grounds to 
expect a direct benefit for the subjects or some benefit for their population following the 
clinical trial.446 Within the US framework, the duty to protect the interests of such 
vulnerable subjects is mainly left to the IRBs’ level. In this context, the FDA recommends 
e.g. that potential subjects’ capacity to give consent is assessed and that methods of 
enhancing the capacity to give consent are used.447 In any event, informed consent norms 
refer to the need for representatives to be involved in giving consent on their behalf.448 
However, first, it appears clear that the EU system sets specific standards to be applied 
in the case of lack of capacity or diminished capacity of the subjects, while the US system 
finds in the IRBs the subjects that can most appropriately address vulnerability concerns. 
Second, interestingly, the EU framework clarifies that subjects with impaired capacity to 
consent can participate in clinical trials only when subjects with full capacity to consent 
cannot, while in the US framework such a clear-cut line is not established.  
As to minors, it can be noted that they are the only category for which both systems 
provide a firm set of rules. In the EU, clinical trials on minors are subject to the following 
requirements: (1) consent of the minor’s representative, (2) information is given to the 
minor in an adequate way and from investigators experienced with children, (3) any wish 
of the minor not to participate is respected, (4) no incentives or financial inducement to 
the legal representative are given, (5) the clinical trial regards conditions that affect only 
children or aims at validating the use on children of data obtained on adults, (6) the trial 
                                                 
445 Article 31, EU CTR 536/2014. 
446 Article 31, EU CTR 536/2014. 
447 FDA, Informed Consent Information Sheet Guidance for IRBs, Clinical Investigators, and Sponsors, 
2014, at p. 35. 
448 E.g. “The information that is given to the subject or the representative shall be in language 
understandable to the subject or the representative.” 21 CFR 50.20. 
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relates directly to a condition from which the minor suffers or can only be conducted on 
children, and (7) there are scientific grounds to expect a direct benefit for the subjects or 
some benefit for their population following the clinical trial.449 If the minor reaches the 
age of legal competence during the clinical trial, his full informed consent is be sought 
immediately.450 In the US context, the two conditions under which children may be 
involved in clinical trials are: (a) no greater than minimal risk to children is presented 
and (b) “adequate provisions are made for soliciting the assent of the children and the 
permission of their parents or guardians.”451 Exceptions to the first condition can be made 
when the risk is justified by the anticipated benefit to the subjects and the benefit-risk 
ratio reaches the same level of other available treatments.452 Interestingly, informed 
consent for clinical trials involving children (minors) can be obtained through child 
assent and paternal/guardian permission.453 The possibility of obtaining the assent from 
children is assessed at the IRBs’ level, but the default option seems to require it. In fact, 
the US CFR specifically lists exceptions under which the assent of children is not to be 
sought.454 The main two differences that can be observed regarding the requirement in 
the EU for the condition addressed in the clinical trial to specifically regard minors (to 
the extent that this is possible) and the eminent role for the assent of children in the US 
system.  
(5) Monitoring  
Following the approval of a clinical trial, institutional actors are generally entrusted with 
ensuring that all the stakeholders involved comply with the applicable legal standards. 
Two contexts in which a comparative analysis of the applicable monitoring provisions is 
                                                 
449 Article 32, EU CTR 536/2014. 
450 Article 32, EU CTR 536/2014. 
451 21 CFR 50.51. 
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2014, at p. 37. 
454 21 CFR 50.55 (c). 
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particularly interesting are those of reporting and inspections, and – especially in light of 
this contribution – the context of admissibility of data obtained through clinical trials 
conducted outside the territories of the regulating states. The next sections will address 
both categories of provisions.  
(a) Reporting and Inspections 
Once clinical trials have obtained approval to be conducted, the most relevant context in 
which human subjects are protected is within monitoring and inspections. 
First, in both the US and the EU frameworks, clinical trials are subjected to constant 
monitoring. Under the EU CTR, sponsors must submit an annual report.455 Similarly, 
under the US CFR, IRBs are expected to review clinical trials not less than once a year.456  
Second, both legal frameworks provide for governmental inspections in order to ensure 
a high protection of human subjects. In the EU framework, two kinds of inspections are 
envisaged: the inspections conducted by Member States – of clinical trials that take place 
on their territory or in a third country – and the controls conducted by the European 
Commission to ascertain Member States’ compliance with the EU CTR.457 Within the 
US framework, the FDA is directly in charge of conducting inspections. Specifically, 
sponsors and investigators are required to permit FDA investigators to access, copy, and 
verify any records or reports relevant to clinical trials.458   
To conclude, both frameworks establish the need for annual reporting/monitoring and the 
possibility of governmental investigations, but at the EU level the latter are managed by 
Member States, while at the US level they are directly conducted by the FDA.  
(b) Admissibility of Foreign Data 
Given that both the EU and the US clinical trial legal frameworks consist of standards 
used in developed economies, in the context of this contribution it is relevant to present 
some observations as to how the two systems deal with results obtained in clinical trials 
conducted abroad (in particular, in developing economies).  
                                                 
455 Article 43, EU CTR 536/2014. 
456 21 CFR 56.108 (a)(1) and 56.109 (f). 
457 Respectively, Article 78 and 79, EU CTR 536/2014. 
458 21 CFR 312.68 and 812.145.  
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The first significant point regards the extent to which the issue is relevant in the two 
systems. Retrieving data on the phenomenon of the import of data obtained by foreign 
clinical trials, as well as on the extent to which those clinical trials are subject to 
inspection procedures ordered by US and EU (or, indirectly, Member States) institutions 
is not an easy task. Such figures are not regularly publicly disclosed, but official sources 
have provided them on some occasions in the last years. For example, the European 
Medicines Agency (EMA) disclosed that 61.9% of the patients in pivotal trials submitted 
in marketing-authorization applications to the Agency between 2005 and 2011 were from 
third countries.459 Similarly, the FDA has noted that, in the period between 2001-2014, 
80% of applications for pharmaceutical marketing authorization contained data from 
non-US studies, and that 78% of all clinical trials subjects were enrolled outside the 
US.460 Both sets of figures support the idea that carrying out clinical trials “abroad” and 
importing the results obtained thereby is a relevant phenomenon in both systems. The 
amount of inspections conducted overseas, however, is still not proportionate to the 
extent of the phenomenon. For example, between 1997 and 2012, 46.5% of inspections 
were requested by the European Medicines Agency for sites in the EU/EEA/EFTA 
region, 26.05% for sites in North America, and 27.45% in the rest of the world.461 
Similarly – and despite the lack of analysis regarding identical time-periods – in 2013, 
FDA inspections regarded US sites in 70% of the cases and for example in 20% of the 
cases European-based sites.462 
Form the regulatory point of view, the EU and US legal framework use different 
approaches – to the extent that the US CFR addresses the issue more explicitly than the 
EU CTR and connected documents – but eventually establish similar standards – given 
that they both heavily rely on the Good Clinical Practice (GCP) framework.  
As to the relevant sources, the EU CTR does not itself provide for a clear-cut rule on the 
admissibility of trials conducted in third countries. Instead, the EU standard emerges 
                                                 
459 Including 27.8% from the ROW region (Africa, Middle East/Asia/Pacific, Australia/New Zealand, 
Central/South America, CIS, Eastern Europe-non EU), and 34.1% from North America. European 
Medicines Agency, Clinical trials submitted in marketing-authorisation applications to the European 
Medicines Agency, 2013, EMA/INS/GCP/676319/2012. 
460 Ayalew, op. cit. 
461 European Medicines Agency, Clinical trials submitted in marketing-authorisation applications to the 
European Medicines Agency, 2013, EMA/INS/GCP/676319/2012. 
462 Ayalew, op. cit. 
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from a combination of various legal provisions and soft-law considerations. A series of 
references to third countries exists also in the EU CTR, but none of its provisions directly 
addresses the issue of data import.463 The main sources in this context are the norms to 
which the EU CTR directly refers: Directive 2001/83/EC and Regulation (EC) No 
726/2004 of the European Parliament and of the Council. Following those sources, 
clinical trials conducted in third countries outside of the EU/EEA and used in marketing 
authorization applications (or in applications for a Scientific Opinion under Article 58 of 
the Regulation (EC) No. 726/2004), “must be conducted on the basis of principles 
equivalent to the ethical principles and principles of good clinical practice applied to 
clinical trials in the EU.”464 Interpretational issues arise when subjects are required to 
interpret and clarify the meaning and scope of “ethical principles and principles of good 
clinical practice.” In fact, a wide array of documents providing for ethical principles 
exists.465 However, first, it is not clear to which extent their nature must be considered 
directly binding in the case of clinical trials conducted in third countries and, second, it 
is not clear how Member States are required to weigh those principles and enforce them. 
As to more immediately and univocally applicable standards, it can be noted that two set 
of provisions (the first being more binding in nature than the second, the second being 
more technical) are helpful in determining the scope and nature of the rules: the Good 
Clinical Practice Directive466 and the considerations presented by the EMA in recent 
                                                 
463 E.g. Articles 42, 53, 74, and 78, EU CTR 536/2014. 
464 European Medicines Agency, Reflection paper on ethical and GCP aspects of clinical trials of medicinal 
products for human use conducted outside of the EU/EEA and submitted in marketing authorisation 
applications to the EU Regulatory Authorities, 2012, EMA/121340/2011. 
465 E.g. Ethical principles governing the conduct of clinical trials are set out in the Charter of Fundamental 
Rights of the European Union (2000), the Council of Europe’s Convention on Human Rights and 
Biomedicine (1997) and its Additional Protocol on Biomedical Research (2005), the Universal 
Declaration of Human Rights (1948), the Convention for the protection of Human Rights and 
fundamental Freedoms (1950), the United Nations’ Convention on the Rights of the Child (1989), the 
Universal Declaration on Bioethics and Human Rights (UNESCO, 2005), the Universal Declaration on 
the Human Genome and Human Rights (UNESCO, 1997), the International Declaration on Human 
Genetic Data (UNESCO, 2003), the CIOMS-WHO International Ethical Guidelines for Biomedical 
Research Involving Human Subjects (Geneva 2002), the Declaration of Helsinki of the World Medical 
Association (2008), Opinion 17 of the European Group on Ethics (2003) and the EU Ethical 
considerations for clinical trials on medicinal products conducted with the pediatric population (2008). 
See also Practical steps to implement ethical requirements are set out in the CPMP/ICH/135/95 
guideline on Good Clinical Practice (1995) (ICH E6) and ICH E11 Note for guidance on clinical 
investigation of medicinal products in the pediatric population (2001). As noted in European Medicines 
Agency, Reflection paper on ethical and GCP aspects of clinical trials of medicinal products for human 
use conducted outside of the EU/EEA and submitted in marketing authorisation applications to the EU 
Regulatory Authorities, 2012, EMA/121340/2011. 
466 Commission Directive 2005/28/EC of 8 April 2005 laying down principles and detailed guidelines for 
good clinical practice as regards investigational medicinal products for human use, as well as the 
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consultations.467 In particular, the latter provides instructions for several issues, such as 
ethics committees and national regulatory authority oversight, informed consent 
procedures, confidentiality standards, fair compensation, protection of vulnerable 
populations, use of placebo, access to treatment following the clinical trials, and 
applicability of data to the European population.468 Additionally, in the EU context, three 
other sub-issues are currently relevant: the rules applicable in case of manufacturing or 
importing investigational medicinal products, Mutual Recognition Agreements (MRAs) 
and related agreements with third countries that regard the mutual acceptance of results 
of manufacturers’ inspections, and the EU-FDA mutual recognition of inspections 
system which recently entered into force.469 It is also worth noting that the sources listed 
so far – which are relevant in the EU context – have until now been interpreted and 
applied in combination with Directive 2001/20/EC;470 given that the latter has been 
repealed by the EU CTR, it is likely that in the short term, following the full 
implementation of the EU CTR, clinical trials practice as well as EU jurisprudence may 
find that the standards to be applied to clinical trials conducted outside the EU are more 
clearly those established by the EU CTR for EU actors. This intuition is supported by the 
inclusion Article 79 in the EU CTR, which directly refers to Directive 2001/83/EC – 
specifically, to a provision included in the Directive which establishes that clinical trials 
conducted outside the EU relating to medicinal products intended to be used in the EU, 
shall be “designed, implemented and reported on what good clinical practice and ethical 
principles are concerned, on the basis of principles, which are equivalent to the provisions 
of Directive 2001/20/EC.”471 Reading the provision updated to the implementation of the 
EU CTR will likely impose that the applicable standards are those equivalent to the new 
EU CTR. An additional observation in support of this finding regards Article 25 (5) of 
                                                 
requirements for authorisation of the manufacturing or importation of such products (the “GCP 
Directive”). 
467 Above all, the European Medicines Agency, Reflection paper on ethical and GCP aspects of clinical 
trials of medicinal products for human use conducted outside of the EU/EEA and submitted in marketing 
authorisation applications to the EU Regulatory Authorities, 2012, EMA/121340/2011. 
468 Ibid.  
469 “Quality of medicines and Good Manufacturing Practices (GMP) - Public Health - European 
Commission.” Public Health, 30 Nov. 2017, ec.europa.eu/health/human-use/quality_en. 
470 Directive 2001/20/EC of the European Parliament and of the Council of 4 April 2001 on the 
approximation of the laws, regulations and administrative provisions of the Member States relating to 
the implementation of good clinical practice in the conduct of clinical trials on medicinal products for 
human use (the “Clinical Trial Directive”). 
471 Articles 79, EU CTR 536/2014. 
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the EU CTR, which provides that foreign clinical trials (when their results are used in the 
context of an EU application) must have been conducted in accordance with principles 
equivalent to those of the EU CTR itself “as regards the rights and safety of the subject 
and the reliability and robustness of the data generated in the clinical trial.”472 Future 
jurisprudence and institutional actions may help to clarify whether such a standard may 
actually be read a contrario as requiring that not all standards set in the EU CTR must 
be respected by EU-regulated foreign clinical trials, but only those regarding the 
protection of subjects and data quality. To conclude, as to the EU framework, it can be 
noted that it is clearly established that the results of clinical trials conducted in third 
countries may be used in EU applications when GCP standards are met; however, GCP 
standards may be of difficult identification and interpretation due to their often general 
nature, and (ii) in any event the reliance on GCP standards does not necessarily impose 
on sponsors the duty to comply with each single provision of the EU CTR, at least until 
further jurisprudence and institutional action helps to clarify this aspect.  
The US CFR provides for a more specific tandem of norms to be applied to data obtained 
via clinical trials conducted overseas. Interestingly, the set of rules distinguishes clearly 
two sub-categories of situations: (a) the case of foreign clinical studies not conducted 
under an IND and (b) the narrower case of an application for marketing approval based 
solely on foreign clinical data.473 (i) In the former case, the FDA accepts “well-designed 
and well-conducted foreign clinical study (i.e. clinical trial) not conducted under an IND” 
provided that two conditions are met.474 First, the clinical trial must have been conducted 
in accordance with GCP.475 This standard is the same as set out in the EU framework and 
potentially has the same limits to the extent that no fixed set of standards is contextually 
listed in the norm. And second, the FDA is able to conduct on-site inspections if 
                                                 
472 Articles 25.5, EU CTR 536/2014. 
473 Respectively 21 CFR 312.120 and 21 CFR 314.106. 
474 21 CFR 312.120 (a). 
475 The US CFR defines what GCP represents in the context of such provision: “For the purposes of this 
section, GCP is defined as a standard for the design, conduct, performance, monitoring, auditing, 
recording, analysis, and reporting of clinical trials in a way that provides assurance that the data and 
reported results are credible and accurate and that the rights, safety, and well-being of trial subjects are 
protected. GCP includes review and approval (or provision of a favorable opinion) by an independent 
ethics committee (IEC) before initiating a study, continuing review of an ongoing study by an IEC, and 
obtaining and documenting the freely given informed consent of the subject (or a subject’s legally 
authorized representative, if the subject is unable to provide informed consent) before initiating a study.” 
21 CFR 312.120 (a)(i). 
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necessary.476 This second aspect seems to be stricter than the parallel EU standard. In 
fact, while several provisions in the EU context envisage the possibility of inspections to 
be conducted in third countries,477 the possibility of running such inspections is not 
explicitly listed as a requirement for the admission of foreign data. (ii) In the case of 
applications based solely on data obtained by foreign clinical trials, the US CFR 
establishes heightened scrutiny. In particular, applicants must prove that: (1) the data is 
applicable to the US population and medical practice; (2) the clinical trials have been 
performed by clinical investigators of recognized competence; and (3) the data may be 
considered valid without the need for on-site inspection (or the inspection may 
nevertheless be conducted, if necessary).478 The presence of a narrower case such as the 
one described is not given in the EU framework, especially with regard to the first 
requirement. In this context, however, it is worth noting that EMA’s recommendations 
suggest applicants take similar aspects into consideration.479 To conclude, in the 
framework of US legislation, the ultimate standard applicable to foreign clinical trials is 
generally that of GCP, similarly to what is established in the EU framework. However, 
(i) the requirement of accessing sites for inspections is more prominent than in the EU 
context, (ii) the case of applications based solely on foreign data is directly regulated, 
and (iii) in the latter case, applicability of the data to the US population is a sine qua non 
condition.  
Given that a common issue in both the EU and the US framework is the identification of 
clear obligations arising from the reliance on GCP standards, it is worth noting that 
substantial improvements in the context of collegial identification and mutual recognition 
                                                 
476 21 CFR 312.120 (a)(ii). 
477 E.g. Article 78, EU CTR 536/2014: “[i]n order to efficiently use the resources available and to avoid 
duplications, the Agency shall coordinate the cooperation between Member States concerned on 
inspections conducted in Member States, in third countries, and inspections conducted in the framework 
of an application for a marketing authorisation (…);” Article 21, Directive 2005/28/EC: “[t]he 
inspectors shall be familiar with the procedures and systems for recording clinical data, and with the 
organisation and regulation of the healthcare system in the relevant Member States and, where 
appropriate, in third countries;” and Article 44, Regulation (EC) No 726/2004: “the Commission may, 
upon receipt of a reasoned request from a Member State or from the said Committee, or on its own 
initiative, require a  manufacturer established  in a third country to submit to an inspection.” 
478 21 CFR 314.106 (b). 
479 Cf. Applicants are invited to take into consideration the applicability of the proposed indication and the 
therapeutic needs of the European population as noted in European Medicines Agency, Reflection paper 
on ethical and GCP aspects of clinical trials of medicinal products for human use conducted outside of 
the EU/EEA and submitted in marketing authorisation applications to the EU Regulatory Authorities, 
2012, EMA/121340/2011 
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of such obligations are constantly fostered. The two main potential sources of 
development in such contexts is the progress under the EU-US mutual recognition of 
inspections of medicines manufacturers system480 and the ICH E6 Good Clinical Practice 
(GCP) Guideline.481 In particular, the latter provides for a unified standard for the EU, 
the US and other states (Japan, Canada, and Switzerland) to facilitate the mutual 
acceptance of data from clinical trials by the regulatory authorities in these 
jurisdictions.482 Its most updated version has been implemented by the EMA in 
December 2016483 while implementation in the US is still pending. The evolution of the 
status of both policies in the EU and US framework remains a major issue to be observed 
in the next months.   
III. Preliminary Conclusions 
To conclude, the comparative analysis presented in this chapter aimed at providing an 
overview of the current legal regime of clinical trials in the EU and the US.  
On the one hand, the analysis presented insights for future researches on the two regimes 
and the requirements that stakeholders are expected to comply with. Such insights, while 
descriptive in nature, can be deemed to be particularly relevant given that an analysis of 
this kind has not yet been developed and, furthermore, considering that the EU CTR here 
studied sets new precise rules to be applied in the EU context, and has not yet been 
comprehensively studied in literature. In particular, this contribution has focused on 
describing how the following elements are addressed in the EU clinical trials legal 
framework and in that of the US: some fundamental preliminary elements – including 
definitions, principles, mechanisms for the delegation of competences, competent 
                                                 
480 In June 2017, the European Commission confirmed that the FDA has “the capability, capacity and 
procedures in place to carry out good manufacturing practice (GMP) inspections at a level equivalent to 
the EU” and in October 2017 the FDA confirmed the capability of eight EU Member States (Austria, 
Croatia, France, Italy, Malta, Spain, Sweden, and United Kingdom). See “EU-US mutual recognition 
of inspections of medicines manufacturers enters operational phase.” European Medicines Agency - 
News and Events - EU-US mutual recognition of inspections of medicines manufacturers enters 
operational phase, 
www.ema.europa.eu/ema/index.jsp?curl=pages%2Fnews_and_events%2Fnews%2F2017%2F10%2Fnew
s_detail_002842.jsp&mid=WC0b01ac058004d5c1. 
481 “Efficacy Guidelines.” ICH, www.ich.org/products/guidelines/efficacy/article/efficacy-
guidelines.html.  
482 Ibid.  
483 European Medicines Agency, Guideline for good clinical practice E6 (R2), Step. 5, Committee for 
Human Medicinal Products, 2016, EMA/CHMP/ICH/135/1995. 
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authorities, and some exceptions (clinical studies not subject to clinical trials regulations 
or only subject to them in a limited way); the scope and technical aspects of the 
applications that sponsors are required to submit to governmental authorities in order to 
obtain an authorization to conduct clinical trials – including a comparison of each 
element of such application e.g. cover letter/sheet, protocols, IB, technical information 
on chemistry, manufacturing, and control, protection of human subjects and informed 
consent practices; the assessment mechanisms – including issues such as their timing, the 
bodies entrusted with the assessment, the applicable criteria, and the possible outcomes 
of the process; some additional issues that focus particularly on concerns connected with 
the protection of human subjects in clinical trials – including the reliance on placebo-
controlled clinical trials and the rules applicable to informed consent practices; finally, 
the monitoring mechanism provided in each legal framework – including, in particular, 
consideration on issues such as reporting, inspections, and admissibility of data acquired 
via clinical trials conducted outside the territory of the EU or the US. 
On the other hand, the analysis presented in this chapter allows for the presentation of 
some conclusions more specific to the goal of providing an educated opinion on the 
similarities and differences of the EU and US clinical trials policy and legislation and 
their capability to influence other attempts to regulate clinical trials at the international 
level or in other countries (as models). In particular, the analysis presented here supports 
the following three general findings.  
First, the ways in which the EU and the US regulate clinical trials are extremely similar 
as of the goals and elements of the regulation and the standards of protection ensured to 
human subjects that take part in clinical trials. Despite the presence of slightly different 
standards and approaches in the two frameworks, the analysis presented did not identify 
extremely divergent elements in the two sets of provisions observed.  
Second, nevertheless, a main difference between the two systems exists, deriving from 
the institutional structure of the EU and the US. In the US context, non-governmental 
actors (IRBs) are entrusted by the legislator with the task of approving and supervising 
clinical trials; in the EU context, governmental actors (Member States) are entrusted by 
the legislator with the task of approving and supervising clinical trials. As of the final 
decisional power, however, it can be noted that in the US, such power is reserved to a 
federal governmental agency (the FDA) and in the EU it remains allocated to the level 
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of the Member States (despite the fact that they must act in compliance with criteria 
established at the EU level). Potentially, as a consequence of the allocation of powers 
just described, as well as a consequence of the fact that the EU CTR has not entered its 
final phase of full implementation yet, the level of information available to stakeholders 
in the two systems (in quantitative terms) is not equal. In particular, the possibility for 
stakeholders of consulting the numerous guidelines produced by the FDA renders the US 
clinical trials regulation more accessible to users.  
Third, it is important to note how the choices of both the EU and the US legislator confirm 
the interests and concerns already identified in this thesis with regard to clinical trials 
conducted at the global level. In fact, in both legal frameworks references to international 
standards (e.g. ICH guidelines), efforts to address challenges connected with the 
globalization of clinical trials (e.g. admissibility mechanism for data obtained via foreign 
clinical trials), and practical attempts to value cooperation between various national and 
international institutions can be found. Nevertheless, it is relevant to highlight how both 
systems chose to address such issues relying on a combination of approaches – that may 
often render the stakeholders’ activity of identification of the precise norms to be applied 
and respected more complex – in certain cases implementing international standards in 
their legislation directly, thereby awarding them fully binding power, and in other cases 
“merely” including broad references to those standards. In this context, it can be expected 
that further legislative developments both at the EU and at the US level will concentrate 
on the challenges provided by those standards in the context of practical implementation 
and compliance.    
Table 2 summarizes the core finding of the comparative analysis presented in this 
chapter.484 
 
Table 2 
Prominent Comparative Elements 
  EU legal Framework US legal framework 
Def: Clinical 
Trials 
Investigation on HS Investigation on HS 
Object are clinical trials (seen as 
sub-category of clinical studies) 
Object are clinical investigations 
                                                 
484 Note that in the table HS stands for human subjects, MS stands for Member States, IB stands for 
investigator’s brochure, and IC stands for informed consent.  
 114 
Variety of aims (mainly safety 
and efficacy) 
Aim at approval for 
commercialization 
Def: Sponsor Open generic List of traditional sponsors (not 
closed) 
Def: 
Investigator 
Default: team-member (principal 
investigator is the leader) 
Default: team-leader (sub 
investigator is the team-member)  
Def: Subject Control or non-control group Control or non-control group 
Principles Protection of human subjects and 
the interest in scientific validity 
Protection of human subjects and 
the interest in scientific validity 
Delegation of 
competences 
under 
Subsidiarity and proportionality Interstate commerce clause  
Competent 
authorities to 
receive the 
application 
MS through the EU Portal FDA 
Exceptions Low-interventional clinical trials 
must still file an application but 
are subject to less stringent rules 
Investigations similar in nature to 
the EU low interventional 
clinical trials are exempted from 
the duty to apply  
Cover 
letter/sheet 
Associated with EU application 
form 
Associated with introductory 
information 
Protocols Extensive list of elements Distinction on the basis of the 
CT's phases     
IB No explicit reference to side 
effects 
Explicit reference to side effects  
 
Mandatory non promotional form 
 
Chemistry, 
manufacturing, 
and control  
Narrow list of elements Extensive list of elements 
Envisages case of products 
already approved/commercialized 
abroad 
Envisages case of products 
already 
approved/commercialized abroad 
Subjects and IC Addressed in application-related 
norms 
Addressed under a specific and 
separate category of norms  
Assessment 
timing 
ca. 55 days ca. 30 days 
Bodies 
entrusted with 
assessment 
Ethic committees in MS Two tiers: IRBs and FDA 
Mandatory laypersons 
involvement 
Diversity concerns 
Assessment 
criteria 
Single set of criteria provided to 
MS 
Two sets of criteria provided: one 
for the IRBs’ level and one for 
the FDA's level 
  
Explicit reference to list of 
vulnerable subjects to be 
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protected from risks of coercion 
and undue influence 
  
Distinction on the basis of CT 
phases 
Possible 
outcomes 
Classical approval-rejection 
mechanism 
Exception granted or imposition 
of clinical hold 
Use of placebo Not prohibited but limited on the 
basis of risk-considerations 
Not prohibited but in practice 
used mainly for add-on 
treatments 
IC Understandability as core concept Understandability as core 
concept 
Must include possibility of 
damage compensation and 
information on involuntary 
termination  
Short and long forms available 
and optional elements can be 
included 
Lowered IC 
standards  
Emergency situations Emergency situations 
Cluster trials Military operations and public 
health emergencies 
Hightened IC 
standards 
Specifc norms for: incapacitated 
subjects, minors, and pregnant or 
breastfeeding women 
Specific norms for: children plus 
FDA Guidelines for: 
incapacitated subjects 
General concerns for: persons 
performing military service, 
persons deprived of liberty, 
persons living in residential care 
institutions, 
economically/socially 
disadvantaged subjects 
General concerns for: prisoners, 
pregnant women, and 
economically or educationally 
disadvantaged persons 
Reporting Yearly reporting Yearly reporting 
Inspections Managed by MS Managed by the FDA 
Admissibility 
of foreign data 
GCP standards apply GCP standards apply  
Distinction: studies based only 
on foreign data, studies not based 
only on foreign data 
 
Prominent role of need for access 
to sites for inspections 
  Applicability of data to US 
population for foreign-data-only 
studies is mandatory 
 
IV. Addendum on the Implementation Framework of the EU Clinical Trials Regulation 
As noted above, this contribution is elaborate although the complete implementation of 
the EU CTR is still pending. On the one hand, the status of such implementation within 
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Member States’ current clinical trials assessment-systems is not publicly known. On the 
other hand, even following the entry into force of the EU CTR, it can be presumed that 
differences among the different assessment-systems between Member States will exist 
(e.g. with regard to ethics committees, given that the EU CTR does not regulate many 
aspects of their functioning). Therefore, in order to provide insights on those issues, this 
addendum will present the results of a series of questions submitted to Member States. 
Despite the lack of statistical value of the results, they can nevertheless be seen as 
providing input on the issues highlighted so far in this analysis.  
(1) Presentation of the Sample  
The first step taken in this part of the activity regarded the identification of contacts for 
Member States. This goal was achieved by compiling a list of the national authorities that 
enforce clinical trials regulations in each Member State and verifying it using the list of 
contact points provided by EMA.485 An individual email was sent to each contact point 
to assess its availability to respond to questions related to the clinical trials’ legal 
framework in the respective Member State. Following these approaches, four contact 
points (representing four Member States) agreed to participate in the survey/interviewing 
process. Preliminarily, it can be noted that the contact points that eventually participated 
in the activity are employed by the national competent authorities of Cyprus, Latvia, 
Lithuania, and Norway.486   
(2) Presentation of the Survey 
Each contact point was provided a list of 23 questions. For some questions, the four 
contact points were asked to select one answer among an available set of alternatives. In 
any event, they were given the possibility to clarify their answers by adding further 
comments. Table 3 lists the topics addressed by each main question (and set of sub-
questions). 
Table 3 
Survey Submitted to Clinical Trials Contact Points for EU Member States  
(Topics addressed by each question) 
Question 1 Contact details and Member State 
                                                 
485 EudraCT, National Competent Authorities Clinical Trials Contacts, EMA/438927/2008. 
486 Note that despite the fact that Norway is not technically an EU Member States, it is still expected to 
comply with the EU CTR due to the relevance of such regulation for EEA Member States (see the title 
of the EU CTR which reads “text with EEA relevance”).  
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Question 2 Opinion on the tendency of clinical trials to have an international 
dimension 
Question 3 Mechanism used in the Member State to approve clinical trials. With 
sub-questions on e.g. proportionality of the oversight’ invasiveness with 
the clinical trials’ invasiveness, protection of vulnerable subjects, etc.  
Question 4 Availability of clinical trials regulatory materials in languages different 
than the one of the Member State 
Question 5 Relationship of the daily operation of clinical trials supervision in the 
Member State with the EMA’s operate 
Question 6 Means of human subjects’ protection and data reliability implemented 
in the Member State. 
Question 7 Opinion on registration and reporting of clinical trials’ results practices 
in the Member State. 
Question 8 Existence of application fees for sponsors and costs for human subjects.  
Question 9 Opinion on the status of the EU CTR implementation. 
 
(3) Results 
The first set of questions regarded the general approach of each Member State towards 
the internationalization of clinical trials. According to the contact points, all four Member 
States consider the involvement of a plurality of states in clinical trials a positive factor. 
However, given the choice between the involvement of EU countries only or EU and 
non-EU countries, two states considered the first option preferable to the second.487  
As to the mechanism used in the Member States to approve clinical trials, the first 
relevant piece of information disclosed by the contact points regards the structure of the 
decision of competence in that context. This element is particularly interesting in the 
context of this contribution, given that the EU CTR grants Member States the power to 
decide how to structure their approval system, enabling the hypothesis that fragmentation 
between Member States will persist. On the basis of the information provided by the four 
contact points, it can be noted that all four Member States rely on the involvement of one 
or more governmental agencies as well as of one or more ethics committees.488 Three of 
the four Member States calibrate the invasiveness of clinical trials’ oversight with the 
level of intervention that the treatment being tested entails.489 All four states require 
sponsors to pay an application fee. As to the availability of materials in languages 
                                                 
487 The Member States being Lithuania and Norway. 
488 In particular, Lithuania relies on ethics committee, Cyprus on the National Bioethics Committee, and 
Norway, in addition to the Norwegian Medicines Agency involves the Directorate of Environment in 
the case of clinical trials entailing the use/testing of GMOs.  
489 The Member States being Latvia, Lithuania, and Norway.  
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different than the one of the Member State, questions to the contact points focused on the 
existence of materials in English. All four Member States provide forms for and/or allow 
the submission of materials in English (however, variability exists with regard to which 
forms are available in English). Finally, when asked whether their Member State involves 
patients/patents’ organizations in the process of authorization of clinical trials, three 
contact points answered negatively and one affirmatively.490  
With regard to the protection of vulnerable subjects, all four Member States require extra 
steps to be taken in the case of authorization and control procedures that involve 
vulnerable subjects. However, the identification of the categories to be deemed 
vulnerable is not uniform; in particular, in all four Member States two categories of 
subjects are univocally considered vulnerable: patients affected by mental health 
conditions and minors. This is consistent with the heightened scrutiny imposed in the 
case of clinical trials involving incapacitated subjects and minors under the EU CTR.491 
Two out of four Member States consider also pregnant women, breastfeeding women, 
and residents in residential facilities (e.g. nursing homes) vulnerable subjects.492 This is 
clearly an issue on which all states will be expected to act upon as soon as the EU CTR 
fully enters into force, given that the EU CTR explicitly awards heightened protection 
standards to pregnant women and breastfeeding women.493 As to clinical trials that focus 
on very rare diseases,494 that under the EU CTR should be fostered, it can be noted that 
none of the interviewed Member States provides for incentives for such clinical trials.  
As to registration and reporting, two member States (Lithuania and Latvia) rely on a 
national clinical trial registry; results are usually reported to the competent authority 
within one year.495  
                                                 
490 Cyprus and Latvia answered negatively and Norway clarified that its Medicines Agency does not but it 
is aware of the fact that the European Commission may do so. Lithuania answered affirmatively. This 
may be seen as conflicting – at least in principle – with the EU CTR. The latter reads: “[w]hen 
determining the appropriate body or bodies, Member States should ensure the involvement of 
laypersons, in particular patients or patients’ organisations.” Preamble (18), EU CTR 536/2014. 
491 Articles 30 and 31, EU CTR 536/2014. 
492 Specifically, Latvia and Lithuania awards particular protection to residents in residential facilities; 
Latvia and Norway do the same for pregnant women and breastfeeding women. At the same time, 
Cyprus is the only Member State that declared to award specific protection to elderlies.  
493 Article 32, EU CTR 536/2014. 
494 Preamble (9), EU CTR 536/2014. 
495 Note that in the case of Latvia results are reported directly in the EudraCT database. 
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With regard to the recruitment of human subjects and obtaining informed consent, it is 
worth noting that only the contact point for Norway declared that its Member State 
provides a preferential authorization procedure in place for clinical trials, which plan to 
recruit subjects on its territory and have already obtained authorization in another 
Member State. It is notable also that Cyprus is the only one of the four Member States 
not requiring interviewers in the recruitment process to take the social status of 
prospective subjects into consideration during the interviewing process. In all four 
Member States, participants are not allowed to pay for investigational medicinal 
products, auxiliary medicinal products, or medical devices used for their administration 
and procedures required by clinical trials. Furthermore, none of the four Member States 
provides for a minimum amount of time that must lapse between the presentation of the 
clinical trial to subjects and obtaining their informed consent.496 However, this does not 
necessarily imply a misalignment with the EU CTR’s informed consent regulation.497 As 
of the subjects allowed to perform recruitment interviews, three of the Member States 
limit the possibility to perform such interviews to medical doctors.498  
Finally, with regard to the transition between Directive 2001/20/EC and the EU CTR, all 
four contact points declare that the national legislation and standards in use in their 
Member State are still subject to revision (and do not meet the EU CTR standards yet).  
To conclude, despite the lack of statistical value of this analysis, it can be noted that in 
the case of the Member States pooled – at least according to the answers provided during 
the interaction with contact points at their national clinical trials competent authorities –
, on the one hand, a common interest in the supra-national regulation of clinical trials 
exists. And on the other hand, variability exists between some of the standards applied in 
different Member States. In the light of the entry in to force of the EU CTR, it is likely 
that such variability will decrease and that specific aspects of national legislations will 
be reformed (e.g. the protection of pregnant or breastfeeding women, the involvement of 
patients or patients’ organizations in the authorization process, the fostering of clinical 
trials focused on ultra-rare disease, etc.).  
                                                 
496 Lithuania specified that “the time should be sufficient.” 
497 Cf. Article 29, EU CTR 536/2014 which reads: “[a]dequate time shall be given for the subject or his or 
her legally designated representative to consider his or her decision to participate in the clinical trial.” 
498 Norway allows it also to other medical professionals (e.g. registered nurses). 
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CHAPTER SIX: CLINICAL TRIALS REGISTRIES – SUCCESSFUL GLOBAL 
DYNAMICS IN CLINICAL TRIALS REGULATION 
 
I. Introduction 
Clinical trials registries are databases of privately and publicly funded clinical studies 
conducted within single countries or worldwide. Understanding their rationale, history, 
and functioning is particularly interesting in the context of this contribution. In fact, the 
development of clinical trials registration standards is one of the aspects of clinical trials 
regulation in which both (i) the global dimension is evident and extremely relevant and 
(ii) in a twenty-year span, the development of an in international set of standards has been 
successfully achieved, thanks to the interaction of different stakeholders and both private 
and public actors.  
The following sections will present an overview of the competing interests that stands 
behind the creation of clinical trial registries, of the history and functional characteristics 
of the principal registries, and some of the challenges still unresolved in the current status 
of clinical trial registries.  
II. Clinical Trials Registries and Competing Interests 
Understanding the rationale and the – sometimes competing – interests behind the 
institution and implementation of clinical trial registries is necessary in order to better 
observe the dynamics that affect the registries and to regulate their evolution.  
On the one hand, the arguments in favor of clinical trials registration often relies on four 
positive effects that widespread registration can produce. First, clinical trials registration 
– especially in macro-regional and international registries – results in increased 
accessibility of clinical trials information.499 Increased accessibility has positive 
implications both for researchers and policymakers that are “making use of the 
                                                 
499 Cf. Pansieri, Claudia, et. al. “Clinical Trial Registries: More International, Converging Efforts are 
Needed.” Trials 18.1 (2017): 86. 
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information that is collected and made publicly available by clinical trial registries”,500 
and for human subjects that can take better decisions regarding their participation and 
can be rewarded for their altruistic choice to participate in clinical trials.501 Second, 
clinical trials registration increase transparency.502 The latter serves, among others, the 
interest of the scientific community, lowering the risk of “publication bias” and selecting 
publication and increasing access to pools of patients for recruitment purposes.503 
Selective publication is the phenomenon under which studies with positive results are 
publicized by publication and negative outcomes are more easily hidden from the 
scientific community and the public eye. Third, clinical trials registration enhances 
standardization in clinical trials.504 And, in this context, standardization has both a global 
scale – which positively matches the current global dimension of clinical trials matters – 
and a positive impact on the protection of human subjects.  
On the other hand, three concerns are generally presented by detractors of the 
implementation of increasingly stringent registration requirements. First, a concern for 
the bureaucratic burden derived from compliance requirements can be observed.505 In 
substance, the risk connected with such a burden would be to make clinical research 
harder to conduct, instead of fostering it.506 Second, a concern shared by both participants 
and sponsors regards the protection of privacy interests – specifically, in the form of 
concerns for participant safety regarding the risk of re-identification of depersonalized 
data.507 Third, primarily among sponsors, there is a widespread concern for the risks 
connected with a potential loss of competitive advantage. This is the result of concerns 
                                                 
500 Viergever, Roderik F., and Keyang Li. “Trends in Global Clinical Trial Registration: An Analysis Of 
Numbers of Registered Clinical Trials in Different Parts of the World From 2004 To 2013.” BMJ open 
5.9 (2015): 7.  
501 De Angelis et al., op. cit. 
502 Cf. Viergever and Li. op. cit. And Sim, Ida, et al. “Clinical Trial Registration: Transparency Is the 
Watchword.” The Lancet 367.9523 (2006): 1631-1633. 
503 See Simes, Robert J. “Publication Bias: The Case for an International Registry of Clinical Trials.” 
Journal of Clinical Oncology 4.10 (1986): 1529-1541. 
504 Cf. Pansieri, op. cit. 
505 Ibid.  
506 Sim et al., op. cit. 
507 Cf. Skoog, M., et al. “Transaprency and Registration in Clinical Research in the Nordic Countries.” 
Nordic Trial Alliance, NordForsk (2015): 1-108. Note that despite the focus of the publication on a few 
countries, the concerns there expressed seem to be consistent with those generally identified and voiced 
at the international level.  
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for the protection of commercial interests such as intellectual property-related issues and 
ownership of the information produced via clinical trials.508 Additional concerns regard 
the challenges that currently undermine the full implementation of clinical trials 
registration and potential; such challenges will be addressed later in this contribution. 
Nevertheless, the presentation of the competing interests – the case in favor of clinical 
trials registration and the one against it – remains a fundamental step to better 
understanding clinical trials registration regulation and evolution.  
III. Creation and Functioning of Clinical Trials Registries 
This section aims at presenting the “historical” evolution of clinical trials registration – 
with a specific focus on the events that lead to the creation of the International Clinical 
Trials Registry Platform (ICTRP) and the functioning of the ICTRP.  
Preliminarily it can be noted that clinical trials registration is supported by several legal 
authorities – both at the international and the national level.509 In particular, the creation 
and implementation of clinical trials registries is consistent with the Declaration of 
Helsinki requirement that “[e]very research study involving human subjects must be 
registered in a publicly accessible database before recruitment of the first subject.”510 The 
Declaration of Helsinki provides also that  
“[r]esearchers, authors, sponsors, editors and publishers all have ethical 
obligations with regard to the publication and dissemination of the results 
of research. Researchers (…) are accountable for the completeness and 
accuracy of their reports. (…) Negative and inconclusive as well as 
positive results must be published or otherwise made publicly available. 
Sources of funding, institutional affiliations and conflicts of interest must 
be declared in the publication.”511  
 
Chronologically, the first operative clinical trial registry was introduced in the US in the 
late 1990s: in 1997, the US Congress introduced a set of rules requiring clinical trials 
                                                 
508 Cf. Ibid. And Zarin, Deborah A., and Tony Tse. “Moving Towards Transparency of Clinical Trials.” 
Science 319.5868 (2008): 1340. 
509 See, e.g. ibid. 
510 Article 35, World Medical Association (WMA). Declaration of Helsinki. Ethical principles for Medical 
Research Involving Human Subjects. op. cit. 
511 Article 36, ibid. 
 124 
registration.512 Following that, in 2000, the National Institutes of Health launched the 
online platform ClinicalTrials.gov.513 Interestingly, several commentators have noted 
how the creation of the registry and its implementation resulted from the pressure 
produced by two actions: the lawsuit against GSK by New York State Attorney General 
Eliot Spitzer, and the endorsement of a comprehensive registry by the American Medical 
Association (AMA).514  
It is worth noting, however, that it is not until a later crucial decision of the International 
Committee of Medical Journal Editors (ICMJE) that the registration rate started to clearly 
and steeply increase.515 In particular, in 2004, the ICMJE published an editorial note 
acknowledging the role of patients’ altruism in advancing clinical research and the 
widespread concern for selective publication.516 The editorial note identified clinical 
trials registration as a means for promoting necessary transparency in clinical trials and 
announced that the ICMJE from mid-2005 on would have only considered for publication 
studies developed on the basis of clinical trials prospectively registered on a free of 
charge and publicly accessible registry.517 The editorial note specified that, first, the 
registry should have respected a list of characteristics and, second, by that time, only the 
platform ClinicalTrials.gov complied with those requirements. To meet the ICMJE-
standard, registries had to: (i) be accessible to the public at no charge; (ii) be open to all 
prospective registrants and managed by a not-for-profit organization; (iii) provide for “a 
mechanism to ensure the validity of the registration data;” (iv) be electronically 
searchable; (v) include at minimum the following information: 
                                                 
512 Food and Drug Administration Modernization Act (FDAMA), enacted Nov. 21, 1997, amended the 
Federal Food, Drug, and Cosmetic Act relating to the regulation of food, drugs, devices, and biological 
products. 
513 “Press Release: National Institutes of Health Launches "ClinicalTrials.Gov".” US National Library of 
Medicine, National Institutes of Health,  
    www.nlm.nih.gov/archive/20040831/news/press_releases/clntrlpr00.html. 
514 See Turner, Erick H. “A Taxpayer-Funded Clinical Trials Registry and Results Database.” Public 
Library of Science (PoLS) Medicine 1.3 (2004): e60. And Steinbrook, Robert. “Public Registration of 
Clinical Rrials.” New England Journal of Medicine 351.4 (2004): 315-317. For the AMA declaration 
see Council on Scientific Affairs, American Medical Association. Featured CSA report: influence of 
funding source on outcome, validity, and reliability of pharmaceutical research (A-04). June 2004. 
515 For data on the increase in registration trends see, e.g. the analysis provided in Viergever and Li, op. 
cit. as well as Viergever, Roderik F., and Davina Ghersi. “The Quality of Registration of Clinical Trials.” 
Public Library of Science (PoLS) One 6.2 (2011): e14701. 
516 De Angelis, op. cit. 
517 Ibid. 
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“a unique identifying number, a statement of the intervention (or interventions) 
and comparison (or comparisons) studied, a statement of the study hypothesis, 
definitions of the primary and secondary outcome measures, eligibility criteria, 
key trial dates (registration date, anticipated or actual start date, anticipated or 
actual date of last follow-up, planned or actual date of closure to data entry, and 
date trial data considered complete), target number of subjects, funding source, 
and contact information for the principal investigator.”518  
Although – as will be described later – nowadays, following some years of proliferation 
in the context of clinical trials registration, ClinicalTrials.gov is by far not the sole 
registry meeting those requirements, it is interesting to note that it has served as a 
practical basis for the creation of following registries, as it was the first one that had to 
be technically structured so as to contain enough information to serve the scientific 
community while preserving accessibility and transparency towards the general public – 
balancing the need for accuracy with recruitment-friendly features.519 Above all, it can 
be noted how the platform has become so prominent: not solely following the 
implementation of binding rules and not solely following the inputs given by the 
scientific community, but as a result of both sources of pressure combined.  
As mentioned above, ClinicalTrials.gov nowadays is not the only widely used and 
accepted clinical trials registry. It is actually one in a constellation of many, in which 
others are acceptable platforms even under the updated ICMJE standards.520 Specifically, 
nowadays the ICMJE will consider for publication any study based on clinical trials 
prospectively registered on the ICTRP or any of the registries affiliated to the ICTRP.521 
In fact, the “most powerful boost” to clinical trials registration is represented by the 
establishment of the ICTRP in 2005.522 The platform was formally launched in 2007 and 
provides users with a single access point to various national and regional registries.523 In 
2007, it was launched by the WHO, providing for a search portal providing a single point 
                                                 
518 Ibid. 
519 McCray, Alexa T., and Nicholas C. Ide. “Design and Implementation of a National Clinical Trials 
Registry.” Journal of the American Medical Informatics Association 7.3 (2000): 313-323. 
520 “Clinical Trial Registration—Looking Back and Moving Ahead.” Editorial, New England Journal of 
Medicine, June 28, 2017, 356. 
521 “Clinical Trial Registration.” ICMJE | Recommendations | Clinical Trial Registration, 
www.icmje.org/recommendations/browse/publishing-and-editorial-issues/clinical-trial-registration.html.  
522 Lemmens and Telfer, op. cit. 
523 Cohen, I. Glenn. The globalization of health care: legal and ethical issues (Oxford University Press, 
2013) at p. 275. 
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of access to studies registered in various international registries.524 As of October 2017, 
more than 390000 clinical trials were accessible through the platform.525 Some relevant 
information regarding the ICTRP encompasses the following elements: 
(1) Content-wise: the platform welcomes the prospective registration of clinical trials 
submitted to other national/regional registers.526 Once trials are registered, they cannot 
be removed. (2) Quality- and validity-wise: the platform will not engage in controls and 
investigations itself. Instead, it relies on the sense of responsibility of registrants and 
national/regional registries to ensure that the person registering the trial and the trial 
exists and that the data submitted is complete.527 (3) Accessibility-wise: the platform 
provides public access at no charge to content in English. It also guarantees access to 
search functions and the possibility to register trials at any time all year long.528 (4) Data 
set-wise: currently, the platform lists 20 items that must be listed by a trial to be 
considered fully registered. The items include the primary registry and trial identifying 
number, the date of registration to the primary registry, any secondary identification 
number, the major source(s) of monetary or material support for the trial, primary and 
secondary sponsors, contacts for public and scientific queries, public and scientific title, 
the conditions studied and the interventions planned, key inclusion/exclusion criteria for 
participation in the study, the study type (e.g. randomized or non-randomized), the 
anticipated or actual date of the first enrollment, the target sample size, the recruitment 
status (e.g. trial still recruiting, suspended, or pending), primary and secondary outcomes 
of the study.529 (5) Participation-wise: the ICTRP is a global platform emerged from a 
                                                 
524  “History, Policies, and Laws.” ClinicalTrials.gov, clinicaltrials.gov/ct2/about-site/history. 
525 Precisely, 456045 records were accessible for 390098 trials. The difference in the two figures is due to 
the fact that – as specified in the first page of the ICTRP’s search portal – “trials are sometimes recorded 
in more than one registry. These records can refer to each other using the ‘Secondary ID’ field. The 
search portal uses these Secondary IDs to group records about the same trial together in the search 
results.” See ICTRP Search Portal, apps.who.int/trialsearch/Default.aspx. To read the number vis a vis 
figures that regard the entity of the registration phenomenon before the introduction of the ICMJE policy 
note, for example, that before the implementation of the policy ClinicalTrials.gov, the largest trial 
registry at the time, contained 13,153 trials (see Laine, Christine, et al., op. cit.) 
526 “WHO ICTRP Registry Criteria.” WHO, World Health Organization, 
http://www.who.int/ictrp/network/criteria/en/. 
527 “WHO ICTRP Registry Criteria.” WHO, World Health Organization, 
 http://www.who.int/ictrp/network/criteria/en/index1.html 
528 “WHO ICTRP Registry Criteria.” WHO, World Health Organization, 
http://www.who.int/ictrp/network/criteria/en/index2.html 
529 “WHO Data Set.” WHO, World Health Organization, www.who.int/ictrp/network/trds/en/. 
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country-led initiative.530 Therefore, it is up to national and regional institutions to decide 
whether to set primary registries for the trials that take place on their territory and whether 
to connect those primary registries with the ICTRP platform. Currently, the platform has 
17 primary registries.531 It lists also three partner registries that do not need to have a 
national/regional remit or the support of government, be managed by a not-for-profit 
agency, or be open to all prospective registrants; however, they must be “affiliated with 
either a Primary Registry in the WHO Registry Network or an ICMJE approved 
registry.”532 As of the relationship between ICMJE standards and WHO standards, there 
seems to be a mutual exchange of standards (or the possibility of this exchange being a 
catch-22). In fact, according to the WHO, ICMJE approved registries – meaning those 
which meet the requirements set by the ICMJE, partially mentioned above in this section 
– are suitable for access to the ICTRP, while according to the ICMJE, the latter “is no 
longer the entity that reviews registries for acceptability (…) Registries that the WHO 
designates as primary registries will be acceptable to the ICMJE.”533 
Similarly to other (primary) registries, the ICTRP has a double-folded goal. First, to 
foster access to trials, thereby increasing both the chances of recruitment and the access 
to the data produced by each trial.534 Second, to increase the quality of registered data.535 
Interestingly, the ICTRP has also two other specific goals that are peculiar to the 
platform: first, to promote and support the creation of additional national/regional clinical 
                                                 
530 International Clinical Trials Registry Platform, WHO, World Health Organization, Brochure available 
at: http://www.who.int/ictrp/ictrp_brochure_en.pdf?ua=1 
531 Australian New Zealand Clinical Trials Registry (ANZCTR), Brazilian Clinical Trials Registry 
(ReBec), Chinese Clinical Trial Registry (ChiCTR), Clinical Research Information Service (CRiS), 
Republic of Korea, Clinical Trials Registry - India (CTRI), Cuban Public Registry of Clinical 
Trials(RPCEC), EU Clinical Trials Register (EU-CTR), German Clinical Trials Register (DRKS), 
Iranian Registry of Clinical Trials (IRCT), ISRCTN, Japan Primary Registries Network (JPRN), Thai 
Clinical Trials Registry (TCTR), The Netherlands National Trial Register (NTR), Pan African Clinical 
Trial Registry (PACTR), Peruvian Clinical Trial Registry (REPEC), and Sri Lanka Clinical Trials 
Registry (SLCTR).  
    See: “Primary Registries.” WHO, World Health Organization, www.who.int/ictrp/network/primary/en/. 
532 “Partner Registries.” WHO, World Health Organization, www.who.int/ictrp/network/partner/en/. The 
partner registries are the following: Clinical Trial Registry of the University Medical Center Freiburg 
(affiliated to DRKS), DeReG - German Registry for Somatic Gene-Transfer Trials Affiliated registry 
(affiliated to DRKS), and Centre for Clinical Trials, Clinical Trials Registry – Chinese University of 
Hong Kong (affiliated to ChiCTR). 
533 “Clinical Trials Registration.” ICMJE | About ICMJE | Clinical Trials Registration, 
www.icmje.org/about-icmje/faqs/clinical-trials-registration/. 
534 International Clinical Trials Registry Platform, WHO, World Health Organization, Brochure, op. cit.  
535 Ibid.  
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trial registries and/or the implementation of enforceable policies to incentivize the 
registration of trials that take place on their territory in any primary registry. Second, to 
specifically reduce the gap between the availability of information regarding trials 
registered/recruiting in high-income countries and those registered/recruiting in low- and 
middle-income countries.536  
To conclude, nevertheless, it can be noted once again how the transition towards a more 
integrated and international dimension of clinical trials management and regulation – 
even if on a specific issue such as registration – provides observers with an example of 
back-and-fourth inputs given by different stakeholders. Not only was the ICTRP created 
following the technical success of ClinicalTrials.gov (which was itself promoted by the 
editorial note of the ICMJE), but, following the introduction of the ICTRP, the ICMJE 
itself decided to adapt its definition of clinical trials to comply with the definition 
proposed by the WHO (the very same organization that gave birth to the ICTRP).537 In a 
nutshell, the creation and success of clinical trial registries is the result of the constant 
and fluid interaction between norm-creators and the scientific community.  
IV. Unresolved Challenges  
Despite its core role in collecting and making clinical trials information available 
globally, the trend in favor of increasing clinical trial registration is not flawless. 
Improvement in the functioning of national/regional registries as well as in the ICTRP is 
sought both at the institutional level and within the scientific community. In fact, 
contributors to the field of clinical trials policy have identified the following concerns: 
(i) First, data quality and completeness. As noted by Pensieri et al., the trial coverage of 
the ICTRP is constantly questioned and the number of trials conducted globally remains 
unknown.538 In other words, while the growth of the registration trend is evident and can 
positively be read in light of striving for increased accessibility to clinical trials 
information, there are still many clinical trials that take place without being registered, 
and quantifying them is extremely difficult. Furthermore, even in the context of trials 
conducted in developed countries, quality of registered data remains a concern. For 
                                                 
536 Ibid. 
537 “Clinical trial registration—looking back and moving ahead.” Editorial, op. cit.  
538 Pansieri, et al., op. cit. 
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example, a study conducted by Chow found that in four years, out of 860 published trials 
randomly selected, only 102 were adequately registered.539  
Technical issues that regulators should address include the need “to minimize inadvertent 
duplicate registrations, to ensure that interventions have unambiguous names, and to have 
a search engine that identifies all trials that meet a user’s specifications.”540 Hence, Good 
compliance with the registration goal requires both the creation of the practical tools 
necessary (complex registries and platforms) and the implementation of compliance 
measures. 
(ii) Second, the challenge of lacking compliance, especially in a context in which the 
proliferation of registries calls for a higher need for standardization.541 As note by 
Viergever and Li following a comprehensive study of registration trends between 2004 
and 2013, improvements in clinical trial registration have not been uniform at the global 
level.542 Their contribution is particularly insightful because it provides evidence of the 
fact that the efficacy of implementation measures varies across the globe. For example, 
accordingly, while arguably the most effective measure is mandatory registration 
required by law, the registration rate has steeply risen in Europe and North America 
following the ICMJE’s announcement (described above) and in Asia following the 
implementation of local measures.543  
Notably, measures that have proven to positively affect the registration trend include 
“enforcement of registration by funders, ethics committees and local journal editors; 
national policies and ethical guidelines that encourage trial registration; and self-
regulation by universities and the pharmaceutical industry.”544  
Consequently, any attempt to further incentivize and regulate clinical trials registration 
at the international level should not disregard that differences exist both in terms of the 
                                                 
539 Anesthesiologynews, Many Published Clinical Trials Inadequately Registered, October 2017,  
http://www.anesthesiologynews.com/Policy-and-Management/Article/10-17/Many-Published-Clinical-
Trials-Inadequately-Registered/44782 
540 Zarin, Deborah A., et al. “Issues in the Registration of Clinical Trials.” Journal of the American Medical 
Association 297.19 (2007): 2112-2120. 
541 Pansieri, et al., op. cit. 
542 Viergever and Li, op. cit. 
543 Ibid. 
544 Viergever and Li, op. cit. 
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“starting point” of different national/regional registries – as of registration rate, data 
quality, accessibility, etc. – and in terms of efficacy of specific policies e.g. guidelines 
for professional organizations, mandatory nation-wide registration, etc. For example, 
consistently with what was suggested by Dickersin and Rennie,545 regulatory provisions 
could be implemented to require: (a) executive governmental agencies to take full 
responsibility to ensure trial registration within the territory of each state; (b) institutions 
and organizations that conduct clinical research (i.e. investigators) to register the trials 
that they are responsible for; (c) industry leaders (i.e. sponsors) to insist on 
comprehensive registration; incidentally, on the matter of industry-driven compliance 
with registration requirements, it is worth noting that pharmaceutical companies such as 
GSK committed to making information regarding its trials available through a private 
registry.546 While the registry confirms GSK’s commitment to registration, first, it is still 
unclear whether it is beneficial for the general public and, second, the registry itself 
includes a disclaimer recommending professionals to “consult prescribing information 
approved in their country,”547 suggesting that the registry mainly targets physicians 
willing to learn about GSK’s products, rather than patients and members of the scientific 
community. (d) Journal editors to implement the ICMJE standards more strictly and to 
require unique registration numbers for trial reports; (e) lawmakers to require ethics 
committees to deem registration mandatory.  
(iii) Third, a further concern regards the accessibility and searchability of results. Two 
issues can be seen as belonging to this context.  
First, the issue of reporting outcomes of completed but unpublished studies. Future policy 
and regulatory decisions should consider fostering complete reporting on clinical trials 
registries, to the benefit of future systematic reviews.548  
The second issue regards data sharing. This aspect is expected to evolve in the next 
months as the ICMJE has recently updated its standards on data sharing statements for 
                                                 
545 Dickersin and Rennie, op. cit.  
546 “About the GSK Clinical Study Register.” GSK Clinical Study Register, www.gsk-
clinicalstudyregister.com/.  
547 Ibid. 
548 Prayle, Andrew P., et al. op. cit. 
 131 
clinical trials.549 The new standards are consistent with the goals shared by the ICMJE 
and the WHO to achieve: universal prospective registration, public disclosure of results 
from all clinical trials, and data sharing.550 Under the new standards: (1) “[a]s of 1 July 
2018 manuscripts submitted to ICMJE journals that report the results of clinical trials 
must contain a data sharing statement”551 and (2) [c]linical trials that begin enrolling 
participants on or after 1 January 2019 must include a data sharing plan in the trial’s 
registration.”552 The abovementioned “sharing statements” must specify: whether 
individual de-identified participant data (including data dictionaries) will be shared; what 
data, in particular, will be shared; whether additional, related documents will be available 
(e.g., study protocol, statistical analysis plan, etc.); when the data will become available 
and for how long; by which access criteria data will be shared (including with whom, for 
what types of analyses, and by what mechanism). The fact that editors may take data 
sharing statements into consideration when making editorial decisions could trigger a 
mechanism similar to that of the 2004 ICMJE’s decision, representing yet a new example 
of powerful interaction between the WHO’s goals and the directive of the scientific 
community.  
While it seems premature to draw observations on the matter, it seems clear that assessing 
the data-sharing issue will (i) once again entail an exercise in balancing the interests of 
subjects in the protection of their privacy as well as in access to transparent clinical trials, 
the interests of the industry in the control over the data potentially relevant for the 
development of new products as well as in lowering the administrative burden, and the 
interests of the investigators’ community in having access to updated data as well as in 
lowering the risk of selective publication. And (ii) in any event, it once again represents 
an attempt to tackle a concern (the attempt towards a responsible data-sharing of clinical 
trials results) that is global and that cannot be effectively regulated without a common 
international effort.  
                                                 
549 Taichman, Darren B., et al. “Data Sharing Statements for Clinical Trials—A Requirement of the 
International Committee of Medical Journal Editors.” (2017): 2277-2279. 
550 Ibid. 
551 Ibid. 
552 Ibid. 
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V. Preliminary Conclusions  
To conclude, in the context of this contribution, the role and evolution of clinical trial 
registries represent an interesting issue. This chapter aimed at providing the reader with 
an overview of the competing interests behind clinical trials registration, with some 
fundamental information about the evolution and functioning of the most relevant 
platforms, and identified current challenges and potential policies related to those 
challenges in the context of clinical trials registration.  
Several conclusions can be presented, in terms of both which interests are involved and 
how to promote and implement change. 
First, the existence of clinical trials registries and in particular of the ICTRP serves as 
evidence that there is global interest in the regulation of clinical trials, as well as the need 
for concrete compliance instruments to achieve uniform and permanent results.  
Second, the dynamic functioning of the registries shows that such regulation can be 
implemented positively by relying on the interaction between institutions and the clinical 
trials community (in primis, representatives of the scientific community such as the 
ICMJE’s).  
Third, it confirms that the interests of several stakeholders are aligned on the issue of 
access, that the trend of increased access is still peaking, and that in the next months it 
will potentially focus on the issue of mandatory data sharing.  
CHAPTER SEVEN: PRACTICAL ANALYSIS OF CLINICAL TRIALS’ DYNAMICS 
 
I. Introduction 
This chapter aims at elaborating some considerations that regard the international 
dimension of clinical trials relying on a “practical” approach. In particular, the two main 
goals of this contribution are the presentation of some opinions collected from clinical 
trials stakeholders and the collection and discussion of recruitment-related data. In 
particular, sub-sections II to V in this chapter present the results of interviews conducted 
with clinical trials sponsors, patients’ and consumer organizations, and investigators. 
Despite the lack of statistical value of the results, the interviews contribute to clarifying 
the approach and position of the main clinical trials’ stakeholders with regard to the 
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current dimension and regulatory challenges of clinical trials. Sub-section VI introduces 
the findings of a simple empirical analysis conducted on the basis of a sample of 394 
clinical trials, and presents some observations that can be drawn from the analysis of such 
data.  
II. Sponsors 
The first survey elaborated aimed at collecting information and opinions from a sample 
of representatives in the category of sponsors i.e. the subjects – sometimes public, often 
private – that traditionally organize and/or finance clinical trials (or some portions of 
clinical trials). The first step of the research regarded the identification of a sample of 
sponsors and will be described in sub-section (1). The second step regarded the 
submission of a list of questions to the sponsors and will be described in sub-section (2). 
Finally, sub-section (3) will introduce some preliminary findings.  
(1) Presentation of the Sample 
In order to identify potential interlocutors to collect the sponsors’ opinion on current 
clinical trial-related challenges, a sample of sponsors to be contacted was identified. In 
order to ensure an accurate yet randomized selection, the following steps were taken.  
First, access to an international database commonly utilized for networking purposes by 
the pharmaceutical sector was obtained. The database lists activity and contact 
information for more than 47.000 companies (including companies active in sectors such 
as biotechnology, pharmaceutical, medical technology, investors, professional services 
and consulting, public and non-profit organizations, health tech, etc.). Its search system 
allows for tailored research on the basis of the sector of industry in which sponsors are 
active, of the area of the world/country in which they are based, and on the basis of 
keywords. By combining keywords and selecting either a specific industry sector or area 
of the world, it is possible to obtain a set of results that are impartially identified by the 
database.  
Second, several searches were run in the database with the objective of obtaining a useful 
sample of contacts. All the searches were run on the same day to avoid variability due to 
changes in the database’s content and/or functioning. The first set of searches used the 
keywords “clinical trials” for five sub-categories of sponsors (divided on the basis of the 
area of activity): biotechnology – therapeutics and diagnostics, biotechnology – research 
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and development services, pharmaceutical, medical technology, and public and non-
profit organizations. Five searches were run, each one selecting one sub-category and 
using the keywords “clinical trials.”553 The first five results of each search were extracted. 
Hence, a pool of 25 sponsors was obtained, each of them representing a 
company/institution active in one of the five sub-categories and specialized in clinical 
trial related activities. The second set of searches used the keywords “clinical trials” for 
seven sub-categories of sponsors (divided on the basis of their geographic location): 
Africa, Asia, Europe, Central America, Oceania, South America, US and Canada. Seven 
searches were run, each one selecting one sub-category and using the keywords “clinical 
trials.”554 The first five results of each search were extracted. Hence, a pool of 35 
sponsors was obtained, each of them representing a company/institution active in one of 
the seven geographic areas and specialized in clinical trials related activities. Of the 60 
contacts obtained, 10 were removed due to overlapping.555  
Third, the 50 sponsors identified were contacted. Each of them was asked to participate 
in a research regarding the regulatory challenges in the clinical trials sector. Four of them 
agreed to be interviewed.556 Their answers were collected within a six-day span. 
Preliminarily, it can be noted that the four companies/institutions that agreed to 
participate in the research are based in the UK, Taiwan, Belgium, and in the US 
respectively.  
                                                 
553 Therefore, the five searched run were the following: (search 1a) “clinical trials” within the sub-category 
of sponsors active in the “biotechnology – therapeutics and diagnostics” sector, (search 2a) “clinical 
trials” within the sub-category of sponsors active in the “biotechnology – research and development 
services” sector, (search 3a) “clinical trials” within the sub-category of sponsors active in the 
“pharmaceutical” sector, (search 4a) “clinical trials” within the sub-category of sponsors active in the 
“medical technology” sector, (search 5a) “clinical trials” within the sub-category of sponsors active in 
the “public and non-profit organizations” sector. 
554 Therefore, the five searched run were the following: (search 1b) “clinical trials” within the sub-category 
of sponsors active in Africa, (search 2b) “clinical trials” within the sub-category of sponsors active in 
Asia, (search 3b) “clinical trials” within the sub-category of sponsors active in Europe, (search 4b) 
“clinical trials” within the sub-category of sponsors active in Central America, (search 5b) “clinical 
trials” within the sub-category of sponsors active in Oceania, (search 6b) “clinical trials” within the sub-
category of sponsors active in South America, (search 7b) “clinical trials” within the sub-category of 
sponsors active in the US and Canada. 
555 Substantially, the 10 contacts would have represented a duplication of the same results. They represent 
companies/institutions that are e.g. among the first five results in search 1a as well as among the first 
five results in search 1b.  
556 The results were registered using online forms. Anonymity was guaranteed to participants.  
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(2) Presentation of the Survey 
Each of the four sponsors that agreed to participate in the survey received a list of 13 
questions. For some questions, sponsors were asked to select one answer among an 
available set of alternatives. In any event, they were given the possibility to clarify their 
answers adding further comments. Table 4 lists the topics addressed by each main 
question (and a set of sub-questions).557  
The first eight questions had the objective of clarifying the nature and size of the activity 
of each company/institution. The last two questions aimed at collecting the opinion of 
the sponsors on the regulation of clinical trials.  
Table 4 
Survey Submitted to Clinical Trials Sponsors  
(Topics addressed by each question) 
Question 1 Name of the company/institution, name of the subject representing it, 
country in which the company/institution is based. 
Question 2 Main field in which the company/institution is active. 
Question 3 Clinical trials’ phases in which the company/institutions involved. 
Question 4 Amount of clinical trials in with the company/institution is involved (on 
a yearly basis). 
Question 5 Countries in which the company/institution operates in the clinical trials 
field (sub-issues: percentage of their clinical trials conducted “abroad” 
and size of such trials, in terms of how many countries they involve). 
Question 6 Recruitment practices used by the company “abroad” (especially with 
regard to reliance on local recruiters). 
Question 7 Involvement of the company/institution in the transfer of foreign-
obtained data in their country. 
Question 8 Main focus of the company (i.e. on quality increment, access increment, 
or cost reduction). 
Question 9 Opinion on the current level of regulation of clinical trials through 
legislation. 
Question 10 Opinion on the benefit/challenges connected with the implementation of 
a binding international (i.e. “universal”) regulation of clinical trials. 
 
(3) Results 
Given that the sample of interviewed companies/institutions encompasses only four 
subjects, the results of the survey here presented do not have statistical value. However, 
                                                 
557 The topics listed in the table are 10, given that two of the 13 original questions are subsidiary to other 
main questions and one of the 13 original questions allowed participants to add further comments, if 
they wanted to.  
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given that the subjects interviewed represent major stakeholders, their input could still 
be deemed interesting to the extent that they help clarify the position of the “average 
sponsor” with regard to the size of the activities conducted and clinical trial regulation. 
As to the activity conducted by each sponsor, its size, and its international nature as stated 
above, the four companies/institutions that agreed to participate in the research are based 
respectively in the UK, Taiwan, Belgium, and in the US. The sectors in which they are 
active are respectively the supply of investigational medicinal products for clinical trials, 
the general organization and carrying out of clinical trials, clinical trials’ monitoring, and 
a broad range of pharmaceutical research and development activities. Three of the four 
sponsors are involved in clinical trials from phase I to IV, one is only involved in phase 
III studies. On average, they are involved in more than 15 clinical trials per year. They 
are all involved in clinical trials that take place in more than one country – but the extent 
to which their activity is of international nature varies: the most “international” of the 
sponsors conducts 90% of its clinical trials in approximately 10 countries.558 Three of the 
four sponsors are involved in recruitment procedures that take place “abroad” and two of 
them consider them “complex enough to require the cooperation of third-party recruiters” 
on-site. As to the import of foreign clinical data (i.e. obtained through clinical trials 
conducted “abroad”), the role of the four sponsors varies significantly, with only one of 
them regularly involved in such activity. This first set of results supports the finding that 
the four interviewed sponsors represent companies/institutions involved in a variety of 
activities, the factors rendering them similar being the fact that they all participate in 
clinical trials with an international dimension.  
As to their opinion on current clinical trials regulatory standards, it is interesting to note 
that the answers given on this topic are almost identical. First, they all consider quality 
to be the pivotal concept in the field of clinical trials, even vis a vis the needs for increased 
access and reduction of costs. Second, they all consider the field of clinical trials to be 
“regulated at a correct level” (hence, currently neither over- nor under regulated).559 
Third, when asked to express their position on the opportunity of implementing a detailed 
                                                 
558 As of the other sponsors: one declined to answer to the question, one declared that 30% of the clinical 
trials in which it is involved take place in at least five countries, another declared that 48% of the clinical 
trials in which it is involved take place in two countries.  
559 However, it is worth noting that the level of regulation of the field of clinical trials varies in the areas 
in which the four different sponsors are active. 
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binding international regulation of clinical trials, on a 7-point Likert scale,560 the sponsors 
replied with opinions varying from point three and point seven in the scale.561 Three 
sponsors out of four consider the opportunity to implement such legislation more 
beneficial than not. Interestingly, the sponsors that expressed a relatively less favorable 
opinion on the benefits of implementing an international regulation are those based in 
Taiwan and Belgium. It can be hypothesized that the reason for which two of the sponsors 
expressed a relatively more positive opinion about the issue lies not necessarily in their 
geographic location, but on the extent to which those two companies/institutions operate 
internationally. In fact, the two sponsors that voted more favorably on the issue are also 
the two that conduct the largest number of clinical trials “abroad.”  
To conclude, two observations can be derived from this portion of research. First, all four 
sponsors interviewed – while engaged in different kinds of activities and based in 
different areas of the world – are active at the international level, confirming that even 
for the small sample here studied clinical trials have an international dimension. Second, 
none of the interviewed sponsors completely denied the fact that implementing a binding 
international (i.e. “universal”) regulation of clinical trials could be associated with some 
benefits; however, the extent to which the four sponsors associate such legislation with 
benefits varies.  
III. Human Subjects 
The second survey elaborated aimed at collecting information and opinions from a 
sample of representatives of patients’ organizations. The main reason for contacting such 
organizations is that they can be seen as giving voice to the concerns and opinions of 
patients i.e. human subjects that either take part in clinical trials or may have the prospect 
of doing so. The first step of the research regarded the identification of a sample of 
patients’ organizations and will be briefly described in sub-section (1). The second step 
regarded the submission of a list of questions to the organizations and will be described 
in sub-section (2). Finally, sub-section (3) will introduce some preliminary findings.  
                                                 
560 The scale provided the possibility to express an opinion from one (not beneficial at all) to seven 
(absolutely beneficial). 
561 Specifically, they picked point-three, point-five, point-six, and point-seven on the scale. 
 138 
(1) Presentation of the Sample 
The primary intention of this study was to pool patients’ organizations at the international 
(global) level. With this goal, several ways of identifying and randomly selecting 
organizations to be contacted were assessed. Due to the lack of an international database 
of such organizations, however, it was deemed appropriate to restrict the sample of 
organizations to be contacted to the those identified at the level of the EU Registry of 
Clinical Trials.562 The list encompasses European branches of international patients’ 
organizations or international organizations themselves when a European branch does 
not exist. Second, contact points for each organization were researched.563 Third, as a 
result, 33 organizations were successfully contacted. Each of them was asked to 
participate in research regarding the regulatory challenges in the clinical trials sector. 
Four of them agreed to be interviewed.564 Their answers were collected in a 20 day span. 
(2) Presentation of the Survey 
Each of the four organizations that agreed to participate in the survey received a list of 
12 questions.565 For some questions, they were asked to select one answer among an 
available set of alternatives. In any event, they were given the possibility to clarify their 
answers by adding further comments.  
The first eight questions had the objective of clarifying the nature and size of the activity 
of each organization. The last two questions aimed at collecting the opinion of the 
organizations on the regulation of clinical trials. Table 5 lists the topics addressed by each 
main question (and set of sub-questions). 
Table 5 
                                                 
562 A list of the EU Clinical Trials Register – “Patients’ and Consumers’ Organisations’ Contact 
Information” list is available at “News update.” EU Clinical Trials Register - Update, 
www.clinicaltrialsregister.eu/.  
563 This step was necessary due to the fact that the list provided on the EU Clinical Trial Register includes 
only links to the organizations’ websites. Furthermore, note that the EU Clinical Trial Register provides 
users also with a list of “Healthcare Professionals’ Organisations contact information.” The list is 
available at “News update.” EU Clinical Trials Register - Update, www.clinicaltrialsregister.eu/. For 
each of the organization in that list a contact point was identified and 27 organizations were effectively 
reached. However, none of them agreed to participate in a survey/interview for the purpose of this 
research.  
564 The results were registered using online forms. Anonymity was guaranteed to participants.  
565 The topics listed in the table are 10 given that one of the 12 original questions is subsidiary to other 
main questions and one of the 12 original questions allowed participants to add further comments, if 
they wanted to. 
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Survey Submitted to Clinical Trials Sponsors  
(Topics addressed by each question) 
Question 1 Name of the organization, name of the subject representing it. 
Question 2 Main field in which the company/institution is active. 
Question 3 Clinical trials’ phases in which the organization’s members are 
involved. 
Question 4 Amount of clinical trials in with the organization is involved (on a yearly 
basis). 
Question 5 Countries in which the organization operates in the clinical trials field 
(sub-issues: percentage of those clinical trials that are conducted at the 
international level). 
Question 6 Opinion of the organization on the recruitment practices used for clinical 
trials. 
Question 7 Involvement of the organization in the transfer of foreign-obtained data 
in their country. 
Question 8 Main focus of the organization (i.e. on quality increment, access 
increment, or cost reduction). 
Question 9 Opinion on the current level of regulation of clinical trials through 
legislation. 
Question 10 Opinion on the benefit/challenges connected with the implementation of 
a binding international (i.e. “universal”) regulation of clinical trials. 
 
(3) Results 
As in the case of the survey addressed to sponsors described in the previous section of 
this chapter, research that entails interviews from only four patients’ organizations does 
not allow for results that are statistically relevant. Nevertheless, given that the subjects 
interviewed represent major stakeholders, their input could still be deemed interesting to 
the extent that they help clarify the position of some patients’ organizations with regard 
to the size of the activities conducted and clinical trial regulation. 
Each of the four organizations that agreed to take part in this research represents patients 
affected by a specific condition. Their main goal varies from improving the quality of 
life of people affected by a certain condition (which was listed by three of the four 
organizations), to providing “a framework for all members to work collaboratively in 
order to accelerate research pathways”566 related to that specific condition (which was 
listed by three of the four organizations), to connecting healthcare professionals and 
researchers interested in the condition and to e.g. support their applications for research 
grants (which was listed by one of the four organizations). Three of the organizations 
                                                 
566 This wording was specifically used by one of the organizations sampled but similar declarations were 
made also by the other three organizations.  
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declared to be active (directly or through their members) in phases I to IV of clinical 
trials, one limits its focus to phases III and IV. All four organizations or their members 
are involved in clinical trials that take place in more than one country.567 When asked 
more information about how many of the clinical trials they deal with are international 
and how many countries they tend to involve, all four organizations declared that 100% 
of the clinical trials that they deal with are international and involve on average four 
countries (in the case of two organizations) and 10 countries (in the case of one 
organization).568 As to their position on recruitment challenges, two organizations 
pointed out that their members are directly involved in the recruitment of participants in 
clinical trials.569 Only one organization is involved in issues regarding the import of data 
obtained in one country to a different one – and the involvement is “rare.” Two of the 
organizations find that the quality of clinical trials is the pivotal value for their action, 
two found that access of as many subjects as possible to clinical trials is the pivotal value 
for their action.   
With regard to the opinion expressed by the four organizations on the current clinical 
trials regulations, it can be noted that two organizations labeled the clinical trials field as 
over-regulated; one organization labeled it as regulated at a correct level; and one defined 
it as “not correctly regulated.”570 Furthermore, when asked to express their position on 
the opportunity of implementing a detailed binding international regulation of clinical 
trials, on a 7-point Likert scale,571 one organization declined to answer the question while 
the other three responded in various ways.572 Interestingly, the organization that finds the 
                                                 
567 Specifically, three of the four organizations are interested/active in clinical trials that take place in more 
than one EU country (but not non-EU countries) while one organization is interested/active in clinical 
trials that take place in more than one country in general, including non-EU countries.  
568 One of the organizations could not precisely provide information about the average number of countries 
involved.  
569 Of the other two organizations, one does not deal with the recruitment-stage in clinical trials and the 
other outsources recruitment-efforts to a third party, due to the complexity of the matter. In general, it 
can be noted that two of the four organizations (independently from whether they directly deal with 
recruitment or not), agreed to disclose the countries in which they are familiar with recruitment policies 
and support physicians and patients: for one organizations such counties are France, Germany, and Italy; 
for another organization they are Australia, the UK, and the US.  
570 In particular, the organization finds that the main that is not correctly regulated is the one of endpoint(s)-
identification.  
571 The scale provided the possibility to express an opinion from one (not beneficial at all) to seven 
(absolutely beneficial). 
572 Specifically, they picked point-three, point-six, and point-seven on the scale.  
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introduction of such a regulation international binding relatively less beneficial than the 
other two, nevertheless pointed out that excessive variations between standards 
applicable in different countries exist and that this variations may “hinder clinical trials 
taking place in some countries.”  
To conclude, on the one hand, similarly to that observed in the case of the sponsors, also 
in the case of patients’ organizations it can be noted that the dimension of clinical trials 
has regularly reached an international scale. However, this may be due to the fact that the 
organizations pooled are mainly active at the European supra-national level or at the 
international level. On the other hand, it can be noted that none of the four organizations 
considers the field of clinical trials to be under-regulated – this, of course, may be due to 
the fact that they are active at the European level, where legislation on clinical trials is 
relatively stringent.  
IV. Investigators  
The third surveys elaborated within this research aimed at collecting input from 
investigators, the third category primarily involved in clinical trials, together with 
sponsors and human subjects. The first step of the research regarded the identification of 
a sample of investigators and will be briefly described in sub-section (1). The second step 
regarded the submission of a list of questions to the investigators and will be described 
in sub-section (2). Finally, sub-section (3) will introduce some preliminary findings.  
(1) Presentation of the Sample 
In order to obtain a pool of contacts of investigators that could participate in the survey, 
the main source was identified as the ICTRP. In fact, its “advanced search” function 
allows the observation of clinical trials registered and recruiting in a multitude of 
countries in chronological order.573 Therefore, first of all, a set of countries was selected. 
53 countries were randomly selected starting from the “Country Classification” section 
included in the United Nations World Economic Situation and Prospects for year 2017.574 
Second, for each of the countries a search on the ICTRP was conducted within a two 
                                                 
573 ICTRP Search Portal Advanced Search, apps.who.int/trialsearch/AdvSearch.aspx.  
574 UN, World Economic Situation and Prospects 2017 (New York, 2017) 153-154. Note that the main 
reason for which this list was used is that it provides for a distinction between developed economies, 
economies in transition, and developing economies. Such distinction will be considered the relevant one 
in Section VI in this Chapter.  
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week span. The three variables used were the selection of phase I to VI of clinical trials, 
the selection of the country, and the date of registration. For every country, the first 10 
results (which are displayed in chronological order- the most recently registered clinical 
trials being displayed first) were taken into consideration with the exception of cases in 
which some of the 10 first clinical trials displayed among the results did not provide for 
the email contact of an investigator (in this case, results after the first 10 were taken into 
consideration in order to nevertheless obtain a sample of 10 clinical trials).575 Table 6 
displays the clinical trials that were sampled on the basis of the countries of recruitment. 
Third, as a result, 424 clinical trials (and investigators’ contacts for each of them) were 
identified. Each of them was contacted and 15 investigators agreed to participate in the 
survey presented here.576 Preliminarily, it can be noted that 10 investigators are based in 
developed economies and five are based in developing economies or economies in 
transition.577  
Table 6 
Clinical Trials sampled to obtain a list of 
investigators to be contacted 
Country N° Clinical 
Trials Sampled 
Afghanistan 4 
Albania 6 
Algeria 10 
Angola 2 
Argentina 10 
Armenia 5 
Australia 9 
Bahrain 7 
Belgium 10 
Belize 1 
Benin 4 
Bolivia 7 
Bosnia and Herzegovina 10 
Bulgaria 10 
Burnei 1 
575 Note that in the case of four counties (Australia, China, Italy, and India) the final sample take into 
consideration encompassed 9 clinical trials, despite the potential availability of 10 results. This choice 
is the consequence of the fact that in those four cases the contacted investigators communicated that her 
study was no longer recruiting.  
576 The results were registered using online forms. Anonymity was guaranteed to participants. 
577 The distinction between such categories is based on UN, World Economic Situation and Prospects 2017 
(New York, 2017) 153-154. 
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Burundi 1 
Cameroon 9 
Canada 10 
Chad 1 
Chile 10 
China 9 
Croatia 10 
Denmark 10 
Dominican Republic 10 
France 10 
Germany 10 
Ghana 8 
Guatemala 10 
Iceland 10 
India 9 
Israel 10 
Italy 9 
Japan 10 
Kenya 10 
Malaysia 10 
Morocco 10 
Namibia 2 
Netherlands 10 
New Zeland 10 
Nigeria 10 
Pakistan 10 
Qatar 10 
Romania 10 
Russian Federation 10 
Senegal 2 
Serbia 10 
Switzerland 10 
Thailand 10 
The Bahamas 1 
Ukraine 10 
United Kingdom 10 
United States 10 
Uruguay 7 
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(2) Presentation of the Surveys
Each of the 15 investigators that agreed to participate in the survey received a list of 11 
questions.578 For some questions, they were asked to select one answer among an 
available set of alternatives. In any event, they were given the possibility to clarify their 
answers by adding further comments. The first set questions had the objective of 
clarifying the nature and size of the activity of each investigator. The second set of 
questions aimed at collecting the opinion of the investigators on the regulation of clinical 
trials. Table 7 lists the topics addressed by each main question (and set of sub-questions).  
Table 7 
Survey Submitted to Clinical Trials Investigators 
(Topics addressed by each question) 
Question 1 Name of the investigator and affiliation (with a company/institution) 
Question 2 Main field in which the company/institution is active. 
Question 3 Clinical trials’ phases in which the investigator involved. 
Question 4 Location of the investigator’s work, of her sponsor, and of the human 
subjects taking part in her clinical trial.  
Question 5 Possible reasons for which the investigator was selected by a specific 
sponsor.  
Question 6 Familiarity of the investigator with clinical trials’ registration.  
Question 7 Main focus of the investigator (i.e. on quality increment, access 
increment, or cost reduction). 
Question 8 Opinion on the current level of regulation of clinical trials through 
legislation. 
Question 9 Opinion on the benefit/challenges connected with the implementation of 
a binding international (i.e. “universal”) regulation of clinical trials. 
A few further methodological considerations are worth noting. 
(i) The questions were divided in two separate surveys, one addressed to investigators
based in developed economies and one for investigators based in developing economies
or economies in transition.579 The rationale behind the submission of two separate
surveys was the willingness to preserve the ability to distinguish participants on the basis
of the countries in which they are active. However, the division of investigators in two
578 The topics listed in the table are 9 given that one of the 11 original questions are subsidiary to other 
main questions and one of the 11 original questions allowed participants to add further comments, if 
they wanted to. 
579 Note that the term “based” in this context technically means “associated as contact point with a “clinical 
trial recruiting in a developed economy/developed economy/economy in transition.” 
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groups a priori (investigators based in developed economies and investigators based in 
developing economies or economies in transition – to which two different surveys were 
sent) proved to be an ineffective strategy.580 Therefore, the results presented here are 
organized on the basis of a division within the same two groups but made a posteriori.581 
This choice is not expected to produce any effect on the quality of the results presented, 
given that the questions included in the surveys are substantially identical.582 This 
methodological choice is nevertheless disclosed in the interest of transparency.  
(ii) Due to the same circumstances discussed in the first methodological note, it was 
possible for an investigator based in Peru to take part in the survey, despite that fact that 
Peru was not one of the sampled countries. The investigator was necessarily listed as a 
contact point for a clinical trial taking place in more than one country i.e. Peru, and one 
of the countries sampled within this research (listed in Table 6). This circumstance is 
arguably not capable of affecting the reliability or relevance of the answers provided by 
the investigator.  
(iii) One investigator among those contacted agreed to participate in the research but 
provided answers that did not appear to be reliable and were therefore discarded.  
To conclude, none of the methodological notes are deemed capable of affecting the 
results presented. Nevertheless, they were disclosed in the interest of transparency.   
                                                 
580 The main reason depends on the fact that investigators serving as contact points for clinical trials 
recruiting in a multitude of countries appear as contact point for clinical trials identified by this research 
as belonging to the sample for one country but may be practically based in another country. For example, 
in the case of a clinical trial with a main investigator in the US, but which recruits participants both in 
Kenya and the US, the contact point available on the ICTRP may be a US-based investigator or a Kenya-
based investigator and appear both among the results of the search run for clinical trials recruiting in the 
US and in Kenya. Therefore, until the submission of the answers submitted by that investigator to the 
survey presented in this contribution it would have not necessarily be possible to predict whether the 
contact point is based in the US or in Kenya.   
581 Following the division a priori, nine investigators filled the survey sent to investigators which served 
as contact points for clinical trials that were recruiting – among others – in developed economies and 
seven filled the survey sent to investigators which served as contact points for clinical trials that were 
recruiting – among others – in developing economies or economies in transition. A posteriori, ten of the 
participant investigators are based in developed economies and 6 are based in developing economies or 
economies in transition. The latter division will be the one taken into consideration from now on in this 
contribution. 
582 Question 5 listed in Table 7 is the only question that differs in the two surveys, given that participants 
were given more options to pick from to respond when they received the survey addressed to 
investigators based in developing economies or economies in transition. 
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(3) Results 
As in the case of the surveys addressed to sponsors and patients’ organizations described 
in the previous sections of this chapter, a research entails interviews of only 15 
investigators does not allow for results that are statistically relevant. Nevertheless, given 
that the subjects interviewed represent major stakeholders, their input could still be 
deemed interesting to the extent that they help to clarify the position of some investigators 
with regard to the size of the activities conducted and clinical trial regulation.  
As noted above, ten of the participant investigators are based in developed economies583 
and 5 are based in developing economies or economies in transition.584  
Ten investigators are employed by Universities, two work for a publicly funded 
governmental agency which engages in clinical research, two for a private company, and 
one for a mixed private-public research center. Five are involved in clinical trials from 
Phase I to IV, the other ten are involved in only one phase (the prevalent being Phase III, 
with four investigators working only on Phase III clinical trials) or a combination of two 
or three phases.  
As to the relationship with sponsors, only one investigator declared to operate without a 
sponsor (being a sponsor-investigator); nine investigators rely on a sponsor based in their 
own country, one relies on a sponsor based in a different country but on the same 
continent, four rely on sponsors based in different continents.585 When asked why the 
sponsor may have chosen to finance a clinical trial conducted on a different continent, 
the four investigators provided a variety of reasons: all four listed the good quality of the 
result generated, one (based in Switzerland) explained that the sponsor is planning to 
commercialize the tested treatment in the country in which the clinical trial is conducted; 
the two investigators based in developing economies or economies in transition 
                                                 
583 Austria, Belgium, Denmark, Italy, New Zealand, Switzerland, the Netherlands (two different 
investigators, for two different clinical trials), and the United Kingdom (two different investigators, for 
two different clinical trials). 
584 Nigeria, Peru, Russia (two different investigators, for two different clinical trials), and Serbia.  
585 In particular, the four investigators conducting clinical trials sponsored by an actor based in a different 
continent are based in New Zealand, Peru, Russia, and Switzerland. 
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(respectively Peru and Russia) referred both to “good availability of participants” as the 
reason for being chosen by the foreign-based sponsor.586  
With regard to human subjects, 12 investigators declared that their work focuses on 
participants based in their same country; three declared that their participants in clinical 
trials are based on a different continent.587 Furthermore, 11 investigators identified the 
quality of clinical trials as the pivotal value for their work, two identified access of as 
many subjects as possible to clinical trials as the pivotal value, and only one (based in 
Serbia) identified convenient costs as pivotal value for her work.588  
When asked to clarify why the clinical trial (or trials) that they are involved in is currently 
registered in a clinical trial registry, investigators replied listing a variety of reasons in 
different combinations. 13 investigators listed “to comply with requirements set by the 
scientific community (e.g. in order to publish the study)” as one of the reasons – among 
those, nine listed such motivation as the only motivation supporting their decision to 
register the clinical trial; six declared that one motivation was the need to comply with 
national legislation – among those, two listed such motivation as the only motivation 
supporting their decision to register the clinical trial; three did it to comply with 
requirements set by their sponsor.  
When asked to express their opinion on the current regulatory standards applicable to 
clinical trials, 11 investigators declared that, in their opinion, the clinical trials field is 
currently regulated at the correct level;589 four investigators defined the field of clinical 
trials as being “over-regulated.” When asked how beneficial they would consider the 
implementation of a detailed binding (“universal”) regulation at the international level 
586 Notably, none of the two investigators listed “relatively low costs” or “relatively low administrative 
burden” as the reason for being chosen by a foreign-based sponsor. 
587 The three investigators are based in Austria (one) and in the United Kingdom (two). 
588 One investigator chose not to pick a single option and declared that “the optimal balance between cost 
and quality” it’s the pivotal value for her work.  
589 One of them, however, specified that despite the correct level of regulation, guidance on how to apply 
the law in the field of clinical trials is still insufficient. Interestingly, when asked to clarify her position, 
the investigator explained that “an international regulation of CTs could be really hard to implement in 
practice as countries can vary so much internationally. Having  a solid harmonized approach to GCP is 
already in place but would be helpful if regulators such as the EMA and FDA could be clearer in how 
the regulations and ICH GCP can be implemented in practice (generally they only publish non-binding 
guidance).” 
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on a 7-point Likert scale,590 the 15 investigators replied in a variety of ways. On average, 
they picked point-4 on the scale.591 Despite the fact that the sample does not allow for 
statistically relevant results, it can be noted that, within the sample, investigators based 
in developed economies labeled the implementation of such a regulation as more 
beneficial than investigators based in developing economies and economies in 
transition.592  
To conclude, three observations can be made in the light of the obtained results. First, it 
can be noted that a prevalent international dimension of clinical trials was not present in 
the operation of the investigators that participated in the research presented, neither with 
regard to the relationship between sponsors and investigators, nor with regard to that 
between investigators and human subjects. Second, interesting opinions emerged in the 
context of compliance with registration requirements, confirming that the main reason 
for which investigators recur to clinical trial registries is the underlying interest in 
publishing their study, rather than the need to comply with legal provisions. Finally, third, 
among investigators, there is no absolutely positive opinion on the benefits associated 
with implementing an international binding clinical trials regulation; also, the association 
of such an idea as being beneficial is more pervasive among sponsors based in developing 
economies; while it is not possible to clearly identify a reason for such divergence, one 
of the possible explanations could be because most of the developing countries pooled 
are EU Member States, and are therefore already used to operating in a context in which 
harmonization and supra-national regulations are fostered when appropriate; on the other 
hand, investigators based in developing countries or economies in transition may see the 
need to comply with western-originated standards as more burdensome (and, potentially, 
as affecting their capability of attract foreign-based sponsors).  
V. Clinical Trials’ Globalization 
The research conducted to collect investigators’ contacts described above had a 
secondary aim: collecting up-to-date information on the dimension of clinical trials. The 
hypothesis with which this portion of research was approached is multifaceted: (a) to test 
                                                 
590 The scale provided the possibility to express an opinion from one (not beneficial at all) to seven 
(absolutely beneficial). 
591 Precisely, 3.9. 
592 In particular, on average, investigators based in developed economies picked point 4,4 on the scale and 
investigators based in developing economies and economies in transition picked point 3 on the scale.  
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to which extent clinical trials have “gone global,” (b) to assess whether some countries 
are more affected by such globalization than others, and (c) to estimate whether there is 
a correlation between the extent to which clinical trials conducted in countries are 
“international” in size, and their economic status (i.e. developed economies, developing 
economies or economies in transition). 
(1) Presentation of the Sample
The sample utilized in this portion of research is the same used to contact investigators 
described above. The only data eliminated in this portion of research is data regarding 
countries in which less than ten clinical trials registered as recruiting in the ICTRP were 
present. This decision was rendered necessary in order to ensure a more uniform 
sample.593 As a result, 41 countries were taken into consideration. One further piece of 
information was retrieved for each clinical trial taken into consideration, in addition to 
that described in the section dedicated to the presentation of the sample for the 
investigators’ survey. In fact, for each of the clinical trials taken into consideration, the 
number of countries in which such clinical trial was recruiting was retrieved. The ICTRP 
makes this possible, given that the individual page dedicated to each clinical trial 
registered lists the countries in which the trial is recruiting.  
The data collected is presented in Table 8. In the table, the first column includes the name 
of each country taken into consideration; the second column clarifies whether the country 
is deemed a developed economy or developing/in transition;594 the third column displays 
how many clinical trials recruiting in each specific country were sampled;595 the fourth 
593 The main concern being the one related to clinical trials of considerable dimension that would have 
weighted relatively more in the case of countries in which a limited number of clinical trials is 
conducted. E.g. only one clinical trial recruiting in the Bahamas was registered in the ICTRP at the time 
in which data was collected. Such clinical trial was recruiting in 196 countries in total. Keeping only 
this data-point into consideration, the Bahamas would have appeared as a country with 100% clinical 
trials taking place on its territory being international in nature. To avoid relying on single (or relatively 
small) data-points, only countries with seven to 10 (or more) registered recruiting clinical trials were 
taken into consideration.   
594 The distinction between such categories is based on United Nations, World Economic Situation and 
Prospects 2017 (New York, 2017) 153-154. 
595 The initial goal was to sample 10 clinical trials per country, but (i) as noted above, in the case of four 
counties (Australia, China, Italy, and India) the final sample take into consideration encompassed 9 
clinical trials, despite the potential availability of 10 results. This choice is the consequence of the fact 
that in those four cases the contacted investigators communicated that her study was no longer 
recruiting. And (ii) in the case of countries with less than 10 recruiting clinical trials registered in the 
ICTRP a minimum of seven clinical trials were taken into consideration. It is worth noting that the same 
clinical trial may have been taken into consideration multiple times. This would be the case, for example, 
of a trial recruiting simultaneously in Germany and Italy. Necessarily, it would represent one of the 10 
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column displays in how many countries clinical trials that are recruiting in each country 
recruit on average. Countries in the table are ordered on the basis of the fourth column. 
The last column is the core data obtained by this portion of research. In order to better 
explain what the figures included in it represent, an example can be provided, taking into 
consideration the case of Chile. The following steps were taken: (pre-i) Chile was 
identified as one of the countries to be taken into consideration i.e. randomly picked from 
a comprehensive list of countries.596 (i) On the ICTRP “advanced search” page,597 a 
search was run picking Phases I to VI and Chile. (ii) The first ten results (i.e. clinical 
trials recruiting in Chile) were taken into consideration. (iii) For each of the clinical trials, 
the information regarding the countries of recruitment was retrieved. A list of countries 
of recruitment is provided on the ICTRP, and the number of countries for each clinical 
trial was counted. (iv) The number of countries of recruitment identified for each of the 
ten clinical trials were summed up (i.e. 129 in the case of Chile) and then divided by the 
number of clinical trials sampled for Chile (i.e. 10). The result obtained (i.e. 12,9 in the 
case of Chile) signifies that on average, on the basis of the analyzed sample, clinical trials 
that recruit participants in Chile recruit participants also in 11,9 other countries.   
Table 8 
Clinical Trials sampled to assess their degree of “globalization” 
Country Developed or  
Developing/in 
Transition 
N°  
Clinical 
Trials 
Sampled  
N° 
Recrutiment 
Countries 
(average) 
Iceland Developed 10 39,5 
Bahrain Developing/Tr. 7 35,1 
Algeria Developing/Tr. 10 34,9 
Bulgaria Developed 10 33,1 
Bosnia and Herzegovina Developing/Tr. 10 32,0 
Bolivia Developing/Tr. 7 31,1 
Morocco Developing/Tr. 10 29,2 
Cameroon Developing/Tr. 9 27,4 
New Zealand Developed 10 27,3 
Uruguay Developing/Tr. 7 25,7 
clinical trials taken into consideration as recruiting in Germany and one of the 10 clinical trials taken 
into consideration as recruiting in Italy. Multiple presences of the same trial in the pool could not have 
been eliminated without scarifying randomization and in any event do not seem to pose any risk to the 
viability of the results obtained. 
596 The one provided in UN, World Economic Situation and Prospects 2017 (New York, 2017) 153-154. 
597 ICTRP Search Portal Advanced Search, apps.who.int/trialsearch/AdvSearch.aspx. 
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Denmark Developed 10 21,5 
United Kingdom Developed 10 21,1 
Guatemala Developing/Tr. 10 19,2 
Romania Developed 10 19,2 
Croatia Developed 10 17,5 
Argentina Developing/Tr. 10 15,4 
Chile Developing/Tr. 10 12,9 
Malaysia Developing/Tr. 10 11,8 
Israel Developing/Tr. 10 10,1 
Serbia Developing/Tr. 10 9,8 
Dominican Republic Developing/Tr. 10 9,5 
Nigeria Developing/Tr. 10 9,3 
Ukraine Developing/Tr. 10 8,3 
Qatar Developing/Tr. 10 7,5 
Russian Federation Developing/Tr. 10 5,3 
Kenya Developing/Tr. 10 5,2 
Canada Developed 10 4,3 
Germany Developed 10 4,0 
Italy Developed 9 4,0 
Pakistan Developing/Tr. 10 4,0 
Ghana Developing/Tr. 8 3,4 
Australia Developed 9 3,3 
France Developed 10 3,0 
Netherlands Developed 10 2,9 
Switzerland Developed 10 2,5 
Belgium Developed 10 1,9 
United States Developed 10 1,7 
China Developing/Tr. 9 1,0 
India Developing/Tr. 9 1,0 
Japan Developed 10 1,0 
Thailand Developing/Tr. 10 1,0 
 
(2) Results 
The study here presented analyzed the areas of recruitment of 394 clinical trials registered 
on the ICTRP. The fact that for each of the 41 countries taken into consideration only 
seven to ten clinical trials were analyzed, renders it difficult to generalize the findings of 
this research. Simultaneously, the fact that the sample was obtained through the ICTRP 
limits the applicability of such findings to the field of clinical trials that are not registered.  
However, following the hypothesis identified above, some considerations may be 
presented. 
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(a) The data displayed in Table 8 confirms that clinical trials have “gone global.” In
particular, it confirms the basic intuition on which this thesis is based: the field of clinical
trials is international in nature. In fact, only four countries out of the 41 countries sampled
host on their territory clinical trials that recruit only within national borders.598 In the case
of “closed-system” countries, in any event, the degree to which the system is isolated
(i.e. virtually all the clinical trials that take place in a country that recruits solely in that
country) or “internationalized” does not provide any indication regarding the level of
protection awarded to human subjects recruited in that country. However, the
consequence of this finding in terms of regulatory considerations is that the vast majority
of countries have an interest in taking into consideration the international dimension of
clinical trials.
(b) Some countries are more affected by the globalization of clinical trials more than
others. In particular, even among the countries that are not “closed-systems,” a certain
degree of variation exists. Some countries host clinical trials that recruit in a pool of other
countries relatively smaller than others – this results in the countries occupying a position
in the bottom part of the list included in Table 8. For example, it can be noted that clinical
trials that take place in Switzerland on average recruit in Switzerland and in one other
country;599 simultaneously, clinical trials that take place in Algeria on average recruit in
Algeria and in 33 other countries.600 Countries that host more international clinical trials
than others, from the regulatory point of view, may have an increased interest in
considering the interaction between their national law and international standards.
(c) The existence of a strong correlation between the extent to which clinical trials
conducted in countries are “international” in size and their economic status (i.e.
developed economies, developing economies or economies in transition) is not supported
by the findings of this research. Of the 41 countries taken into consideration, 17 represent
developing economies. Ten of those fall to the bottom part of the list included in Table
8, meaning that they have a slight tendency to host clinical trials that recruit in relatively
small pools of countries. However, such distribution in the list is not particularly evident
and does not allow for the conclusion that there is a correlation between the average size
598 The four “closed-system” countries are China, India, Japan, and Thailand. 
599 Precisely, 1,5 
600 Precisely, 33,9 
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of recruitment pools (in terms of countries) and economic status of countries of 
recruitment.  
VI. Preliminary Conclusions
To conclude, this chapter aimed at providing some insights regarding the global 
dimension of clinical trials and the characteristics and positions of some stakeholders. It 
achieved those goals by presenting a set of “case studies” which assessed the opinion of 
a small pool of sponsors, patients’ and consumers’ organizations, and investigators; and 
by extracting and analyzing recruitment-related data obtained through the ICTRP.  
While conclusions specific to each section are presented above, a few broad observations 
deriving from this chapter as a whole can be presented. First, the research conducted 
through contacts with clinical trial stakeholders (sub-sections II-IV) confirmed that in 
their action the international dimension is persistently relevant. It also confirms that 
stakeholders have mixed opinions – often depending on their role and geographic 
location – regarding the optimal level of regulation of clinical trials and the benefits 
associated with the implementation of a binding international (i.e. “universal”) regulation 
of clinical trials. Second, the research conducted on recruitment pools on the basis of data 
retrieved from the ICTRP by collecting of up-to-date information, confirmed that the 
international dimension is the prevalent dimension in clinical trials and that the vast 
majority of countries have a virtual interest in the regulation of clinical trials – or at least 
the opportunity to take into consideration the international scale of the recruitment 
activities that they host – in the light of such a “global” phenomenon.  
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CONCLUSIONS 
This thesis identified some of the risks and opportunities of a globalized clinical research 
environment, with the aim of providing some insights on how to improve the protection 
of human subjects in clinical trials. In general, the thesis focused on the global dimension 
of clinical trials and on their status and challenges in developing economies vis-à-vis 
developed economies; it also analyzed the role that different stakeholders play in the field 
of clinical trials in light of the need to balance their competing interests. To achieve its 
goals, it adopted a variety of approaches – especially the descriptive, the comparative, 
and the empirical. It also borrowed and built upon sources from various areas of 
literature, including international healthcare law and policy literature, as well as scientific 
research. 
Each chapter attempted to respond to the research questions presented in the introduction. 
The specific answers to the question (or questions) addressed in the chapters are 
presented at the conclusion of each chapter, in the form of preliminary conclusions.  
Therefore, the conclusions presented in this section will not focus on findings that derive 
from single chapters taken alone, but rather on the big picture that can be observed 
through the lenses manufactured in this contribution. They can be presented in the form 
of four questions, with elements taken from each of this thesis’ chapters contributing by 
providing their respective answers.  
(i) The first question regards the rationale behind the regulation of clinical trials: why
should clinical trials be objects of legislation? Chapter Two provides some tools to
support a positive answer to this question. In fact, the regulation of clinical trials is
necessary in order to fully respect and implement the right to health and the right to
information. In particular, regulating clinical trials means addressing specific issues due
to which those rights may be negatively affected. In this context, Chapter Two discusses
the challenges and opportunities connected with the issue of sample tailoring, subject
recruitment, placebo-controlled clinical trials and standards of care, clinical trial
registration – which is also addressed in Chapter Six – and informed consent.
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(ii) The second question regards the pushing and pulling forces that confront legislative
forces in the field of clinical trials regulation: which are the interests to be balanced in
clinical trials regulation? To provide an answer to this question, Chapter Three presents
a “taxonomy” of clinical trial paradigms and competing interests. It suggests that
legislators should take into consideration the interests of three stakeholders – human
subjects, sponsors, and investigators – and that those interests can be effectively
categorized in the light of three competing paradigms – access, cost, and quality. The
categorization of clinical trial related issues in these terms represents an original
contribution to clinical trial literature. Moreover, with regard to the action of
stakeholders, Chapter Four identifies a series of best practices that private stakeholders
may take into consideration to preserve the protection of the highest attainable ethical
standards when conducting clinical research.
(iii) The third question regards the issue of allocating competences in the regulation of
clinical trials: at which institutional level should clinical trials be regulated? A few
decades ago, “what eventually came to be called syphilis was known as ‘the Neapolitan
disease’ among the French and ‘the French disease” among Italians. Russians called it
“the Polish disease’ and the Polish called it ‘the German disease.’”601 Nowadays,
arguably, conditions requiring treatments for which clinical trials are on-going do not
stop at national borders – consequently, clinical research is far from adopting a solely
national (and nationalist) approach. In this context, the empirical analysis included in
Chapter Seven (in particular, sub-section V) confirms that the globalized dimension of
clinical trials is currently prevalent. In a nutshell, it finds that the vast majority of the 394
clinical trials sampled in the study recruit in more than one country at the same time and
that the vast majority of the 41 countries sampled have a virtual interest in appreciating
the international dimension of clinical trials that recruit human subjects in their territory.
Furthermore, the conclusions of Chapter Two suggest that the nature of some of the
challenges that are prominent in the field of clinical trials – in particular, issues such as
local standards of care, registration, and informed consent in international clinical trials
– require legislative efforts to be promoted at the international level, given that they touch
upon rights that belong to human subjects as such, and are not (or should not be) bound
601 “Why do we call it that? Backstories of seven disease names.” STAT, 24 Oct. 2017, 
www.statnews.com/2017/10/24/etymology-disease-names/. 
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to national borders. As to the division of competences between the international and 
national level, Chapter Four suggests steadily introducing the reliance on the principle of 
subsidiarity in order to fully and effectively implement clinical trial legislation at the 
most appropriate level of institutional power.  
(iv) The fourth question regards the challenges that legislative efforts face, especially if
carried out taking into consideration the answer provided to the third question: how
should legislators regulate the globalized field of clinical trials? The findings of this
thesis in this context can be summarized in three indications. First, legislators – being at
the national, regional, or international level – should be aware of the nature of the
challenges that clinical trials pose, as well as of the interests triggered by clinical trials,
not to mention the successful dynamics already developed at the international level. In
this sense, Chapter Three and Chapter Seven (sub-sections II-IV, dedicated to the
description of the opinions expressed by a pool of stakeholders) confirm that the interests
of stakeholders are relevant at any institutional level. Furthermore, Chapter Six sees in
the development of the ICTRP an example of successful interaction of the
complementary regulatory efforts promoted by public actors and the scientific
community. Second, the global nature of clinical trials becomes particularly relevant in
the case of legislative efforts regarding multi-regional clinical trials and the import of
foreign-obtained data. Hence, Chapter Five presents a comparative analysis of the
provisions implemented in the EU and the US with regard to globalized clinical trials.
The analysis identifies similarities and differences between the two systems in order to
provide both private actors interested in compliance and institutional actors interested in
law-reform with an up-to-date comparative analysis. Given that the latter relies on the
new EU “Clinical Trials Regulation” – which is soon to enter into force and has not yet
been object of extensive contributions in literature – it represents a particularly original
analysis within clinical trial literature. It is also complemented by an addendum of the
status of the EU “Clinical Trials Regulation” in four Members States that agreed to share
some information while this thesis was redacted. Third, globalized clinical trials cannot
be regulated without taking into high consideration the need to effectively implement
common ethical standards. Therefore, Chapter Four in this thesis provides a concrete
hypothesis as to the shape that such standards should assume within clinical trial
legislation, taking into consideration the challenges posed by the phenomenon of
“outsourcing” clinical trials in developing economies.
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To conclude, in the dawn of the 20th Century, Joseph Conrad wrote that “[t]he conquest 
of the earth, which mostly means the taking it away from those who have a different 
complexion or slightly flatter noses than ourselves, is not a pretty thing when you look 
into it too much.”602 In light of the research developed and presented within this thesis, 
it can be said that the same risk applies to the highly modernized and technical, yet 
extremely “social” in nature and globalized field of clinical trials. In this context, wise 
legislative efforts, capable of acknowledging complex dynamics – in terms of interests 
involved, ethical considerations, and geographical challenges – represent the best tool to 
cast some light into the heart of clinical trial darkness.  
602 Conrad, Joseph.  Heart of Darkness (New York:  Bantam Books, 1981), at p. 65. 
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ADDITIONAL DOCUMENTS 
(1) Zusammenfassung der Dissertation: Recht und Praxis klinischer Studien:
Probandenschutz und globale Dynamiken 
Die vorliegende Dissertation beschäftigt sich mit den Auswirkungen klinischer 
Forschung – genauer, klinischer Studien – bezüglich des Rechts und der Praxis auf 
internationaler Ebene. Sie identifiziert einige der Risiken und Möglichkeiten eines 
globalisierten Umfelds klinischer Studien und zielt darauf ab, Einblicke in die 
Verbesserung des Menschenrechtsschutzes in klinischen Studien zu geben. Allgemein 
konzentriert sie sich auf die globale Dimension klinischer Studien und ihres Status und 
die Herausforderungen in Entwicklungsländern vis a vis entwickelten Ländern; Sie 
analysiert darüber hinaus die Rolle, die verschiedene Akteure im Bereich klinischer 
Studien, hinsichtlich der Notwendigkeit, die konkurrierenden Interessen 
auszubalancieren, spielen. Um diese Ziele zu erreichen, werden eine Reihe von Ansätzen 
verfolgt – insbesondere der beschreibende, vergleichende und der empirische Ansatz. Sie 
baut auf Quellen verschiedener literarischer Bereiche auf (und trägt zu diesen bei), 
einschließlich des internationalen Gesundheitsrechts, der einschlägigen Literatur sowie 
wissenschaftlicher Forschung. 
Jedes Kapitel versucht, auf spezifische Forschungsfragen einzugehen: 
Kapitel Eins stellt eine umfassende Überprüfung der Literatur im Bereich des Rechts und 
der Praxis klinischer Studien dar, mit einem besonderen Fokus auf deren internationale 
Dimension. Kapitel Zwei beschreibt die wesentlichen Rechte, die bei der Durchführung 
von und Teilnahme an klinischen Studien berührt werden. Insbesondere werden das 
Recht auf Gesundheit sowie das Recht auf Information angesprochen. Kapitel Drei 
beschreibt Hauptakteure klinischer Studien (teilnehmende Personen, Sponsoren und 
Forscher) und wie ihre Interessen koordinieren oder kollidieren angesichts der 
Notwendigkeit, drei widerstreitende traditionelle Paradigmen des Gesundheitswesens 
auszubalancieren: Zugang, Kosten und Qualität. Kapitel Vier stellt konkrete rechtliche 
Formulierungen sowie Beispiele einer Umsetzung einer Reihe ethischer Prinzipien vor 
und erweitert diese mit einem zusätzlichen ethnischen Prinzips, welches auf 
internationale klinische Studien Anwendung findet. Kapitel Fünf stellt eine 
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vergleichende Analyse des rechtlichen Rahmens für klinische Studien in der 
Europäischen Union und den Vereinigten Staaten von Amerika dar. Kapitel Sechs 
konzentriert auch auf das Thema der Registrierung klinischer Studien. Das Ziel einer 
verpflichtenden Registrierung wird in die Überlegungen dieser Dissertation 
eingebunden, da die globale Dimension von besonderer Bedeutung ist und die 
Entwicklung eines internationalen Standards diesbezüglich erfolgreich erreicht wurde 
dank der Interaktion verschiedener Akteure. Kapitel Sieben nimmt einen „praktischeren“ 
Ansatz ein. Es stellt die Ergebnisse einiger Interviews vor, die im Zusammenhang mit 
Sponsoren, Patienten- und Verbraucherorganisationen und Forschern entstanden sind, 
und stellt die Ergebnisse einer einfachen empirischen Analyse, gerichtet auf die Dynamik 
der Personeneinstellung, basierend auf einer Probe von 394 klinische Studien, vor.  
Den Mehrwert, den die vorliegende Dissertation zu leisten vermag, kann in Form von 
vier Fragen dargestellt werden, wobei Elemente jedes Kapitels der Arbeit dazu beitragen, 
eine jeweilige Antwort zu formulieren. 
(i) Die erste Frage bezieht sich auf die hinter der Regulierung klinischer Studien
stehenden Begründung: Warum sollten klinische Studien Gegenstand legislativer
Maßnahmen sein? Kapitel Zwei stellt einige Instrumente bereit, um eine positive
Antwort auf diese Frage zu finden. Genauer gesagt ist die Regulierung klinischer Studien
notwendig, um das Recht auf Gesundheit und das Recht auf Information vollständig zu
respektieren und umzusetzen. Insbesondere bedeutet das Regulieren klinischer Studien,
dass spezifische Fragen, in denen diese Rechte negativ beeinflusst werden, angesprochen
werden. In diesem Zusammenhang bespricht Kapitel Zwei die Herausforderungen und
Möglichkeiten, die mit den Fragen der Probandeneigenschaften, der konkreten
Rekrutierung von Probanden, Placebo-gesteuerter klinischer Studien und
Sorgfaltsstandards, der Registrierung klinischer Studien – welche auch in Kapitel Sechs
diskutiert werden – und Einwilligungserklärungen zusammenhängen.
(ii) Die zweite Frage berücksichtigt die Schub- und Zugkräfte, die Legislativorganen im
Bereich der Regulierung klinischer Studien begegnen: Welche Interessen müssen in der
Regulierung klinischer Studien ausbalanciert werden? Um eine Antwort auf diese Frage
zu geben, präsentiert Kapitel Drei eine Klassifizierung von Paradigmen klinischer
Studien und widerstreitender Interessen. Es schlägt vor, dass Legislativorgane die
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Interessen dreier Akteure berücksichtigen sollten – der teilnehmenden Probanden, 
Sponsoren und Forschern – und dass diese Interessen effektiv in Anbetracht dreier 
widerstreitender Paradigmen – Zugang, Kosten und Qualität ¬¬– kategorisiert werden 
können. Die Kategorisierung von Themen klinischer Studien diesbezüglich repräsentiert 
einen eigenständigen Beitrag zur Literatur über klinische Studien. Darüber hinaus 
identifiziert Kapitel Vier mit Blick auf die Handlungen der Akteure eine Reihe von 
optimalen Vorgehensweisen (best practice), die private Akteure berücksichtigen 
könnten, um den Schutz des höchstmöglichen ethnischen Standards in klinischen Studien 
sicherstellen zu können. 
(iii) Die dritte Frage berücksichtigt die Thematik der Zuweisung von Kompetenzen in
der Regulierung klinischer Studien: Auf welcher intentionellen Ebene sollten klinische
Studien reguliert werden? (Krankheits-)Zustände, die eine Behandlung benötigen, für die
klinische Studien derzeit am Laufen sind, machen heutzutage wohl nicht vor nationalen
Grenzen Halt – konsequenterweise sind klinische Studien weit davon entfernt, einen
allein nationalen (und nationalistischen) Ansatz anzunehmen. In diesem Zusammenhang
bestätigt die empirische Analyse, die in Kapitel Sieben enthalten ist (genauer,
Unterkapitel V), dass die globalisierte Dimension klinischer Studien derzeit
vorherrschend ist. Kurz gesagt stellt sie fest, dass die überragende Mehrheit der 394
klinischen Studien, die in der Studie aufgeführt sind, in mehr als einem Staat gleichzeitig
Probanden rekrutiert und dass die überragende Mehrheit der 41 aufgeführten Staaten ein
Interesse daran hat, die internationale Dimension der klinischen Studien, die Probanden
in ihrem Staatsgebiet rekrutieren, anzuerkennen. Ferner lassen die Schlüsse aus Kapitel
Zwei darauf schließen, dass die Natur einiger Herausforderungen, die im Bereich
klinischer Studien herausragend sind – insbesondere Themen wie die lokalen Standards
der Pflege, Registrierung und Einwilligungserklärung in internationalen klinischen
Studien – die Förderung legislativer Bemühungen auf internationaler Ebene erfordern,
da sie Rechte berühren, die den (menschlichen) Probanden als solchen zustehen und nicht
an nationale Grenzen gebunden sind (bzw. sein sollten). Bezüglich der Teilung der
Kompetenzen zwischen der internationalen und nationalen Ebene schlägt Kapitel Vier
vor, das Vertrauen und Verlassen auf das Prinzip der Subsidiarität stetig als Maßnahme,
um Gesetzgebung zu klinischen Studien vollständig und effektiv auf der angemessenen
Ebene institutioneller Macht umzusetzen, einzubringen.
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(iv) Die vierte Frage berücksichtigt die Herausforderungen, denen Legislativmaßnahmen
begegnen, insbesondere, wenn sie unter Berücksichtigung der Antwort auf die dritte
Frage umgesetzt werden: Wie sollte die Legislative den globalisierten Bereich klinischer
Studien regulieren? Die Ergebnisse dieser Dissertation in diesem Zusammenhang können
in drei Indikatoren zusammengefasst werden. Erstens sollte die Legislative – sei es auf
nationaler, regionaler oder internationaler Ebene – sich der Art der Herausforderungen
klinischer Studien, der durch klinische Studien berührten Interessen und der
erfolgreichen, bereits auf internationaler Ebene entwickelten Dynamik bewusst sein. In
diesem Sinne bestätigen Kapitel Drei und Sieben (Unterkapitel II-IV, die sich mit der
Beschreibung der Ansichten, die durch Bündel von Akteuren geäußert wurden,
auseinandersetzen), dass die Interessen der Akteure auf jeder institutionellen Ebene
Bedeutung haben. Ferner wird in Kapitel Sechs in die Entwicklung der ICTRP ein
Beispiel einer erfolgreichen Interaktion der ergänzenden  regulierenden Anstrengung
gelesen, die durch öffentliche Autoren und die wissenschaftliche Gemeinschaft
beworben wurde. Zweitens wird die globale Natur klinischer Studien insbesondere in den
Fällen legislativer Anstrengungen bezüglich multiregionaler klinischer Studien und des
Imports von im Ausland erhobener Daten relevant. Daher wird in Kapitel Fünf eine
vergleichende Analyse der Regelungen dargestellt, die in der EU und den USA bezüglich
globalisierter klinischer Studien eingeführt wurden. Die Analyse identifiziert
Ähnlichkeiten und Unterschiede der zwei Systeme, um sowohl privaten Akteuren mit
Interessen im Bereich Compliance als auch institutionellen Akteuren mit Interessen in
der Reformierung des Rechts eine aktuelle vergleichende Analyse zur Verfügung zu
stellen.  Angesichts dessen, dass letztere auf der neuen europäischen Verordnung über
klinische Prüfungen basiert – welche in Kürze in Kraft treten wird und bislang noch nicht
Gegenstand ausführlicher Literaturbeiträge war –, repräsentiert insbesondere sie eine
eigenständige Analyse im Bereich der Literatur bezüglich klinischer Prüfungen. Sie wird
darüber hinaus ergänzt durch ein Addendum des Status der europäischen Verordnung
über klinische Prüfungen in vier Mitgliedstaaten, die sich während der Erstellung der
vorliegenden Dissertation darauf verständigt haben, Informationen zu teilen. Drittens
können globalisierte klinische Studien nicht reguliert werden, ohne dass die
Notwendigkeit der effektiven Umsetzung gemeinsamer ethnischer Standards hohe
Berücksichtigung findet. Daher beinhaltet Kapitel Vier der vorliegenden Dissertation
konkrete Hypothesen bezüglich der Ausgestaltung, die solche Standards innerhalb der
Gesetzgebung im Bereich klinischer Studien erfahren soll, unter Berücksichtigung der
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Herausforderungen, die durch das Phänomen des „Outsourcing“ klinischer Studien in 
Entwicklungsländer hervorgerufen werden. 
Abschließend ist festzustellen, dass die vorliegende Dissertation durch die oben 
beschriebenen Kapitel darauf abzielt, einen eigenständigen Beitrag im Bereich des 
Rechts klinischer Studien und dessen Praxis im internationalen Szenario abzubilden. In 
diesem Zusammenhang stellen wohlüberlegte legislative Anstrengungen, die die 
komplexen Dynamiken – hinsichtlich der involvierten Interessen, ethnischen 
Überlegungen und geographischen Herausforderungen – berücksichtigen, das beste 
Werkzeug dar, um Licht auf die Risiken und Chancen des Probandenschutzes in 
klinischen Studien zu werfen.  
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3Introduction
Highlights
• Focus on risks and opportunities of a globalized clinical research
environment, with the aim of providing some insights on how to
improve human subjects’ protection in clinical trials
• Focus on the global dimension of clinical trials and on their status and
challenges in developing economies vis-à-vis developed economies
and on the role that different stakeholders play in the field of clinical
trials in the light of the need to balance their competing interests
• A variety of approaches: descriptive, comparative, and empirical
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Issue one: Why 
Why should CTs be regulated?
See Chapter Two discusses the right to health and the right to 
information and grey areas such as:
• Sample tailoring
• Subjects’ recruitment
• Placebo-controlled clinical trials and standards of care
• CTs registration
• Informed consent
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Issue two: How 
How are CTs regulated?
• See Chapter Four identifies a series of potential best practices that
private stakeholders may take into consideration to preserve the
protection of the highest attainable ethical standards when conducting
clinical research
• See Chapter Five presents a comparative analysis of the provisions
implemented in the EU and the US with regard to globalizes CTs
(including an addendum on the CTR application-framework)
• See Chapter Six reads in the development of the ICTRP as example of
successful interaction of the complementary regulatory efforts
promoted by public actors and the scientific community
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Issues 3 and 4: Who and Where
Which are the interests to be balanced in CTs regulation? 
• Chapter Three presents a model (a “taxonomy”) that categorizes
interests of CTs stakeholders in light of competing paradigms
• Chapter Seven presents the results of surveys conducted with
sponsors, investigators, and patients
At which institutional level should CTs be regulated?
• Chapter Seven presents the results of an empirical analysis regarding
CTs in 41 countries
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By way of background
Clinical trial (CT):  “Any research study that prospectively assigns human 
participants or groups of humans to one or more health related 
interventions to evaluate the effects on health outcomes.”
-- WHO, World Health Organization (2018)
8
Regulators
SponsorsInvesti-gators
Human
subjects • Key stakeholders in CTs (at
any given level)
• Four phases
Grey areas
When is consent informed?  Should placebo-controlled trials be 
conducted only when no best proven alternatives exist or when no local
alternatives exist? 
9
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Original Contributions
(1) Gostin’s model: revisited
Three competing paradigms: regulatory interventions affecting any of 
those paradigms will likely produce results on one or more of the others 
And three categories of stakeholders: patients, sponsors, investigators
11
Access
Cost Quality
The taxonomy
Access Cost Quality
Human
Subjects
(1) Access to CTs
(2) Public access
to CT data
(1) Cost of
participation
(2) Cost of
compliance
(1) Safety of CTs
(2) Safety and
effectiveness of
the CTs’ outcome
Investigators (1) To sponsors
(2) To CT data
(1) Costs of
compliance
(1) Of CT data
(2) Safety and
effectiveness of
the CTs’ outcome
Sponsors (1) To investi-
gators
(2) Disclosure
concerns
(1) Costs of CTs
per se
(2) Costs of
compliance
(1) Of CT data
(2) Safety and
effectiveness of
the CTs’ outcome
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Relevance
How can the model help?
• Analysing the way in which each stakeholder – human subjects,
investigators, and sponsors – develops specific concerns and interests
within each paradigm provides us with a better understanding of the
dynamics of CTs, both at local and at global levels
• Understanding the taxonomy helps to explain why the global
dimension of CTs is now the dominant one (escalation effect)
• Contributing to better predict the results of clinical trials regulations
and reforms
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(2) “On the ground” analysis
• Surveys conducted with CTs sponsors, patients’ and consumer
organizations, and investigators. The interviews contribute to clarifying
the approach and position of the main clinical trials’ stakeholders with
regard to the current dimension and regulatory challenges of CTs
• Simple empirical analysis conducted on the basis of a sample of 394
ICTRP CTs
• Limits: sample size
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Survey I: sponsors (I)
Sample selection
• Cross-industry factor: biotechnology – therapeutics and diagnostics,
biotechnology – research and development services, pharmaceutical,
medical technology, and public and non-profit organizations
• Geographical factor: Africa, Asia, Europe, Central America, Oceania,
South America, US and Canada
• Four sponsors agreed to participate in the research are based in the
UK, Taiwan, Belgium, and in the US (on average, more than 15 CTs /
year)
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Survey I: sponsors (II)
• 10 questions, including:
• Countries in which the company/institution operates in the CTs field
• Recruitment practices used by the company “abroad” (reliance on CROs)
• Involvement of the company/institution in the transfer of foreign data
• All four sponsors interviewed – while engaged in different kinds of
activities and based in different areas of the world – are active at the
international level, confirming that even for such a small sample CTs
have an international dimension
• Is an international regulatory action needed? The sponsors replied
with opinions varying from point three and point seven in the Lickert
scale
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Survey II: investigators (I)
Sample selection
• 15 investigators agreed to participate in the survey
• 10 investigators based in developed economies and five based in developing
economies or economies in transition)
• 10 investigators employed by Universities, two by a publicly funded
governmental agency which engages in clinical research, two for a private
company, and one for a mixed private-public research centre
• 10 questions, including:
• Location of the investigator’s work, of her sponsor, and of the human
subjects taking part in her clinical trial.
• Possible reasons for which the investigator was selected by a specific
sponsor.
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Survey II: investigators (II)
• No prevalent international dimension of CTs in the operation of the
investigators
• Compliance is driven by underlying interest in publishing their study,
rather than the need to comply with legal provisions
• No absolutely positive opinion on the benefits associated with
implementing an international binding CTs regulation
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ICTRP: empirical analysis
Underlying question: at which institutional level should CTs be 
regulated?
Sub-goals:
• Test to which extent CTs
have “gone global”
• Assess whether some countries are
more affected by such globalization
than others
• Estimate whether there is a correlation between the extent to which
CTs conducted in countries are “international” in size, and their
economic status (i.e., developed economies, developing economies or
economies in transition).
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Sample selection
• 53 countries randomly selected from the “Country Classification”
section included in the United Nations World Economic Situation and
Prospects for year 2017
• For each of the countries a search on the WHO ICTRP was conducted.
• Search variables:
• Phase I to VI of clinical trials
• Country
• Date of registration
Data utilized: top 10 results (plus adjustments e.g., halted recruitment 
or have less than 10 recruiting trials) i.e., 394 CTs in 41 countries
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Relevant countries
21
Data pooling
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Results
• Only four countries host on their territory clinical trials that recruit only
within national borders (hypothesis confirmed)
• Some countries host clinical trials that recruit in a pool of other
countries relatively smaller than others (hypothesis confirmed)
• For example, CTs that take place in Switzerland on average recruit in
Switzerland and in one other country; CTs that take place in Algeria on
average recruit in Algeria and in 33 other countries
• The existence of a strong correlation between the extent to which
clinical trials conducted in countries are “international” in size and their
economic status is not supported by the findings of this research
(hypothesis not confirmed)
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Conclusions
Outcome (I)
Why should CTs be regulated?
• In order to fully respect and implement the right to health and the right
to information
• In particular, regulating CTs means to address specific issues (i.e., grey
areas) in which those rights may be negatively affected
How are CTs regulated?
Efforts to regulate CTs are far-reaching, as confirmed by the analysis of 
the EU and US legal frameworks. Currently, important regulatory 
challenges regard multi regional clinical trials and the import of foreign-
obtained data
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Outcome (II)
Which are the interests to be balanced in CTs regulation? 
• The interests of human subjects, sponsors, and investigators (balancing
exercise)
• Vis-à-vis trade-offs between three competing paradigms: cost, access,
and quality
At which institutional level should CTs be regulated?
The globalized dimension of CTs is currently prevalent. The nature of
some of the challenges that are prominent in the field of CTs require
legislative efforts to be effective on the global level
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Next steps
Short-term expansions:
• Expansion of Chapter Five, including secondary sources and an
overview of the pre-CTR legal framework
• Run an updated version of the empirical analysis
Long-term expansions:
• Expansion of the comparative analysis, to include other jurisdictions
and ICH standards
• Expansion or analysis of relevant legislation to include
pharmacovigilance and marketing authorization processes
27
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Questions?
